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The	  system	  Xc-­‐	  (SXc-­‐)	  transporter	  functions	  under	  normal	  physiological	  conditions	  in	  
astrocytes	  to	  mediate	  the	  exchange	  of	  extracellular	  cystine	  (L-­‐Cys2)	  for	  intracellular	  
glutamate	  (L-­‐Glu).	  	  The	  internalized	  L-­‐Cys2	  serves	  as	  a	  rate-­‐limiting	  precursor	  in	  the	  
biosynthesis	   of	   glutathione	   (GSH),	   while	   the	   externalized	   L-­‐Glu	   can	   access	   EAA	  
receptors	   and	   contribute	   to	   either	   excitatory	   signaling	   or	   excitotoxcity.	   	  Although	  
the	  regulation	  of	  SxC-­‐	  has	  been	  studied	  in	  a	  variety	  of	  cells,	  particularly	  as	  related	  to	  
xenobiotic	  exposure,	  much	  less	   is	  known	  about	   its	  regulation	   in	  astrocytes.	   	   In	  the	  
present	   study	   the	   influence	   of	   phenotype	   (culturing	   in	   the	   presence	   of	   dibutyryl-­‐
cAMP)	   and	   GSH	   levels	   on	   the	   expression	   of	   SxC-­‐	   was	   investigated	   in	   cultures	   of	  
primary	  astrocytes	  prepared	  from	  neonatal	  rats.	  	  We	  report	  that	  SxC-­‐	  activity	  in	  the	  
dbcAMP-­‐treated	  cells	  was	  nearly	  7-­‐fold	  greater	  than	  in	  untreated	  astrocytes	  (100	  ±	  
21	  and	  15	  ±	  4	  pmol/min/mg	  protein	  respectively)	  and	  that	  this	  uptake	  was	  further	  
upregulated	   (~3-­‐fold)	   in	   these	   cells	   following	   the	   depletion	   of	   intracellular	   GSH	  
levels	  with	  buthionine	  sulfoximine	  (BSO,	  500	  µM,	  24	  hrs).	   	  Changes	   in	  SxC-­‐	  activity	  
correlated	  with:	  increases	  in	  both	  protein	  and	  mRNA	  levels	  of	  the	  xCT	  subunit	  of	  the	  
SxC-­‐	  heterodimer,	  an	  increase	  in	  the	  Vmax	  for	  SxC-­‐-­‐mediated	  L-­‐Glu	  uptake	  (147	  ±	  5	  in	  
untreated	   astrocytes	   to	   350	   ±	   15	   pmol/min/mg	   protein	   in	   dbcAMP-­‐treated),	   and	  
was	   linked	   temporally	   to	   alterations	   in	   GSH	   levels.	   The	   GSH	   depletion-­‐induced	  
induction	   of	   SxC-­‐	   was	   not	   mimicked	   by	   tBHQ	   or	   non-­‐specific	   oxidants	   and	   was	  
partially	   preventable	   by	   the	   co-­‐administration	   of	   cell	   permeant	   thiols	   GSH-­‐ethyl	  
ester	   (5	   mM)	   and	   N-­‐acetylcysteine	   (NAC).	   	   These	   findings	   demonstrate	   that	   the	  
expression	  of	  SxC-­‐	  on	  astrocytes	  is	  dynamically	  regulated	  by	  intracellular	  GSH	  levels	  
in	   a	   cell-­‐	   and	  phenotype-­‐dependent	  manner.	   	   The	   presence	   of	   this	   pathway	   likely	  
reflects	   the	   inherent	   vulnerability	   of	   the	   CNS	   to	   oxidative	   damage	   and	   raises	  
interesting	  questions	  as	  to	  the	  functional	  consequences	  of	  changes	  in	  SxC-­‐	  activity	  in	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   1	  
Chapter	  1.	  Introduction	  
1.1	  System	  xC-­	  functional	  characteristics	  	  
Membrane	  transporters	  on	  neurons	  and	  glia	  serve	  to	  regulate	  both	  intracellular	  and	  
extracellular	  environments	  of	  the	  CNS.	  	  Uptake	  provides	  a	  route	  of	  entry	  for	  needed	  
metabolites,	   as	   well	   as	   a	   mechanism	   through	   which	   synaptic	   and	   extrasynaptic	  
concentrations	   of	   neuroactive	   molecules	   can	   be	   controlled.	   	   The	   system	   Xc-­‐	   (SXc-­‐)	  
transporter	   functions	   under	   normal	   physiological	   conditions	   to	   mediate	   the	  
exchange	  of	  extracellular	  L-­‐cystine	  (L-­‐Cys2)	  for	  intracellular	  glutamate	  (L-­‐Glu).	  	  
Much	   of	   the	   initial	   identification	   and	   comprehensive	   characterization	   of	   SxC-­‐	   was	  
first	  described	  in	  IMR-­‐90	  cells	  by	  Shiro	  Bannai	  and	  colleagues	  (Bannai	  1984;	  Bannai	  
1986a;	  Bannai	  and	  Kitamura	  1980;	  Bannai	  and	  Kitamura	  1981).	  Their	  initial	  kinetic	  
and	  amino	  acid	  analysis	  revealed	  that:	  1.)	  L-­‐Cys2	  and	  L-­‐Glu	  are	  exchanged	  in	  a	  1:1	  
molar	  ratio	  at	  a	  single	  carrier	  and	  act	  as	  competitive	  substrates	  for	  one	  another	  on	  
either	   side	   of	   the	   plasma	  membrane,	   2.)	   the	   exchange	   process	   is	   independent	   of	  
sodium	   ion	   availability	   and	   dependent	   on	   chloride	   ions	   (chloride	   component	  
demonstrated	   by	   Waniewski	   and	   Martin	   (Waniewski	   and	   Martin	   1984)),	   3.)	  
exchange	   is	  electroneutral	  and	  dependent	  on	  each	  substrate	  having	  a	  net	  negative	  
charge	  which	   in	   turn	   is	   dependent	  on	  pH,	   and	  4.)	   internally	   transported	  L-­‐Cys2	   is	  
reduced	  to	  L-­‐cysteine	  (L-­‐CysH)	  (often	  by	  reacting	  with	  glutathione	  (GSH)	  to	  form	  a	  
GSH-­‐CysH	   disulphide	   and	   free	   L-­‐CysH),	   which,	   in	   turn	   serves	   as	   the	   rate-­‐limiting	  
precursor	  for	  the	  synthesis	  of	  GSH.	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The	   first	   isolation	   of	   mouse	   xCT	   (the	   protein	   subunit	   of	   SxC-­‐	   responsible	   for	  
substrate	  specificity)	  by	  expression	  cloning	  was	  obtained	  from	  mouse	  macrophages	  
stimulated	  with	  LPS	  (Sato	  et	  al.	  1999).	  The	  human	  variants	  of	  xCT	  (xCTa	  and	  xCTb)	  
were	   subsequently	   cloned	   from	  WI26VA4	   lung	   fibroblasts	   (Sato	   et	   al.	   2000)	   and	  
U87	  glioma	   cells	   (Kim	  et	   al.	   2001)	   respectively.	   	   Sxc-­‐	   has	  now	  been	   identified	   in	   a	  
wide	  variety	  of	  CNS	  cells	  (e.g.,	  astrocytes	  (Allen	  et	  al.	  2001;	  Cho	  and	  Bannai	  1990;	  
Gochenauer	  and	  Robinson	  2001),	  microglia	  (Piani	  and	  Fontana	  1994),	  retinal	  Muller	  
cells	  (Kato	  et	  al.	  1993),	  immature	  cortical	  neurons	  (Murphy	  et	  al.	  1990),	  and	  glioma	  
cell	   lines	   (Cho	   and	   Bannai	   1990;	   Ye	   et	   al.	   1999)),	   as	   well	   as	   fibroblasts,	  
macrophages,	  hepatocytes	  and	  endothelial	  cells	  (Bannai	  1986b;	  Hosoya	  et	  al.	  2002;	  
Sasaki	  et	  al.	  2002;	  Sato	  et	  al.	  1999).	  SXc-­‐	  is	  also	  present	  (and	  inducible)	  at	  the	  blood	  
brain	   barrier,	   where	   it	   may	   serve	   as	   a	   point	   of	   entry	   for	   L-­‐Cys2,	   as	   well	   as	  
structurally	  related	  drugs	  and	  neurotoxins	  (Guebel	  and	  Torres	  2004;	  Hosoya	  et	  al.	  
2002;	  Nagasawa	  et	  al.	  2005;	  Warren	  et	  al.	  2004).	  	  
Following	   the	   initial	   findings	   that	   identified	   L-­‐Glu	   and	   L-­‐Cys2	   as	   endogenous	  
substrates	  of	  SxC-­‐,	  numerous	  pharmacological	   studies	  have	  continued	   to	  probe	   the	  
specificity	   of	   the	   transporter.	   	   Structure-­‐activity	   studies	   employing	   amino	   acid	  
analogs	   of	   the	   endogenous	   substrates	   have	   demonstrated	   that	   L-­‐aspartate	   acts	   as	  
neither	  a	  substrate	  nor	  inhibitor,	  and	  that	  L-­‐homocysteate,	  L-­‐alpha-­‐aminoadipate,	  L-­‐
alpha-­‐aminopimelate,	   quisqualate,	   4-­‐S-­‐carboxyphenylglycine	   (4-­‐S-­‐CPG),	   ibotenate,	  
(RS)-­‐4-­‐Br-­‐homoibotenate,	   (RS)-­‐5-­‐Br-­‐willardine,	   are	   competitive	   inhibitors	   (Bannai	  
1986a;	   Cho	   and	   Bannai	   1990;	   Patel	   et	   al.	   2004;	   Ye	   et	   al.	   1999).	   A	   structurally	  
unrelated	  compound,	  sulfasalazine,	  has	  also	  been	  shown	  to	  act	  as	  a	  potent	  inhibitor	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of	  SxC-­‐	  (Chung	  et	  al.	  2005).	  While	  a	  number	  of	  inhibitors	  have	  been	  defined,	  the	  lack	  
of	   selectivity	   among	   them	   poses	   a	   challenge	   to	   performing	   experiments	   using	  
physiological	   preparations.	   For	   example,	   quisqualate	   acts	   as	   an	  AMPA	   and	  mGluR	  
agonist	  (Balazs	  et	  al.	  2006),	  ibotenate	  acts	  as	  an	  NMDA	  and	  mGluR	  agonist	  (Ebert	  et	  
al.	  1991),	  and	  4-­‐S-­‐CPG	  is	  a	  Group	  I	  mGluR	  antagonist	  (Bedingfield	  et	  al.	  1995)	  (for	  
pharmacology	  review	  see	  Bridges	  and	  Patel	  2009).	  
SxC-­‐	  is	  a	  heterodimer	  composed	  of	  the	  two	  proteins,	  xCT	  and	  4F2hc	  (aka	  CD98)	  (Sato	  
et	   al.	   1999).	   The	   xCT	   subunit	   (502	   a.a.,	   ~	   40	   kDa)	   is	   a	  member	   of	   solute	   carrier	  
family	   7	   (SLC7),	   which	   is	   divided	   into	   two	   subgroups,	   the	   cationic	   amino	   acid	  
transporters	  (CAT)	  and	  the	  light	  chains	  of	  the	  heteromeric	  amino	  acid	  transporters	  
(HAT)	   (human	   genome	  mapping	  workshop	   designation	   SLC7A11)	   (for	   review	   see	  
Verrey	   et	   al.	   2004).	   xCT	   and	   members	   of	   this	   “light	   chain”	   family	   are	  
characteristically	  hydrophobic,	  contain	  12-­‐transmembrane-­‐spanning	  domains,	  	  non-­‐
glycosylated,	   and	   require	   one	   of	   two	   disulphide-­‐linked	   heavy	   chain	   type-­‐II	   N-­‐
glycoproteins	  (4F2hc	  or	  rBAT)	  for	  surface	  expression	  (Fig.	  1.1).	  In	  the	  case	  of	  xCT,	  
unlike	   some	  members	   of	   the	   HAT	   family,	   the	   4F2hc	   subunit	   is	   required	   both	   for	  
trafficking	   of	   xCT	   to	   the	   plasma	   membrane	   (Nakamura	   et	   al.	   1999)	   and	   for	   SxC-­‐	  
function.	   Sato	   and	   coworkers	   isolated	   cDNA	   from	   mouse	   macrophages	   and	  
demonstrated	   that	   L-­‐Cys2/L-­‐Glu	   exchange	   is	   observed	   only	   when	   both	   xCT	   and	  
4F2hc	  proteins	  are	  expressed	  together	  in	  xenopus	  oocytes,	  but	  not	  separately	  (Sato	  
et	  al.	  1999).	  Similar	  experiments	  with	  the	  human	  homolog	  of	  SxC-­‐	  (hxCT)	  (Bassi	  et	  al.	  
2001)	  demonstrated	  that	  the	  expression	  of	  both	  subunits	  was	  required	  to	  develop	  a	  
stably	  transfected	  mammalian	  line	  (Bridges	  and	  Zalups	  2005).	  The	  evidence	  for	  the	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ability	  of	  xCT	  to	  be	  functionally	  expressed	  with	  rBAT	  remains	  inconclusive	  (Bassi	  et	  
al.	  2001;	  Wang	  et	  al.	  2003).	  Amino	  acid	  transport	  appears	  to	  serve	  as	  only	  one	  of	  the	  
many	  potential	   functions	  of	   the	  4F2hc	  protein.	  With	  a	  nearly	  universal	  expression	  
profile	  in	  tissues	  and	  cell	  lines,	  the	  additional	  roles	  (of	  which	  amino	  acid	  transport	  
could	   be	   potentially	   related)	   of	   the	   heavy	   chain	   subunits	   in	   tumor	   proliferation,	  
lymphocyte	   activation	   and	   proliferation,	   differentiation,	   and	   adhesion,	   implicate	  
these	  subunits	  in	  the	  potential	  pathologies	  of	  a	  number	  of	  organ	  systems	  (for	  review	  
see	  Deves	  and	  Boyd	  2000).	  	  
	  
	  
Figure	  1.	  1.	  Topology	  model	   of	   xCT.	  Both	   the	  N	   and	  C	   termini	   of	   xCT	   are	   located	  
intracellularly	  and	   the	  12-­‐transmembrane	  domains	  are	  numbered	  and	   include	   the	  
residues	   that	   define	   the	   limits	   of	   each	   segment.	   The	   CysH	   residue	   that	   forms	   the	  
disulphide	  bond	  with	  4F2hc	  is	  shown	  (CysH158).	  The	  re-­‐entrant	  loop	  between	  TM2	  
and	  3,	  as	  well	  as	  regions	  of	  TM8	  of	  the	  xCT	  subunit	  are	  thought	  to	  be	  responsible	  for	  
substrate	   binding	   and	   transport	   activity	   (Gasol	   et	   al.	   2004;	   Jimenez-­‐Vidal	   et	   al.	  
2004).	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1.2	  Physiological	  features	  of	  the	  exchanger	  
L-­‐Cys2	  and	  L-­‐Glu	  act	  as	  competitive	  substrates/inhibitors	  (i.e.,	  Km’s	  for	  L-­‐Cys2	  and	  L-­‐
Glu	   in	   the	  50-­‐100	  µM	   range)	   for	   one	   another	   at	   SxC-­‐,	   therefore	   the	  direction	  of	   L-­‐
Glu/L-­‐Cys2	   exchange	   through	   the	   antiporter	   is	   determined	   by	   the	   concentration	  
gradients	   of	   either	   substrate	   across	   the	   plasma	   membrane	   (Fig.	   1.2)	   (Bannai	  
1986b).	  Under	  normal	  physiological	  conditions,	  the	  system	  XAG-­‐	  transporters	  (aka	  
EAATs)	   function	   to	   concentrate	   L-­‐Glu	   into	   neurons	   and	   glia.	   This	   establishes	   a	  
concentration	   gradient	   where	   intracellular	   L-­‐Glu	   concentration	   (mM)	   greatly	  
exceeds	   that	   of	   the	   extracellular	   space	   (Danbolt	   2001).	   This	   and	   the	   nearly	  
undetectable	   levels	   of	   L-­‐Cys2	   in	   the	   CSF	   (Sagara	   et	   al.	   1993a;	  Wang	   and	   Cynader	  
2000)	   dictate	   that	   the	   transporter	   exchanges	   one	  molecule	   of	   extracellular	   L-­‐Cys2	  
for	  one	  of	   intracellular	  L-­‐Glu.	  As	  a	  consequence	  of	  this	  bidirectional	  transport,	  SxC-­‐	  
mediates	   two	   distinct	   actions	   -­‐-­‐	   the	   influx	   of	   L-­‐Cys2,	   which	   once	   reduced	  
intracellularly	  to	  L-­‐CysH,	  acts	  as	  the	  rate-­‐limiting	  precursor	  for	  the	  synthesis	  of	  GSH,	  
an	  antioxidant	  important	  for	  both	  glial	  and	  neuroprotection,	  and,	  the	  efflux	  of	  L-­‐Glu,	  
which,	  depending	  on	  spaciotemporal	  conditions	  and	  concentration,	  may	  contribute	  
to	  both	   extrasynaptic	   signaling	   and	  excitotoxicity	   (Baker	   et	   al.	   2002a;	  Baker	   et	   al.	  
2002b;	  Choi	  1990;	  Chung	  et	  al.	  2005;	  Sontheimer	  2008).	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Figure	  1.2.	  The	  physiological	  significance	  of	  SxC-­‐	   is	  related	  to	   the	   import	  of	  L-­‐Cys2	  
and	   the	   export	   of	   L-­‐Glu.	   SxC-­‐	   can	  undergo	  homo-­‐	   or	   hetero-­‐exchange	  with	  both	  L-­‐
Cys2	  and	  L-­‐Glu	  depending	  on	  concentration	  gradients.	  Under	  normal	  physiological	  
conditions,	  the	  low	  levels	  of	  extracellular	  L-­‐Cys2	  coupled	  with	  the	  high	  intracellular	  
levels	  of	  L-­‐Glu	  (established	  by	  the	  activity	  of	  the	  EAATs),	  dictate	  that	  SxC-­‐	  functions	  
by	  exchanging	  an	  intracellular	  L-­‐Glu	  molecule	  for	  one	  extracellular	  L-­‐Cys2.	  	  
	  
1.2.1	  GSH	  
GSH	   is	  synthesized	   in	   two	  ATP-­‐dependent	  steps	   to	   form	  a	   tripeptide	  comprised	  of	  
the	  amino	  acids	  L-­‐Glu,	  L-­‐CysH,	  and	  L-­‐glycine	  and	  is	  present	  in	  virtually	  all	  cell	  types	  
(Fig.	  1.4).	  In	  the	  CNS,	  GSH	  is	  the	  most	  prevalent	  antioxidant	  (it	  comprises	  97%	  of	  the	  
acid-­‐soluble	  thiols	  in	  the	  cerebral	  cortex	  and	  approximately	  80%	  of	  the	  total	  soluble	  
thiol	  groups	  and	  in	  whole	  brain,	  the	  concentration	  of	  total	  glutathione,	  consisting	  of	  
both	   oxidized	   and	   reduced	   forms,	   ranges	   from	   0.5	   to	   3.4	   µmoles/gm	   tissue	   (for	  
reviews	   see	   Dringen	   et	   al.	   2000;	   Meister	   and	   Anderson	   1983;	   Orlowski	   and	  
Karkowsky	   1976).	   Depending	   on	   culture	   conditions	   and	   analytical	  methods	   used,	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intracellular	   GSH	   levels	   in	   CNS	   derived	   cell	   cultures	   and	   immortalized	   lines	   can	  
range	   from	  ~7-­‐50	  nmoles/mg	  protein	  (Cho	  and	  Bannai	  1990;	  Dringen	  et	  al.	  1999;	  
Gegg	   et	   al.	   2005;	   Sagara	   et	   al.	   1993a;	   Sagara	   et	   al.	   1993b).	   Consistent	   with	   the	  
localization	  of	  SxC-­‐	  on	  glia	  (Sato	  et	  al.	  2002),	  the	  majority	  of	  GSH	  in	  the	  brain	  is	  also	  
found	  in	  astrocytes	  (Ben-­‐Yoseph	  et	  al.	  1996;	  Sagara	  et	  al.	  1993b;	  Slivka	  et	  al.	  1987),	  
which	   consequently	   can	   withstand	   higher	   levels	   of	   H2O2	   induced	   toxicity	   than	  
neurons	  (Desagher	  1996;	  Philbert	  et	  al.	  1991;	  Raps	  et	  al.	  1989).	  	  
	  
	  
Figure	  1.3.	  The	  chemical	  structure	  of	  glutathione	  (GSH).	  
For	   a	   seemingly	   simple	   molecule,	   GSH	   serves	   as	   a	   multifaceted	   detoxification	  
strategy	  for	  the	  cell.	  Much	  of	  this	  is	  due	  to	  the	  L-­‐CysH	  moiety	  which	  allows	  GSH	  to	  
react	   non-­‐enzymatically	   with	   oxidants	   such	   as	   the	   highly	   damaging	   hydroxy	   and	  
peroxynitrite	   radicals	   (for	   reviews	   see	   Juurlink	   and	   Patterson	   1998;	   Meister	   and	  
Anderson	  1983;	  Orlowski	  and	  Karkowsky	  1976).	  Peroxides,	  by-­‐products	  of	  aerobic	  
respiration	  and	  superoxide	  metabolism	  and	  potential	  precursors	  for	  more	  reactive	  
radicals,	  are	  detoxified	  enzymatically	  by	  glutathione	  peroxidase	  and	  GSH	  (Juurlink	  
and	  Patterson	  1998;	  Meister	  and	  Anderson	  1983;	  Orlowski	  and	  Karkowsky	  1976).	  
There	   are	   a	   large	   group	   of	   metals	   and	   reactive	   electrophiles,	   many	   of	   which	   are	  
known	  or	  suspected	  carcinogens,	   that	  are	  also	  efficiently	  conjugated	  and	  removed	  
by	  the	  action	  of	  glutathione-­‐S-­‐transferase	  (GST)	  enzymes	  (Hayes	  et	  al.	  2005).	  







Figure	  1.4.	  Glutathione	  synthesis	  and	  detoxification	  reactions.	  The	  rate-­‐limiting	  
reaction	  for	  GSH	  synthesis	  is	  catalyzed	  by	  γ-­‐glutamylcysteine	  synthetase	  (1.)	  γ-­‐
Glutamylcysteine	  and	  glycine	  then	  react	  to	  form	  the	  final	  product	  in	  the	  second	  
synthesis	  step,	  which	  is	  catalyzed	  by	  GSH	  synthetase	  (2.).	  As	  GSH	  scavenges	  
oxidants	  and	  free	  radicals	  it	  is	  converted	  to	  the	  oxidized	  form	  GSSG	  through	  the	  
action	  of	  GSH	  peroxidase	  (3.).	  Regeneration	  of	  GSH	  from	  GSSG	  requires	  the	  reducing	  
cofactor	  NADPH	  and	  the	  enzyme	  GSH	  reductase	  (4.).	  Additionally,	  GSH	  also	  reacts	  	  
with	  xenobiotics	  including	  electrophiles	  and	  metals	  (X)	  through	  the	  GSH-­‐S-­‐
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1.2.1.1	  GSH	  cycling	  between	  astrocytes	  and	  neurons	  –	  the	  L-­Cys2/L-­CysH	  
shuttle	  
Maintaining	  intracellular	  GSH	  levels	  is	  largely	  dependent	  upon	  the	  availability	  of	  the	  
rate-­‐limiting	   precursor	   L-­‐CysH	   (Bannai	   1986a;	   Orlowski	   and	   Karkowsky	   1976).	  
Instead	  of	  transporting	  L-­‐CysH	  directly,	  L-­‐Cys2,	  transported	  into	  astrocytes	  through	  
SxC-­‐,	   is	  reduced	  intracellularly	  and	  serves	  as	  the	  primary	  source	  of	  L-­‐CysH	  for	  GSH	  
synthesis	   (Cho	  and	  Bannai	  1990;	  Kranich	  et	  al.	  1998;	  Sagara	  et	  al.	  1993a).	   In	   fact,	  
culturing	  cells	  in	  L-­‐Cys2	  -­‐free	  media	  or	  applying	  a	  high	  concentration	  of	  extracellular	  
L-­‐Glu	   are	   both	   effective	   means	   by	   which	   to	   deplete	   cellular	   GSH	   levels	   (Cho	   and	  
Bannai	   1990;	   Sagara	   et	   al.	   1993a;	   Sagara	   et	   al.	   1993b).	   Consistent	  with	   this,	  mice	  
that	   do	   not	   express	   xCT,	   exhibit	   plasma	   levels	   of	   L-­‐Cys2	   that	   are	   double	   that	   of	  
wildtype	  controls,	  as	  well	  as	  GSH	  levels	  half	  that	  of	  wildtype	  mice	  (Sato	  et	  al.	  2005).	  
Interestingly,	   depriving	   neuronal	   cultures	   of	   L-­‐Cys2	   does	   not	   result	   in	   depleted	  
levels	   of	   neuronal	   GSH	   (Sagara	   et	   al.	   1993b).	   When	   astrocytes	   are	   grown	   in	   co-­‐
culture	   with	   neurons,	   neuronal	   GSH	   increases,	   and	   this	   can	   be	   mimicked	   by	  
supplying	  neuronal	  cultures	  with	  L-­‐CysH	  (Dringen	  et	  al.	  1999;	  Sagara	  et	  al.	  1993b).	  
However,	  L-­‐CysH	  levels	  in	  astrocyte	  media	  or	  CSF	  decrease	  if	  SxC-­‐	  is	  inhibited	  by	  L-­‐
Glu	  or	   if	  L-­‐Cys2	   is	   removed	   (Dringen	  et	  al.	  1999;	  Sagara	  et	  al.	  1993a;	  Sagara	  et	  al.	  
1993b;	  Wang	  and	  Cynader	  2000).	  The	  link	  between	  extracellular	  L-­‐CysH	  generation	  
and	   SxC-­‐	   function	   appears	   to	   be	   the	   synthesis	   and	   efflux	   of	   GSH.	   Current	   evidence	  
suggests	  that	  extracellular	  L-­‐CysH	  is	  a	  metabolic	  product	  of	  extracellular	  GSH	  that,	  
once	   released	   from	   astrocytes	   can	   react:	   1.)	   non-­‐enzymatically	   with	   extracellular	  
cystine	  to	  form	  L-­‐CysH	  and	  GSH-­‐CysH,	  or	  2.)	  with	  γ-­‐glutamyltranspeptidase	  (γGGT)	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to	   produce	   cysteinylglycine,	   which	   is	   then	   subject	   to	   additional	   cleavage	   by	   a	  
dipeptidase	  into	  L-­‐CysH	  (Dringen	  et	  al.	  1999;	  Wang	  and	  Cynader	  2000).	  Therefore,	  
the	   generation	   of	   extracellular	   L-­‐CysH	   completes	   the	   cycle	   of	   thiol	   exchange	  
between	   astrocytes	   and	   neurons,	   briefly:	   L-­‐Cys2	   uptake	   via	   SxC-­‐	   determines	  
intracellular	  and	  subsequently,	  extracellular	  GSH	  levels.	  Extracellular	  L-­‐CysH	  arises	  
as	  a	  byproduct	  of	  reactions	  with	  GSH	  on	  the	  cell	  surface	  and	  extracellular	  space,	  and	  
neurons	   utilize	   extracellular	   L-­‐CysH	   for	   GSH	   synthesis	   (Fig.	   1.5).	   In	   this	  way	   glial	  
cells	   are	   primarily	   responsible	   for	   maintaining	   neuronal	   GSH	   level	   (Chen	   2001;	  
Drukarch	  et	  al.	  1997;	  Sagara	  et	  al.	  1993b).	  SxC-­‐	  has	  been	  found	  to	  localize	  primarily	  
on	  cellular	  membranes	  facing	  the	  CSF	  (Sato	  et	  al.	  2002),	  the	  origin	  of	  L-­‐Cys2	  for	  CNS	  
transport.	  This	  specialized	  localization	  and	  efficient	  activity	  of	  SxC-­‐	  may	  explain	  the	  
nearly	   undetectable	   levels	   of	   L-­‐Cys2	   in	   the	   CSF	   (Sagara	   et	   al.	   1993a;	   Wang	   and	  
Cynader	  2000).	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Figure	  1.5.	  The	  L-­‐Cys2/L-­‐CysH	  shuttle.	  The	  influx	  of	  L-­‐Cys2	  through	  SxC-­‐	  provides	  an	  
intracellular	   source	   of	   L-­‐CysH	   for	   GSH	   synthesis	   in	   glia.	   Upon	   release	   from	  
astrocytes,	  GSH	  can	  react	  nonenzymatically	  with	  extracellular	  L-­‐Cys2	  to	  form	  L-­‐CysH	  
and	  CysH-­‐GSH	  (1.),	  as	  well	  as	  undergo	  enzymatic	  catabolism	  (through	  the	  action	  of	  
γ-­‐glutamyltranspeptidase	  (GGT))	  (2.)	  to	  result	  in	  the	  formation	  of	  γ-­‐glutamyl	  amino	  
acids	  (if	  the	  nucleophilic	  acceptor	  is	  an	  amino	  acid	  (A.A)),	  γ-­‐glutamyl-­‐GSH	  (if	  GSH	  is	  
the	   acceptor),	   or	   L-­‐Glu	   (if	   H2O	   acts	   as	   the	   nucleophile)	   and	   L-­‐CysHGly,	   which	   is	  
subsequently	  cleaved	  by	  a	  dipeptidase.	  L-­‐CysH	  is	  not	  thought	  to	  be	  released	  by	  glia	  
directly	  (Wang	  2000).	  The	  L-­‐CysH	  produced	  as	  a	  result	  of	  reactions	  1.	  and/or	  2.	  then	  
enters	  neurons	  for	  use	  in	  the	  synthesis	  of	  GSH.	  
	  
1.2.1.2	  SxC-­	  confers	  neuroprotective	  function	  to	  astrocytes	  
Two	  main	  features	  of	  the	  CNS	  make	  it	  especially	  vulnerable	  to	  oxidative	  damage;	  (1)	  
the	   capacity	   for	   reactive	   oxygen	   species	   production	   is	   great,	   owing	   in	   part	   to	  
specialized	   ROS	   generating	   systems	   (i.e.	   MAO	   and	   nNOS)	   and	   the	   high	   aerobic	  
metabolic	   demands	  of	   the	  CNS,	   and	   (2)	   the	  neuronal	   specialization	  present	   in	   the	  
CNS	  is	  membrane	  based,	  the	  primary	  components	  of	  which	  (lipids	  and	  protein)	  are	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targets	  of	  oxidants	  (see	  Halliwell	  1992	  for	  review).	  Synaptic	  transmission,	  from	  the	  
establishment	   of	   the	   action	   potential	   to	   the	   termination	   of	   the	   signal	   is	   highly	  
dependent	  on	  membrane	  function	  and	  integrity.	  As	  the	  most	  abundant	  antioxidant	  
in	   the	   mammalian	   CNS,	   GSH	   serves	   to	   protect	   neurons	   from	   oxidative	   damage.	  
Accordingly,	   astrocytes	   play	   a	   critical	   neuroprotective	   role	   in	   the	   CNS	   as	   neurons	  
rely	  heavily	  upon	  astrocytes	  for	  GSH	  precursors	  (for	  review	  see	  Dringen	  et	  al.	  2000).	  
Using	   co-­‐culture	   systems,	   a	   number	   of	   studies	   have	   demonstrated	   the	   profound	  
ability	   of	   astrocytes	   to	   protect	   neurons	   from	  oxidative	   stress	   (H2O2)	   and	   L-­‐DOPA.	  
Indeed,	  a	  cellular	  ratio	  of	  as	  few	  as	  1	  astroglial	  cell	  to	  20	  neurons	  has	  been	  shown	  to	  
be	   protective	   against	   H2O2	   toxicity	   (Desagher	   1996).	   As	   the	   primary	   L-­‐Cys2	  
transport	   system	   in	   glia,	   it	   is	   perhaps	   not	   surprising	   that	   SxC-­‐	   function	   has	   been	  
directly	   linked	   to	   the	   neuroprotective	   capabilities	   of	   astrocytes.	   For	   instance,	   glia	  
are	   able	   to	  protect	   neurons	   from	  neurotoxic	   levels	   of	   L-­‐Glu	   (3	  mM)	  and	  H2O2	   (30	  
µM)	   following	   the	   expression	   of	   Phase	   II	   detoxification	   and	   antioxidant	   related	  
genes,	  including	  xCT	  (Shih	  et	  al.	  2003).	  While	  a	  diverse	  list	  of	  genes	  are	  known	  to	  be	  
induced	   in	   this	   scenario	   (xCT,	   GST,	   NQO1,	   HO-­‐1,	   γGCS,	   GSHS,	   GGT,	   etc),	   the	  
protective	   effect	   of	   glia	   is	   lost	   when	   GSH	   levels	   are	   depleted,	   suggesting	   that	   the	  
protective	   effects	   are	   linked	   to	   those	   genes	   involved	   in	   either	   the	   synthesis	   or	  
maintenance	   of	   GSH	   levels.	   In	   support	   of	   this,	   in	   vitro	   data	   has	   shown	   that	   xCT	  
overexpression	   alone	   is	   sufficient	   to	   achieve	   neuroprotection	   in	   these	   toxicity	  
paradigms	  (Shih	  et	  al.	  2006).	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1.2.2	  L-­Glu	  
In	  addition	   to	   the	  uptake	  of	  L-­‐Cys2	  by	  SxC-­‐	  and	   the	  subsequent	  production	  of	  GSH,	  
the	  other	  side	  of	  the	  exchange	  reaction,	  the	  export	  of	  L-­‐Glu,	  is	  now	  being	  shown	  to	  
be	   critically	   important	   for	   signaling	   processes	   within	   the	   CNS.	   A	   longstanding	  
problem	   for	  neurochemists	  has	  been	   resolving	   the	   cellular	   source	   and	   function	  of	  
extrasynaptic	   L-­‐Glu	   in	   the	   CNS.	   Recently,	   microdialysis	   studies	   in	   the	   nucleus	  
accumbens	  and	  striatum	  indicate	  that	  the	  primary	  source	  of	  in	  vivo	  extrasynaptic	  L-­‐
Glu	   is	   glial,	   specifically	   originating	   from	   the	   efflux	   activity	   of	   SxC-­‐.	   Through	   a	  
mechanism	   of	   tonic	   stimulation	   of	   mGlurR2/3	   receptors,	   L-­‐Glu	   is	   thought	   to	  
negatively	   regulate	   the	   synaptic	   release	   of	   both	   L-­‐Glu	   and	   dopamine	   (Baker	   et	   al.	  
2002b).	   This	   signaling	   capability	   has	   been	   best	   demonstrated	   by	   its	   effect	   on	  
withdrawal	  and	  relapse	  behavior	  in	  models	  of	  cocaine	  addiction	  (Baker	  et	  al.	  2003;	  
Moran	  et	  al.	  2005).	  	  
	  
1.3.	  Alteration	  of	  SxC-­	  function	  and	  neuropathology	  	  
Likely	  as	  a	  consequence	  of	  its	  contribution	  to	  both	  GSH	  and	  L-­‐Glu	  levels,	  situations	  
characterized	   by	   the	   loss	   of	   as	   well	   as	   increases	   in	   SxC-­‐	   activity	   are	   thought	   to	  
mediate	   a	   number	   of	   pathologies	   and	   clinical	   phenomena,	   including	  
neurodegeneration,	   the	   prevention	   and	   potentiation	   of	   addiction	   relapse,	   gliomas,	  
and	   neuroinflammation.	   For	   example,	   the	   loss	   of	   functional	   xCT	   protein	   during	  
development	  (Chintala	  et	  al.	  2005)	  has	  been	  associated	  with	  reduced	  brain	  size	  and	  
is	   associated	  with	   cortex	   thinning,	   striatum	   shrinkage,	   and	   ventricle	   enlargement	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(Shih	  et	  al.	  2006).	  There	  is	  also	  data	  to	  suggest	  that	  the	  motor	  neuron	  degeneration	  
and	   spastic	   paraparesis	   observed	   in	   human	   neurolathyrism	   may	   involve	   the	  
inhibition	   of	   SxC-­‐	   (Warren	   et	   al.	   2004).	   Additionally,	   withdrawal	   from	   chronic	  
cocaine	   administration	   reduces	   extracellular	   glutamate	   levels	   in	   the	   nucleus	  
accumbens	   of	   rats	   by	   decreasing	   SxC-­‐	   activity.	   This	   reduction	   in	   activity	   is	   in	   turn	  
associated	   with	   susceptibility	   to	   relapse.	   Conversely,	   increased	   SxC-­‐	   function	   is	  
capable	   of	   preventing	   cocaine-­‐induced	   drug	   seeking	   behavior	   (Baker	   et	   al.	   2003;	  
Moran	  et	  al.	  2005).	  	  
There	  are	  also	  situations	  where	  increases	  in	  SxC-­‐	  activity	  may	  be	  detrimental,	  such	  
as	  in	  cancers	  of	  the	  CNS.	  High-­‐grade	  tumors	  have	  increased	  metabolic	  demands	  for	  
glucose	   and	   oxygen	   and	   these	   features	   underlie	   both	   diagnostic	   and	   treatment	  
strategies.	  Likely	  as	  a	  result	  of	  higher	  metabolic	  demand,	  gliomas	  and	  astrocytomas	  
also	   exhibit	   increased	   levels	   of	   SxC-­‐	   activity	   (Ye	   et	   al.	   1999)	   and	   intracellular	  GSH	  
levels,	  both	  of	  which	  increase	  as	  the	  grade	  of	  the	  tumor	  increases	  (Sontheimer	  2008	  
for	   review).	   In	   fact,	   there	   is	   growing	   support	   for	   the	   idea	   that	   the	   proliferative	  
potential	  of	  a	  cell	  is	  related	  to	  the	  reduction	  state	  of	  cell,	  i.e.	  GSH	  levels	  could	  be	  part	  
of	  what	  directs	  a	  cell	  toward	  cancer	  (Nkabyo	  et	  al.	  2005).	  Increased	  GSH	  synthesis	  
enables	   tumors	   to	   maintain	   rapid	   metabolic	   rates	   by	   protecting	   cells	   from	  
endogenously	   produced	   reactive	   oxygen	   and	   nitrogen	   species,	   while	   at	   the	   same	  
time,	  by	  endowing	  tumors	  with	  enhanced	  resistance	  to	  radiation	  and	  chemotherapy	  
it	  frustrates	  certain	  therapeutic	  approaches	  that	  rely	  on	  overwhelming	  the	  GST	  and	  
GSH-­‐mediated	   mechanisms	   (Sontheimer	   2008).	   Additionally,	   extracellular	   L-­‐Glu	  
derived	   from	   increased	   SxC-­‐	   activity	   may	   contribute	   to	   the	   development	   of	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excitotoxicity	   and	   further	   promote	   cancer	   growth	   in	   the	   CNS	   (Choi	   and	   Rothman	  
1990;	  Chung	  et	  al.	  2005;	  Chung	  and	  Sontheimer	  2009;	  Lo	  et	   al.	  2008;	  Lyons	  et	   al.	  
2007).	   The	   release	   of	   L-­‐Glu	   via	   glioma	   cells	   has	   been	   linked	   to	   both	   peritumoral	  
seizures	   and	   excitotoxic	   injury	   and	   death	   to	   surrounding	   neurons,	   potentially	  
resulting	   in	   new	   space	   for	   increased	   tumor	   growth.	   Recent	   experiments	   using	  
treatments	   that	  selectively	   inhibit	  SxC-­‐	  have	  resulted	   in	  decreased	  L-­‐Glu	  efflux	  and	  
GSH	  levels	  and	  have	  successfully	  reduced	  tumor	  growth	  and	  volume	  in	  vivo	  (Chung	  
et	   al.	   2005;	   Chung	   and	   Sontheimer	   2009;	   Sontheimer	   2008).	   This	   association	  
between	  GSH	  and	  L-­‐Glu	  levels	  and	  glioma	  growth	  suggests	  a	  connection	  between	  a	  
cell’s	  proliferative	  capability	  and	  SxC-­‐	  activity	  (Nkabyo	  et	  al.	  2005).	  In	  support	  of	  this	  
it	   has	   been	   shown	   that	   cells	   (astrocytes,	   fibroblasts,	   and	  meningeal	   cells)	   isolated	  
from	  mice	  with	   deficient	   (Sato	   et	   al.	   2005)	   or	  mutated	   xCT	   (Shih	   et	   al.	   2006)	   are	  
unable	  to	  proliferate	  normally	  in	  culture,	  while	  the	  overexpression	  of	  SxC-­‐	  enables	  a	  
cell	  to	  evade	  cell	  cycle	  arrest	  (Lastro	  et	  al.	  2008).	  	  
Excessive	   glutamate	   release	  within	   the	   CNS,	   as	  well	   as	   outside	   the	   CNS,	  may	   also	  
contribute	  to	  pathology	  incurred	  by	  neuroinflammation	  and	  injury.	  Inflammation	  is	  
commonly	  considered	  to	  be	  a	  non-­‐specific	  protective	  response	  to	  antigen	  exposure	  
(for	   reviews	   see	   Haslett	   et	   al.	   1989;	   Ryan	   and	  Majno	   1977).	   However,	   acute	   and	  
chronic	   inflammation	   are	   also	   thought	   to	   contribute	   to	   pathology,	   including	   the	  
neurotoxicity	  observed	  in	  CNS	  infections	  and	  in	  certain	  neurodegenerative	  diseases	  
such	  as	  Alzheimer’s	  and	  Multiple	  Sclerosis	  (Matyszak	  1998;	  Skaper	  2007).	  Microglia,	  
the	  primary	  antigen	  presenting	  cells	  of	  the	  CNS,	  mediate	  the	  inflammatory	  response	  
in	  the	  CNS.	  In	  response	  to	  infection,	  infiltrating	  microglia/macrophages	  express	  high	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levels	  of	  SxC-­‐	   (Barger	  and	  Basile	  2001;	  Piani	  and	  Fontana	  1994)	  and	   in	  addition	  to	  
pro-­‐inflammatory	   factors,	   also	   release	   L-­‐Glu	   (Piani	   et	   al.	   1991).	   Therefore,	   the	  
excitotoxic	   damage	   and	   neuroinflammation	   often	   associated	   with	   CNS	   infections	  
and	   injury	   may	   be	   a	   consequence	   of	   glutamate	   release	   via	   SxC-­‐.	   Additionally,	  
excessive	  levels	  of	  L-­‐Glu	  levels	  outside	  the	  CNS	  may	  also	  direct	  the	  final	  outcome	  of	  
CNS	  infection/injury.	  Under	  normal	  conditions,	  activated	  T-­‐cells	  are	  thought	  to	  act	  
in	   a	   neuroprotective	   capacity	   following	   infection/injury	   (Pacheco	   et	   al.	   2007).	  
However,	  when	  L-­‐Glu	   is	   released	   from	  antigen	  presenting	   cells	   (APCs)	   via	   SxC-­‐	   (in	  
response	  to	  LPS	  or	  other	  inducers	  (Pacheco	  et	  al.	  2006;	  Sato	  et	  al.	  1995),	  it	  can	  bind	  
to	   mGluR5	   receptors	   located	   on	   resting	   T-­‐cells	   and	   subsequently	   impair	   T-­‐cell	  
activation,	   proliferation,	   and	   cytokine	   production	   (likely	   through	   the	   inhibition	   of	  
ERK	   and	   JNK	   and	   activation	   of	   NF-­‐KB)	   (Aandahl	   et	   al.	   2002).	   In	   this	   way,	   L-­‐Glu	  
promotes	   a	   high	   threshold	   for	   T-­‐cell	   activation.	   Therefore,	   deregulation	   of	   L-­‐Glu	  
release	   through	   SxC-­‐	   could	   promote	   neurotoxic	   outcomes	   in	   two	   ways,	   first,	   as	   a	  
result	   of	   microglia-­‐mediated	   inflammation	   and	   excitotoxicity,	   and	   second,	   by	  
mediating	  alterations	  in	  the	  protective	  T-­‐cell	  response.	  
In	  both	  cases,	  where	  either	  SxC-­‐-­‐activity	  and	  GSH	   levels	  are	  compromised	  or	  when	  
SxC-­‐	   and	   GSH	   production	   are	   robust,	   resolving	  whether	   or	   not	   the	   changes	   in	   SxC-­‐	  	  
(and	   consequently	   in	  GSH)	   are	   part	   of	   the	   disease	  mechanism	  or	   a	   compensatory	  
cellular	   response	   to	   reduce	   disease	   progression,	   remains	   a	   major	   challenge.	  
Additionally,	   depending	   on	   the	   overall	   effect	   (up-­‐	   or	   down-­‐regulation	   of	   SxC-­‐	   in	  
balance	  with	   other	  modulators	   of	   L-­‐Glu)	   of	   SxC-­‐	   function,	   the	   resulting	   changes	   in	  
GSH	  and	  L-­‐Glu	  levels	  can	  contribute	  to	  both	  therapeutic	  outcomes	  (neuroprotection,	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preventing	   oxidative	   stress	   and	   relapse	   behavior)	   as	   well	   as	   pathology	   (tumor	  
chemoresistance	  and	  growth,	  dysfunctional	  immune	  response,	  and	  susceptibility	  to	  
drug-­‐induced	   relapse).	  The	   tight	  balance	  between	  protection	  and	  pathology	  belies	  
the	  inherent	  challenges	  and	  opportunities	  for	  therapeutic	  intervention	  at	  the	  level	  of	  
GSH,	  L-­‐Glu	  and	  SxC-­‐.	  Therefore,	  in	  order	  to	  study	  SxC-­‐,	  an	  increased	  understanding	  as	  
to	   how	   SxC-­‐	   is	   regulated	   under	   normal	   conditions	   and	   in	   response	   to	   injury	   and	  
disease	  is	  important,	  and	  may	  yield	  information	  useful	  for	  therapeutic	  intervention	  
in	  neuropathology.	  
	  
1.4.	  Regulation	  of	  SxC-­	  
Given	  the	  link	  between	  GSH	  production	  and	  SxC-­‐	  activity,	  it	  is	  perhaps	  not	  surprising	  
that	  some	  of	  the	  first	  investigations	  into	  the	  induction	  of	  SxC-­‐	  involved	  the	  treatment	  
of	  cells	  with	  electrophilic	  agents	  in	  an	  attempt	  to	  deplete	  GSH	  (Bannai	  1984).	  In	  the	  
late	   1980’s	   and	   early	   1990’s	   research	   began	   to	   link	   the	   ability	   of	   electrophilic	  
compounds	   to	   induce	  phase	   II	   enzymes	   such	  as	  glutathione-­‐S-­‐transferases	   (GSTs),	  
NAD(P)H:	   quinone	   oxidoreductase	   (NQO1),	   epoxide	   hydrolase,	   and	   UDP	  
glucuronosyltransferases	  (Prochaska	  et	  al.	  1985;	  Spencer	  et	  al.	  1991;	  Talalay	  1989;	  
Talalay	   et	   al.	   1988).	   At	   around	   the	   same	   time,	   cis-­‐acting	   upstream	   enhancer	  
elements	   of	   mouse	   and	   rat	   liver	   GST	   genes	   that	   respond	   to	   these	   electrophilic	  
inducers	   were	   identified	   as	   nearly	   identical	   41-­‐bp	   segments	   termed	   the	   EpRE	  
(electrophile	   response	   element	   and	   the	   antioxidant-­‐response	   element	   (ARE)	  
respectively	   (Prestera	   et	   al.	   1993;	   Prestera	   and	   Talalay	   1995).	   These	   sites	   were	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shown	   to	   be	   distinct	   from	   AP-­‐1	   binding	   sites	   and	   tert-­‐butylhydroquinone	   (tBHQ)	  
was	   identified	   as	   one	   of	   a	   number	   of	   electrophiles	   shown	   to	   activate	   the	   EpRE	  
(Prestera	  and	  Talalay	  1995)	  via	  the	  transcription	  factor	  Nrf2	  (see	  Itoh	  et	  al.	  2004	  for	  
review).	   Consistent	   with	   the	   up-­‐regulation	   of	   GSH-­‐dependent	   enzymes	   and	   other	  
detoxification	  mechanisms,	  SXc-­‐	  was	  also	  among	  the	  proteins	  known	  to	  be	  regulated	  
through	  the	  EpRE	  (Ishii	  et	  al.	  2000;	  Sasaki	  et	  al.	  2002)(For	  a	  more	  detailed	  historical	  
discussion	   into	   the	   regulation	   of	   SxC-­‐	   by	   Nrf2	   and	   other	   transcription	   factors,	   see	  
appendix).	   	   However,	   this	   level	   of	   regulatory	   control	   appears	   to	   differ	   among	   cell	  
types	   (Qiang	   et	   al.	   2004;	   Sasaki	   et	   al.	   2002;	  Wang	   et	   al.	   2006)	   and	   accumulating	  
evidence	  suggests	  other	  mechanisms	  for	  SxC-­‐	  regulation	  exist.	  For	  example,	  similar	  
to	  tBHQ	  and	  other	  electrophiles,	  LPS	  is	  also	  capable	  of	  inducing	  SxC-­‐	  in	  macrophages	  
(Sato	   et	   al.	   1995).	  However,	   this	   same	   induction	   is	   also	   observed	   in	  macrophages	  
from	  mice	  deficient	  in	  Nrf2	  (Ishii	  et	  al.	  2000).	  In	  addition,	  there	  is	  now	  evidence	  that	  
the	  up-­‐regulation	  of	  SxC-­‐	  through	  L-­‐Cys2	  deprivation,	  assumed	  to	  be	  mediated	  by	  the	  
amino	   acid	   response	   element	   (AARE),	   is	   mediated	   not	   by	   Nrf2	   but	   by	   the	  
transcription	  factor	  ATF4	  (Lewerenz	  and	  Maher	  2009;	  Sato	  et	  al.	  2004).	  	  
SxC-­‐	   is	   also	   up-­‐regulated	   in	   primary	   astrocyte	   cultures	   following	   treatment	   with	  
dibutyryl-­‐cAMP	   (dbcAMP)	   (Gochenauer	   and	   Robinson	   2001)	   presumably	   through	  
the	  activation	  of	  the	  cAMP	  response	  element	  (CRE)	  (Daniel	  et	  al.	  1998).	  The	  addition	  
of	   dbcAMP	   to	   the	   culture	   medium	   results	   in	   a	   pronounced	   morphological	   and	  
functional	  differentiation	  of	  astrocytes	  that	  is	  thought	  to	  model	  a	  more	  in	  vivo	  cell-­‐
type	   (for	   reviews	   see	   Hertz	   et	   al.	   1998;	   Juurlink	   and	   Hertz	   1985),	   specifically	   a	  
reactive	   phenotype,	   a	   specialized	   glial	   subtype	   that	   accompany	   pathological	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situations	  such	  as	  stroke,	  MS,	  and	  neuroplasia	  (Daginakatte	  et	  al.	  2008).	  Astrocytes	  
cultured	  in	  the	  presence	  of	  dbcAMP	  express	  increased	  levels	  of	  GFAP	  (Le	  Prince	  et	  
al.	   1991),	   glutamate	   transporters	   (Schlag	   et	   al.	   1998;	   Swanson	   et	   al.	   1997),	  
glutamine	  synthetase	  (GS)(Stanimirovic	  et	  al.	  1999),	  GABA(A)	  receptors	  (Hosli	  et	  al.	  
1997),	  and	  SxC-­‐	  (Gochenauer	  and	  Robinson	  2001).	   It	   is	   likely	  that	  dbcAMP	  induces	  
changes	   in	   protoplasmic	   astrocytes	   similar	   to	   those	   resulting	   from	   noradrenergic	  
innervation	   in	   vivo	   (Hertz	   et	   al.	   1998)	   and	   the	   action	   of	   the	   pituitary	   adenylate	  
cyclase-­‐activating	   polypeptide	   (PACAP),	   a	   peptide	   synthesized	   by	   neurons	   which	  
selectively	   acts	   on	   astroglia	   involved	   in	   glutamate	   turnover	   (Figiel	   and	   Engele	  
2000).	  The	  functional	  consequences	  of	  dbcAMP-­‐induced	  changes	  in	  glial	  phenotype	  
may	   result	   in	   the	   enhancement	   of	   several	   neuroprotective	   and	   neurotrophic	  
functions,	   transforming	   these	  highly	  pleiotropic	   cells	   into	  a	   reactive	   cell	   type	  with	  
potentially	  increased	  abilities	  to	  promote	  neuron	  survival	  and	  recovery	  from	  injury	  
(for	   review	   see	   Escartin	   and	   Bonvento	   2008).	   For	   example,	   in	   the	   CNS,	  
glutamatergic	  neurotransmission	  is	  terminated	  predominantly	  by	  the	  rapid	  uptake	  
of	   synaptically	   released	   glutamate	   into	   astrocytes	   through	   the	   Na+-­‐dependent	  
excitatory	  amino	  acid	  transporters	  (EAAT1	  and	  EAAT2,	  also	  designated	  GLAST	  and	  
GLT-­‐1	   respectively).	   It	   is	   subsequently	   converted	   into	   glutamine	   by	   the	   enzyme	  
glutamine	   synthetase	   (GS).	   The	   only	   condition	   known	   to	   affect	   the	   expression	   of	  
glial	   glutamate	   transporters	   and	   GS	   is	   the	   co-­‐culturing	   of	   glia	   with	   neurons	   or	  
exposure	   to	   dbcAMP	   (Schlag	   et	   al.	   1998;	   Stanimirovic	   et	   al.	   1999;	   Swanson	   et	   al.	  
1997).	  In	  addition	  to	  EAATs	  and	  GS,	  astrocytes	  treated	  with	  dbcAMP	  are	  also	  known	  
to	   support	   increased	   neurite	   outgrowth	   (Miller	   et	   al.	   1994),	   exhibit	   increased	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immunoreactivity	  for	  the	  GABA(A)-­‐	  receptor	  (Hosli	  et	  al.	  1997).	  SxC-­‐	  may	  represent	  
another	   of	   these	   important	   functional	   changes	   brought	   about	   by	   culturing	  
astrocytes	  with	  dbcAMP.	  The	  changes	  in	  SxC-­‐	  seen	  upon	  dbcAMP	  administration	  may	  
represent	   an	   important	   strategy	   for	   synthesizing	   GSH	   and	   combating	   oxidative	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Chapter	  2.	  Rationale	  and	  Specific	  Aims	  
	  
2.1	  Rationale	  	  
Changes	   in	   GSH	   status	   have	   been	   associated	   with	   a	   number	   of	   pathological	  
conditions.	  Sufficient	  GSH	  concentrations	  in	  astrocytes	  are	  critical	  for	  the	  survival	  of	  
dopaminergic	   neurons,	   and	   neuronal	   GSH	   loss	   tends	   to	   correlate	   with	   disease	  
severity	   in	  Parkinson’s	  Disease	   (PD)	  patients	   (for	   review	  see	  Schulz	   et	   al.	   2000b).	  
Interestingly,	   GSH	   is	   also	   decreased	   during	   the	   preclinical	   asymptomatic	   phase	   of	  
the	  disease,	  suggesting	  an	  early	  role	  for	  GSH	  in	  pathogenesis.	  Decreases	  in	  GSH	  have	  
also	  been	  observed	  in	  schizophrenics	  in	  vivo	  as	  well	  as	  in	  in	  vitro	  models	  (Do	  et	  al.	  
2000)	   and	   polymorphisms	   in	   GSH-­‐metabolism	   and	   synthesis	   genes	   (i.e.	   GSTT1,	  
GCLC,	  and	  GCLM)	  are	  associated	  with	  increased	  susceptibility	  to	  the	  disorder	  (Berk	  
et	  al.	  2008).	  Conversely,	  in	  cancers	  of	  the	  CNS,	  GSH	  content	  increases	  as	  the	  glioma	  
grade	   increases	   (for	   review	  see	  Sontheimer	  2008).	  There	   is	  now	  growing	   support	  
for	   the	   idea	  that	   the	  proliferative	  potential	  of	  a	  cell	   is	  related	  to	  reduction	  state	  of	  
cell,	  i.e.	  GSH	  levels	  could	  be	  part	  of	  what	  directs	  a	  cell	  toward	  cancer	  (Nkabyo	  et	  al.	  
2005).	  	  
If	   a	   regulatory	   relationship	   exists	   between	   SxC-­‐	   and	   GSH	   levels,	   then	   the	   above	  
situations	   characterized	  by	  either	  a	  decrease	  or	  an	   increase	   in	  GSH	  may	   involve	  a	  
dysfunction	   in	   the	  GSH-­‐dependent	   regulatory	   control	   of	   SxC-­‐	   transport,	   potentially	  
altering	  the	  ability	  of	  the	  cell	  to	  act	  in	  a	  neuroprotective	  or	  neuropathological	  role.	  	  
Relatively	  little	  is	  known	  about	  the	  relationship	  between	  GSH	  levels	  and	  SxC-­‐	  activity	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in	  astrocytes	  and	  the	  data	  appears	  to	  be	  inconsistent	  both	  between	  and	  among	  cells	  
types.	   For	   example,	   GSH-­‐depletion	   has	   been	   reported	   to	   have	   no	   effect	   on	   L-­‐Cys2	  
transport	  in	  BHK21	  fibroblasts	  (Sasaki	  et	  al.	  2002)	  and	  rat	  kidney	  fibroblasts	  (Kang	  
and	  Enger	  1992),	  an	  inductive-­‐effect	  in	  astrocytes	  (no	  dbcAMP)	  (Allen	  et	  al.	  2001),	  
C1	   cells	   	   (Qiang	   et	   al.	   2004)	   and	  brain	   homegenates	   (Limon-­‐Pacheco	   et	   al.	   2007),	  
and	   a	   down-­‐regulatory	   effect	   in	   astrocytes	   (treated	   with	   dbcAMP)	   (Bender	   et	   al.	  
2000)	  and	  HAIN-­‐6	  lung	  fibroblasts	  (Bannai	  1984).	  We	  hypothesize	  that	  SxC-­‐,	  likely	  as	  
a	   consequence	   of	   its	   role	   in	   GSH	   supply	   in	   the	   CNS,	  will	   be	   regulated	   via	   GSH	   or	  
through	  a	  thiol-­‐mediated	  event,	  in	  primary	  astrocytes.	  This	  hypothesis	  is	  supported	  
by	   recent	   evidence	   suggesting	   the	   redox	   state	   of	   protein	   sulfhydryl	   moieties	   can	  
serve	   as	   signaling	   intermediates	   in	   a	   number	   of	   transcriptional	   activation	   events	  
(Ahn	  and	  Thiele	  2003;	  Delaunay	  et	  al.	  2002;	  Limon-­‐Pacheco	  et	  al.	  2007;	  Tachibana	  
et	  al.	  2009).	  
In	   the	   present	   study	   we	   used	   a	   dbcAMP	   treated	   astrocyte	   model	   to	   examine	   the	  
potential	   regulatory	   relationships	   between	   GSH	   levels	   and	   SxC-­‐	   activity.	   Astrocyte	  
cultures	  were	  treated	  with	  buthionine	  sulfoximine	  (BSO),	  an	  efficient	  and	  selective	  
strategy	  for	  GSH	  depletion	  (Meister	  1991)	  in	  culture	  models	  (BSO	  does	  not	  cross	  the	  
BBB)	   that	   avoids	   the	   complicating	   effects	   of	   other	  GSH-­‐depletion	   agents	   (i.e.	   non-­‐
selectivity	   and	   the	   propensity	   to	   activate	   GSH	   enzymes	   as	   a	   consequence	   of	  
electrophilic	  properties)	  (Bannai	  1984;	  Ishii	  et	  al.	  2000;	  Meister	  1991).	  Therefore	  by	  
using	   BSO	   to	   inhibit	   GSH	   synthesis	   directly,	   GSH	   was	   able	   to	   be	   depleted	   and	  
repleted	   directly,	   allowing	   the	   examination	   of	   how	   these	   changes	   affected	   SxC-­‐	   in	  
both	   cell	   phenotypes.	   	  We	   find	   that	   SxC-­‐	   activity	   in	   the	   dbcAMP-­‐treated	   cells	   was	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nearly	   7-­‐fold	   greater	   than	   in	   untreated	   astrocytes	   (100	   ±	   21	   and	   15	   ±	   4	  
pool/min/mg	   protein	   respectively)	   and	   that	   uptake	   was	   up-­‐regulated	   further	   in	  
dbcAMP-­‐treated	  cells	  (~3-­‐fold)	  following	  GSH	  depletion	  (BSO,	  500	  µM,	  24	  hrs).	  The	  
changes	  in	  SxC-­‐	  activity	  correlated	  with	  increases	  in	  both	  protein	  and	  mRNA	  levels	  of	  
the	  xCT	  subunit,	  an	  increase	  in	  the	  Vmax	  for	  L-­‐Glu	  (147	  ±	  5	  in	  untreated	  astrocytes	  to	  
350	  ±	  15	  pmol/min/mg	  protein	  in	  dbcAMP-­‐treated),	  and	  was	  linked	  temporally	  to	  
GSH	   levels.	  The	  effect	  of	  GSH	  depletion	  was	  not	  mimicked	  by	   tBHQ	  or	  oxidants	   in	  
this	  phenotype	  and	  was	  not	  preventable	  by	  exogenously	  added	  GSH.	  However,	   the	  
BSO-­‐effect	   was	   partially	   preventable	   by	   GSH-­‐ethyl	   ester	   (5	   mM)	   and	   N-­‐
acetylcysteine	   (NAC).	   The	   results	   suggest	   not	   only	   that	   the	   regulation	   of	   SxC-­‐	   is	  
highly	   dynamic	   and	   phenotype-­‐dependent,	   but	   also,	   in	   the	   instance	   of	   dbcAMP	  
differentiated	  astrocytes,	   that	  GSH	  plays	  a	  distinct	  role	   in	   the	  regulation	  of	  cystine	  
transport.	   	   This	   regulation	   may	   be	   particularly	   relevant	   in	   interpreting	   the	  
contributions	   and	   consequences	   of	   changes	   in	   GSH	   and	   SxC-­‐	   in	   CNS	   disease	  
mechanisms.	  
	  
2.2	  Specific	  Aims	  
Aim	   I.	   Evaluate	   the	   effect	   of	   GSH-­‐depletion	   on	   SxC-­‐	   activity	   in	   primary	   astrocytes	  
cultured	  with	  and	  without	  dbcAMP	  
	  
Specific	  Experiments:	  
1.	   Examine	   time	   dependence	   of	   dbcAMP	   treatment	   on	   SxC-­‐	   activity	   by	   employing	  
Na+-­‐independent	  [3H]-­‐L-­‐glutamate	  transport	  assays	  as	  a	  measure	  of	  SxC-­‐	  activity	  
2.	   Deplete	   GSH	   in	   both	   untreated	   and	   dbcAMP-­‐treated	   astrocytes	   and	   examine	  
differences	  in	  content	  and	  disappearance	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3.	  Determine	   if	   intracellular	  GSH	   levels	   in	  untreated	  and	  dbcAMP-­‐treated	  cells	  are	  
dependent	  on	  precursor	  (cysteine	  or	  cystine)	  availability	  or	  SxC-­‐	  inhibition	  
4.	   Quantify	   changes	   in	   SxC-­‐	   activity	   in	   GSH-­‐depleted	   astrocytes	   cultured	   with	   and	  
without	  dbcAMP	  
5.	  Determine	  if	  effect	  on	  SxC-­‐	  is	  dependent	  on	  dosing	  order	  of	  dbcAMP	  and/or	  BSO	  
6.	   Quantify	   changes	   using	   well	   characterized	   EpRE-­‐mediated	   inducers	   of	   SxC-­‐	  
activity	  i.e.	  tBHQ	  
7.	  Determine	  if	  changes	  in	  SxC-­‐	  are	  consistent	  with	  SxC-­‐	  pharmacology	  
8.	  Perform	  GSH-­‐depletion	  and	  uptake	  experiments	  under	  Na+-­‐dependent	  conditions	  
to	  see	  if	  changes	  are	  unique	  to	  Na+-­‐independent	  transport	  
	  
Hypothesis:	  	  
Astrocytes	   cultured	   in	   the	   presence	   of	   dbcAMP,	   likely	   as	   a	   consequence	   of	  
representing	  a	  more	  in	  vivo	  phenotype,	  exhibit	  a	  more	  sensitive	  feedback	  response	  
to	   GSH-­‐depletion	   by	   upregulating	   SxC-­‐	   activity	   in	   order	   to	   provide	   for	   more	  
intracellular	  cysteine	  for	  GSH	  synthesis.	  
	  




1.	   Perform	   a	   kinetic	   analysis	   of	   SxC-­‐	   transport	   to	   determine	   if	   the	   changes	   in	  
response	  to	  GSH-­‐depletion	  are	  related	  to	  the	  Vmax	  or	  Km	  of	  the	  transporter	  
2.	   Determine	   if	   GSH-­‐depletion	   results	   in	   functional	   changes	   in	   SxC-­‐	   -­‐	   mediated	  
accumulation	  of	  extracellular	  L-­‐glutamate	  in	  response	  to	  L-­‐cystine	  availability	  using	  
a	  fluorescence-­‐coupled	  assay	  
3.	  Determine	  whether	  or	  not	   the	  changes	   in	  SxC-­‐	  activity	  correspond	  to	  changes	   in	  
protein	  by	  performing	  immunoblots	  for	  both	  xCT	  and	  4F2hc	  
4.	  Analyze	  mRNA	  changes	  in	  response	  to	  GSH-­‐depletion	  using	  RT-­‐PCR	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5.	  Determine	  if	  SxC-­‐	  uptake	  recovers	  to	  control	  levels	  as	  GSH	  levels	  are	  restored	  
6.	  Determine	  the	  ability	  of	  GSH,	  GSH-­‐metabolites,	  thiols,	  and	  antioxidants	  to	  prevent	  
the	  effect	  of	  GSH-­‐depletion	  on	  SxC-­‐	  activity	  
7.	  Evaluate	  the	  relationship	  between	  the	  level	  of	  ROS	  production	  and	  GSH-­‐depletion	  
in	  dbcAMP-­‐treated	  astrocytes	  using	  carboxy-­‐H2DCFDA	  
8.	  Determine	  if	  the	  effect	  of	  BSO	  on	  SxC-­‐	  can	  be	  mimicked	  by	  ROS,	  electrophiles,	  and	  
L-­‐cystine	  uptake	  inhibition	  	  
	  
Hypothesis:	  	  
The	   change	   in	   SxC-­‐	   activity	   as	   a	   result	   of	   GSH-­‐depletion	  may	   be	   a	   consequence	   of	  
increased	  ROS	  and/or	   the	  removal	  of	  constitutive	   thiol-­‐mediated	  regulation	  of	   the	  
transporter.	   Cultures	   exposed	   to	  ROS,	   or	   transporter	   inhibition,	   should	  mimic	   the	  
effect	  of	  BSO	  and	  a	  pre-­‐treatment	  with	  GSH	  or	  GSH	  metabolites	  that	  bypass	  the	  BSO-­‐
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Chapter	  3.	  Materials	  and	  Methods	  
	  
3.1	  Cell	  culture	  and	  treatment	  regimen	  
Primary	  astrocytes	  were	  isolated	  and	  cultured	  from	  the	  cerebral	  cortices	  of	  1-­‐3	  day	  
old	  Sprague-­‐Dawley	  rats	  using	  a	  standard	  protocol	  (McCarthy	  and	  de	  Vellis	  1980).	  	  
Briefly,	   cortices	   were	   removed	   and	   dissociated	   by	   repeated	   trituration	   with	   a	  
borosilicate	  glass	  pipette	  and	  distributed	  into	  150	  cm2	  flasks	  containing	  DMEM/F12	  
(Invitrogen)	  supplemented	  with	  15%	  FBS	  (Hyclone).	  Following	  a	  24	  hr	  incubation,	  
the	  medium	  was	  replaced	  with	  DMEM/	  F12	  w/	  10%	  FBS	  to	  remove	  non-­‐adherent	  
cells.	  Cultures	  were	  maintained	  at	  37o	  C	  for	  approximately	  two	  weeks	  with	  medium	  
changes	   occurring	   twice	   a	   week	   until	   80%-­‐90%	   confluency	   was	   achieved.	   The	  
cultures	  were	  then	  shaken	  at	  280	  rpm	  for	  24	  hrs	  at	  37o	  C	  to	  remove	  contaminating	  
cell	   types.	   At	   100%	   confluency	   astrocyte	   cultures	  were	   plated	   as	   follows:	   12-­‐well	  
plates,	  3.0-­‐4.0	  x	  104	  cells/well;	  100	  mm	  dishes,	  3.0-­‐5.0	  x	  105	  cells/dish;	  and	  96-­‐well	  
plates,	   5.0	   x	   103	   cells/well.	   Ten	   to	   fourteen	   days	   post-­‐plating	   astrocytes	   reached	  
confluency	  and	  were	  designated	  as	  experimental	  day	  0.	  Starting	  on	  day	  0	  and	  every	  
3	  days	  afterward,	  culture	  media	  was	  changed	  and	  cultures	  either	  were	  given	  media	  
alone	  or	  media	  containing	  250	  mM	  dbcAMP	   for	  a	   total	  of	  7	  days.	  Unless	   indicated	  
otherwise,	   astrocytes	   receiving	  buthionine	   sulfoximine	   (BSO,	  Sigma-­‐Aldrich),	  GSH-­‐
ethyl	   ester	   (Sigma-­‐Aldrich),	   tert-­‐butylhydroquinone	   (tBHQ,	   Alfa	   Aesar),	   N-­‐
acetylcysteine	   (NAC,	   Sigma	   Aldrich),	   glutathione	   (GSH,	   Sigma	   Aldrich),	   or	   other	  
agents,	   were	   added	   to	   the	   astrocyte	   cultures	   for	   the	   final	   24	   hrs	   of	   the	   7-­‐day	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regimen.	   Astrocyte	   cultures	   were	   >95%	   positive	   for	   glial	   fibrillary	   acidic	   protein	  
(GFAP)	  and	  exhibited	  the	  well	  described	  polygonal	  to	  stellate	  change	  in	  morphology	  
following	  exposure	  to	  dbcAMP	  (Hertz	  et	  al.	  1998).	  	  
	  
3.2	  Transport	  activity	  assays	  
Sxc-­‐	   activity	  was	   assayed	   using	   a	   protocol	   previously	   described	   (Patel	   et	   al.	   2004;	  
Warren	  et	  al.	  2004).	  Briefly,	  on	  the	  day	  of	  the	  assay,	  growth	  media	  (DMEM/F12	  w/	  
10%	   FBS)	   was	   removed	   from	   cells	   grown	   in	   12-­‐well	   culture	   plates	   and	   replaced	  
with	   a	  Na+-­‐free	  buffer	   (mM),	  CaCl2	   (1.1),	  KCl	   (5.36),	  KH2PO4	   (0.77),	  MgSO4	   (0.71),	  
choline	  chloride	  (137.5),	  D-­‐glucose	  (11),	  HEPES	  (10),	  pH	  7.4.	  Following	  a	  5	  minute	  
pre-­‐incubation	  in	  Na+-­‐free	  buffer	  (30o	  C),	  the	  buffer	  was	  aspirated	  and	  replaced	  with	  
buffer	  containing	  100	  µM	  [3H]-­‐L-­‐glutamate	  (New	  England	  Nuclear).	  Following	  a	  5-­‐
min	   incubation	   at	   30o	   C,	   the	   assays	   were	   terminated	   by	   three	   sequential	   1-­‐mL	  
washes	  with	  ice-­‐cold	  buffer	  and	  then	  the	  cells	  were	  dissolved	  in	  1	  mL	  of	  0.4	  M	  NaOH	  
for	  24	  hrs.	  An	  aliquot	   (200	  µL)	  was	   transferred	   into	  a	  5-­‐mL	  glass	  scintillation	  vial	  
and	   neutralized	   with	   5	   µL	   glacial	   acetic	   acid,	   followed	   by	   the	   addition	   of	   3.5	  mL	  
Liquiscint	  scintillation	  fluid	  (National	  Diagnostics)	  to	  each	  sample.	  Incorporation	  of	  
radioactivity	   was	   quantified	   by	   liquid	   scintillation	   counting	   (LSC,	   Beckman	   LS	  
6500).	  All	   transport	  activity	  rates	  were	  normalized	   for	  protein	  determined	  via	   the	  
BCA	  method	   (Pierce).	   Values	   are	   reported	   as	  mean	   pmol/min/mg	   protein	   ±	   SEM	  
and	  are	  corrected	  for	  nonspecific	  uptake	  (e.g.,	   leakage	  and	  binding)	  by	  subtracting	  
the	  amount	  of	  [3H]-­‐L-­‐glutamate	  accumulated	  at	  4o	  C.	  To	  determine	  EAAT	  activity,	  a	  
protocol	   identical	   to	   the	   above	   was	   employed,	   with	   the	   exception	   of	   using	   the	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appropriate	  Na+-­‐dependent	  ionic	  conditions	  ((mM),	  KCl	  (5.3),	  KH2PO4	  (0.441),	  NaCl	  
(137.9),	  Na2HPO4	  (0.336),	  D-­‐glucose	  (11),	  CaCl2	  (1.1),	  MgSO4	  (0.71),	  HEPES	  (10),	  pH	  
7.4)	   and	   substrate	   ([3H]-­‐D-­‐aspartate,	   25	   µM).	   Maximal	   velocity	   and	   affinity	   (Km)	  
determinations	   were	   performed	   using	   nonlinear	   curve	   fitting	   analyses	  
(Kaleidagraph	  3.6.5).	  Data	  plots	  followed	  Michaelis-­‐Menten	  kinetics	  and	  were	  fitted	  
to	  the	  equation:	  y	  =	  m1*m0/(m2+m0).	  	  
	  
3.3	  Glutathione	  determination	  	  
Intracellular	   levels	   of	   GSH	   were	   quantified	   using	   an	   enzymatic-­‐recycling	   assay	  
described	   by	   Anderson	   (Anderson	   1985).	   At	   the	   incubation	   times	   indicated,	   the	  
culture	  medium	  was	  removed	  from	  astrocytes	  grown	  in	  12-­‐well	  plates	  and	  the	  cells	  
were	  rinsed	  2x	  with	  Dulbecco’s	  PBS.	  The	  plates	  were	  placed	  on	  ice	  and	  500	  µL	  ice-­‐
cold	   1%	   sulfosalicylic	   acid	   (Sigma-­‐Aldrich)	   was	   added	   to	   each	   well.	   Cells	   were	  
harvested	   by	   scraping.	   Samples	  were	   subjected	   to	   one	   freeze-­‐thaw	   cycle	   prior	   to	  
assaying	   for	   total	   GSH	   levels	   (GSH/GSSG).	   On	   the	   day	   of	   the	   assay,	   samples	  were	  
thawed	  and	  sonicated	  on	  ice	  for	  10	  seconds,	  and	  centrifuged	  (15,000	  x	  g,	  5	  minutes,	  
4o	  C).	  The	  assay	  was	  performed	  by	  combining	  40	  µL	  of	  sample	  supernatant,	  40	  µL	  2x	  
EDTA	  buffer	  (12.6	  mM	  EDTA	  tetrasodium	  salt,	  286	  mM	  sodium	  phosphate,	  pH	  7.8),	  
50	  µL	  2.4	  mM	  DTNB	  (Sigma-­‐Aldrich),	  50	  µL	  0.8	  mM	  NADPH	  (Sigma-­‐Aldrich),	  and	  20	  
µL	  GSH	  reductase	  (Roche)	  in	  individual	  wells	  of	  a	  96-­‐well	  microplate	  (Fisher).	  Final	  
concentrations	   were	   as	   follows:	   0.2	   mM	   NADPH,	   0.6	   mM	   DTNB,	   1.0	   U/mL	   GSH	  
reductase.	  The	  rate	  of	  TNB	  production	  was	  monitored	  at	  405	  nm	  for	  5	  min	  at	  30o	  C	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on	  a	  ThermoMax	  plate	  reader	  (Molecular	  Devices)	  and	  represents	  total	  glutathione	  
content.	   GSH	   values	   were	   normalized	   for	   protein	   using	   the	   BCA	   protein	   assay	  
(Pierce).	  	  
	  
3.4	  L-­Glutamate	  efflux	  determination	  	  
Fluorometric	   determination	   of	   extracellular	   L-­‐Glu	   was	   quantified	   using	   a	  
modification	   of	   a	   previously	   published	   procedure	   (Patel	   et	   al.	   2004).	   Confluent	  
monolayers	  of	  primary	  rat	  astrocytes	  grown	  in	  12-­‐well	  Costar	  tissue	  culture	  plates	  
were	   washed	   3X	   with	   a	   modified	   Krebs	   buffer	   ((mM),	   KCl	   (5.3),	   KH2PO4	   (0.441),	  
NaCl	   (137.9),	   Na2HPO4	   (0.336),	   D-­‐glucose	   (11),	   CaCl2	   (1.1),	   MgSO4	   (0.71),	   HEPES	  
(10),	   pH	   7.4)	   and	   then	   incubated	   in	   500	   µL	   of	   Na+-­‐free	   buffer	   with	   or	   without	  
substrates/inhibitors	   for	  15	  min	  at	  30o	  C.	  Following	  the	   incubation,	   the	  buffer	  was	  
removed	  from	  each	  well	  and	  stored	  at	  -­‐20oC	  for	  subsequent	  analysis	  of	  extracellular	  
[L-­‐Glu].	   Fluorometric	   determinations	   of	   L-­‐Glu	   were	   quantified	   using	   a	   Hitachi	   F-­‐
2000	   fluorescence	   spectrophotometer	   fitted	   with	   a	   thermo-­‐controlled	   cuvette	  
holder	   and	   a	   1	   cm2	   electronically	   driven	   magnetic	   stirrer	   platform.	   Following	  
equilibration	  of	  NADP+	  (1mM)	  and	  glutamate	  dehydrogenase	  (GDH,	  50U)	  in	  buffer	  
for	  200	  seconds,	  200	  µL	  of	   individual	   samples	  were	  added	   to	   the	   cuvette	   through	  
the	  injection	  port	  and	  the	  resulting	  NADPH	  fluorescence	  was	  recorded	  for	  300	  sec	  @	  
Ex	  370nm	  and	  Em	  450nm.	  Intracellular	  L-­‐Glu	  levels	  were	  determined	  by	  lysing	  cells	  
in	  0.1%	  Triton-­‐X	  for	  1	  hr	  at	  RT.	  Total	  nanomoles	  of	  intracellular	  or	  extracellular	  L-­‐
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Glu	   in	   the	   samples	   were	   then	   calculated	   using	   a	   standard	   curve	   generated	   from	  
fluorescence	  readings	  of	  sequential	  additions	  of	  4	  nanomoles	  L-­‐Glu.	  	  
	  
3.5	  Immunoblotting	  
Whole-­‐cell	   and	  nuclear	   lysate	   samples	  were	  prepared	   from	  astrocyte	  cultures	  and	  
analyzed	   for	   xCT,	  4F2hc,	   and	  Nrf2	  proteins.	   For	   the	  whole-­‐cell	   lysate	  preparation,	  
confluent	  cultures	  of	  astrocytes	  grown	  in	  100	  mm	  or	  150	  mm	  dishes	  were	  rinsed	  in	  
DPBS	   and	   cells	   were	   harvested	   by	   scraping	   in	   pre-­‐chilled	   DPBS/Cømplete	   lysis	  
buffer	   (Roche).	   	   The	   crude	   lysate	   was	   centrifuged	   @	   1200	   x	   g	   for	   10	   minutes,	  
resuspended	  in	  500	  µL	  DPBS/Cømplete,	  triturated	  on	  ice	  through	  a	  27G	  needle,	  and	  
following	   protein	   quantification	   (Bradford	   assay,	   Pierce),	   lysates	  were	   stored	   at	   –
20o	   C	   until	   use.	  Nuclear	   extracts	  were	   obtained	   from	  100	  mm	  dishes	   of	   confluent	  
astrocytes	   using	   NE-­‐PER	   reagents	   supplemented	   with	   HALT	   protease	   inhibitor	  
cocktail	  (Thermo	  Scientific).	   	  Nuclear	  lysate	  proteins	  were	  quantified	  with	  the	  BCA	  
assay	   (Pierce).	   Whole-­‐cell	   and	   nuclear	   lysate	   samples	   were	   subjected	   to	   SDS-­‐
polyacrylamide	  gel	  electrophoresis	  in	  Tris/glycine/SDS	  buffer	  using	  4-­‐15%	  Tris-­‐HCl	  
Ready	  Gels	  (Bio-­‐Rad).	  Prior	  to	  loading,	  thawed	  whole-­‐cell	  lysates	  were	  suspended	  in	  
2X	   reducing	   (containing	   2-­‐mercaptoethanol,	   (2ME))	   or	   non-­‐reducing	   Laemmli	  
Buffer	  (Bio-­‐Rad).	  Nuclear	  extract	  samples	  were	  boiled	  (2	  min,	  95o	  C)	  and	  10-­‐30	  µg	  of	  
protein	   (for	   both	   whole-­‐cell	   and	   nuclear	   samples)	   was	   loaded.	   Proteins	   were	  
transferred	   to	   a	   Hybond-­‐P	   PVDF	  membrane	   in	   Towbin	   buffer	   (Tris/glycine/20%	  
methanol	  pH	  8.3)	  and	  Kaleidoscope	  Molecular	  Weight	  Markers	  (Bio-­‐Rad)	  were	  used	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to	   monitor	   transfer.	   Immunoreactive	   proteins	   were	   visualized	   using	   enhanced	  
chemiluminescence	   (ECL)	   LumiGLO	   reagents	   (Cell	   Signaling)	   on	   a	   Fuji LAS-3000 
Intelligent Dark Box.	   Following	  detection,	  blots	  were	  often	   stripped	  using	  2%	  SDS,	  
100	   mM	   2ME,	   and	   62.5	   mM	   Tris-­‐HCl	   pH	   6.8	   (30	   min	   @	   50o	   C),	   blocked	   and	   re-­‐
probed	   for	   loading	   standards	   or	   other	   proteins.	   Density	   differences	   between	  
proteins	  of	   interest	  were	  determined	  with	  ImageGauge	  software.	  All	  samples	  were	  
background	   subtracted	   and	   normalized	   against	   GAPDH.	   Antibodies	   used	   in	   this	  
study	   included	  α-­‐xCT	   (1:500,	   generated/purified	   by	  Bethyl	   Labs),	  α-­‐CD98	   (1:200,	  
Santa	  Cruz	  Biotechnology	  (sc-­‐7094)),	  GAPDH	  (1:500,	  sc-­‐20357),	  α-­‐Nrf2	  (1:200,	  sc-­‐
722),	   donkey	   α-­‐rabbit	   IgG-­‐F(ab’)2-­‐HRP	   (1:2000,	   Cell	   Signaling)	   α-­‐biotin	   (1:1000,	  
Cell	   Signaling),	   donkey	   α-­‐goat	   IgG-­‐HRP	   (1:2000,	   SC-­‐2020).	   The	   rabbit	   xCT	  
polyclonal	   antibody	   was	   commercially	   generated	   and	   affinity	   purified	   (Bethyl	  
Laboratories)	   against	   a	   15	   a.a.	   synthetic	   peptide	   near	   the	   N-­‐terminus	   of	   hxCT	  
(MVRKPVVSTISKGGY)	   as	   described	   elsewhere	   (Kim	   et	   al.	   2001).	   Immunostaining	  
specific	   to	   xCT	  was	   present	   in	   positive	   controls	   (cell	   lines	   and	   oocyte	   expression	  
system)	  and	  were	  absent	  when	  preadsorbed	  with	  peptide	  (data	  not	  shown).	  
	  
3.6	  RNA	  extraction,	  cDNA	  synthesis,	  and	  real-­time	  PCR	  analysis	  
Total	   RNA	   was	   isolated	   from	   astrocytes	   grown	   in	   100mm	   dishes	   using	   TRIzol	  
Reagent	  	  (Invitrogen)	  followed	  by	  clean-­‐up	  using	  the	  E.Z.N.A	  Total	  RNA	  Kit	  I	  (Omega	  
Bio-­‐tek).	  Following	  RNA	  spectrophotometric	  quantification,	  the	  integrity	  of	  the	  RNA	  
was	  verified	  through	  denaturing	  agarose	  gel	  electrophoresis	  performed	  on	  1.5	  mg	  of	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RNA	  sample	  resulting	  in	  distinct	  28s	  and	  18s	  rRNA	  bands.	  A	  500	  ng	  aliquot	  of	  each	  
RNA	  sample	  was	  used	  to	  generate	  cDNA	  using	  the	  qScript	  cDNA	  Supermix	  (Quanta)	  
in	  a	  10	  µL	  reaction.	  The	  cDNA	  product	  was	  diluted	  5-­‐fold	  (50	  µL)	  and	  5	  µL	  of	  each	  
was	  used	   in	   subsequent	  PCR	   reactions.	  All	   real-­‐time	  primers	  were	  designed	  using	  
Roche	   ProbeFinder	   software.	   The	   following	   primers	   were	   used:	   xCT	  
(NM_001107673.2)	   fwd	   5’-­‐TCCATGAACGGTGGTGTGT-­‐3’	   rev	   5’-­‐
CCCTTCTCGAGATGCAACAT-­‐3’,	   4F2hc	   (AB015433.1)	   fwd	   5’-­‐
CAGCTATGGGGATGAGCTTG-­‐3’,	   rev	   5’-­‐TCATTCCACAGCATGATGAATGG-­‐3’;	   and	  
GAPDH	   (M17701.1)	   fwd	   5’-­‐AGCTGGTCATCAATGGGAAA-­‐3’,	   rev	   5’-­‐
ATTTGATGTTAGCGGGATCG-­‐3.’	   The	   25	   µL	   PCR	   reaction	   volume	   contained	   1x	  
Universal	  Master,	   the	  appropriate	  probe	  corresponding	  to	  the	  primer	  set	   from	  the	  
Roche	   Probefinder	   library,	   and	   primers	   at	   0.2	   mM	   final	   concentration.	   Real-­‐time	  
PCR	  reactions	  were	  performed	  on	  the	  BioRad	  iQ5	  for	  95o	  C	  for	  3	  minutes,	  95o	  C	  for	  
15	   seconds,	   and	   60o	   C	   for	   1	  minute.	   All	   signals	   were	   normalized	   to	   GAPDH	   from	  
identical	   cDNA	   preparations	   and	   fold	   changes	   in	   xCT	   or	   4F2hc	   expression	   were	  
determined	  from	  CT	  values	  using	  the	  formula	  2-­‐ΔΔCt.	  	  
 
3.7	  ROS	  detection	  
Carboxy-­‐H2DCFDA	   (Molecular	   Probes,	   Invitrogen,	   C400)	   was	   used	   as	   an	  
intracellular	  indicator	  of	  ROS	  production.	  Briefly,	  primary	  astrocytes	  were	  seeded	  @	  
5.0	   x	   103	   cells/well	   in	   black,	   clear-­‐bottomed	   96-­‐well	   plates	   (Corning).	   Astrocytes	  
were	  either	  untreated	  or	  given	  dbcAMP	  treatments	  for	  7-­‐days	  and	  received	  BSO	  or	  
BSO	  with	  antioxidants/thiols,	  for	  the	  final	  24hrs	  of	  the	  time	  course.	  On	  day	  7,	  cells	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were	  rinsed	  with	  DPBS	  2x,	  loaded	  with	  10	  µM	  carboxy-­‐H2DCFDA	  in	  200	  µL	  DPBS	  for	  
25	  min	  @	  37o	  C.	  Following	  the	  incubation,	  cells	  were	  rinsed	  2x	  in	  DPBS.	  Cells	  were	  
incubated	   in	  a	  Gemini	  Thermomax	  microplate	  reader	  (Molecular	  Devices)	  @	  30o	  C	  
with	   pre-­‐warmed	   DPBS.	   Multiple	   fluorescence	   readings	   (once	   every	   5	   minutes,	  
bottom	   read)	   were	   taken	   (Ex	   485λ,	   Em	   530λ)	   over	   a	   30	   min	   time	   course	   to	  
determine	   the	   suitable	   preincubation	   time	   for	   esterase	   hydrolysis.	   Optimal	   dye	  
response	   occurred	   following	   a	   5	  minute	   preincubation.	   Values	  were	   corrected	   for	  
autofluorescence	   by	   subtracting	   fluorescence	   units	   from	   dye-­‐free	   cell	   samples.	   A	  
cell-­‐free	   sample	   of	   DPBS	   containing	   Carboxy-­‐H2DCFDA	   was	   used	   to	   assess	  
background	  fluorescence	  due	  to	  spontaneous	  or	  atmospheric	  oxidation.	  Values	  are	  
reported	  in	  relative	  fluorescence	  units	  (RFUs).	  	  
	   34	  
Chapter	  4.	  Results	  
	  
	  
4.1	  SxC-­-­mediated	  uptake	  of	   [3H]-­L-­glutamate	   increases	   in	  primary	  astrocytes	  
treated	  with	  dbcAMP	  and	  BSO	  
To	  establish	  basal	  activity	  levels	  of	  system	  xC-­‐	  (SxC-­‐)	   in	  primary	  astrocytes,	  rates	  of	  
[3H]-­‐L-­‐glutamate	   uptake	   were	   determined	   under	   Na+-­‐independent	   conditions	   (i.e.	  
Na+-­‐free)	  in	  cultures	  maintained	  over	  a	  7-­‐day	  period	  in	  either	  normal	  growth	  media	  
(DMEM/F12	  w/	   10%	   FBS)	   or	  media	   supplemented	  with	   250	  µM	  dbcAMP	   (media	  
replaced	  every	  3	  days).	  The	  change	  in	  morphological	  phenotype	  induced	  by	  dbcAMP	  
is	  illustrated	  in	  Figure	  4.1.	  As	  described	  in	  Methods,	  uptake	  rates	  reported	  represent	  
specific	  transport;	   i.e.,	  values	  that	  have	  been	  corrected	  for	  non-­‐specific	  uptake	  and	  
leakage	  determined	  at	  4oC.	  Preliminary	  time-­‐course	  experiments	  demonstrated	  that	  
cultures	  grown	  in	  the	  presence	  of	  dbcAMP	  for	  7	  days	  exhibited	  the	  most	  robust	  and	  
reproducible	  changes	   in	  SxC-­‐	  activity	  (Fig.	  4.2).	  The	  specific	  uptake	   in	  the	  dbcAMP-­‐
treated	  cells	  at	  this	  time	  point	  was	  nearly	  7-­‐fold	  greater	  than	  in	  untreated	  astrocytes	  
(100	  ±	  21	  and	  15	  ±	  4	  pmol/min/mg	  protein	  respectively)(Fig.	  4.2).	   	  This	  observed	  
increase	   in	   SxC-­‐	   activity	   is	   consistent	   with	   previous	   reports	   (Gochenauer	   and	  
Robinson	  2001).	  	  With	  respect	  to	  the	  magnitude	  of	  the	  increase	  in	  uptake,	  it	  should	  
be	   noted	   that	   the	   relatively	   low	   levels	   of	   activity	   present	   in	   the	   astrocytes	   not	  
cultured	   with	   dbcAMP	   led	   to	   a	   high	   degree	   of	   variation	   between	   experiments,	  
making	   it	   harder	   to	   quantify	   absolute	   levels	   of	   specific	   uptake.	   	   For	   example,	   the	  
untreated	   astrocytes	   often	   exhibited	   non-­‐specific	   	   rates	   of	   activity	   (i.e.	   rates	  
measured	   at	   4oC)	   that	   were	   50%	   or	   more	   of	   the	   total	   activity	   (Fig.	   4.3).	   By	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comparison,	   dbcAMP-­‐treated	   cells	   had	   non-­‐specific	   rates	   that	   were	   typically	   less	  
than	  20%	  of	   total	  activity	   (Fig.	  4.3).	  This	   is	  not	  characteristic	  of	  all	   forms	  of	  L-­‐Glu	  
transport	  processes	  however	  as	  the	  total	   levels	  of	  uptake	  are	  much	  higher	  and	  the	  
relative	  levels	  of	  non-­‐specific	  rates	  are	  much	  lower	  under	  Na+-­‐dependent	  conditions	  
(to	   isolate	   EAAT	   activity)(Fig.	   4.4).	   Given	   these	   low	   levels	   of	   activity	   and	   the	  
observation	  that	  dbcAMP-­‐treated	  cells	  exhibit	  many	  of	  the	  morphological	  (Fig.	  4.1)	  
and	  biochemical	  markers	  that	  typify	  astrocytes	  in	  vivo	  (e.g.,	  increased	  expression	  of	  
EAATs,	  glutamine	  synthetase,	  GABA-­‐A,	  GFAP	  etc.	   (Daginakatte	  et	  al.	  2008;	  Hosli	  et	  
al.	  1997;	  Le	  Prince	  et	  al.	  1991;	  Miller	  et	  al.	  1994;	  Stanimirovic	  et	  al.	  1999;	  Swanson	  
et	  al.	  1997),	  subsequent	  experiments	  were	  primarily	  limited	  to	  astrocytes	  grown	  in	  
the	  presence	  of	  dbcAMP.	  	  
Astrocytes	  were	   cultured	   under	   the	   conditions	   described	   above	  with	   and	  without	  
the	   γ-­‐glutamylcysteine	   synthetase	   inhibitor	   BSO	   (500	   µM	   final	   concentration)	  
during	  the	  final	  24	  hrs	  of	  the	  treatment	  regimen	  to	  deplete	  intracellular	  GSH	  levels	  
(Griffith	   1982;	   Meister	   1991).	   As	   expected,	   the	   intracellular	   GSH	   content	   in	   both	  
untreated	   and	  dbcAMP-­‐treated	   astrocytes	   cultures	  was	   depleted	   to	   below	  10%	  of	  
that	   found	   in	   controls	   24	   hrs	   following	   an	   exchange	   of	  media	   that	   contained	  BSO	  
(Fig.	  4.5).	  There	  also	  appeared	  to	  be	  a	  difference	  in	  the	  rates	  at	  which	  the	  GSH	  levels	  
decreased	  during	  the	  early	  part	  of	  the	  time	  course.	  	  For	  instance,	  at	  2	  hrs	  following	  
the	  addition	  of	  BSO,	  intracellular	  GSH	  levels	  in	  untreated	  astrocytes	  were	  86	  ±	  2	  %	  
of	  control	  levels	  compared	  to	  62	  ±	  4	  %	  of	  control	  in	  the	  dbcAMP-­‐treated	  cells	  (p	  =	  
0.002)	  (Table	  4.1).	   	   It	   is	  also	  worth	  noting	  that	  at	  the	  start	  of	  the	  24	  hr	  incubation	  
(time	  0	  hr),	  the	  levels	  of	  intracellular	  GSH	  in	  the	  untreated	  astrocytes	  were	  less	  than	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those	  in	  the	  dbcAMP-­‐treated	  astrocytes	  (3.8	  ±	  0.4	  vs.	  5.2	  ±	  0.7	  nmol/mg	  protein,	  p	  =	  
0.006).	   	   Further,	   in	   those	   cultures	   not	   administered	   BSO,	   this	   difference	   grew	   to	  
almost	   2-­‐fold	   (192.0	   ±	   8.8	   %,	   p	   =	   0.004)	   in	   dbcAMP-­‐treated	   astrocytes	   24	   hrs	  
following	  the	  exchange	  of	  fresh	  media	  (Fig.	  4.5).	  The	  levels	  of	  L-­‐Cys2/L-­‐CysH	  in	  the	  
media	  (0.1	  mM	  each)	  appear	  to	  be	  saturating	  in	  terms	  of	  intracellular	  GSH	  synthesis	  
as	   additions	   of	   both	   (L-­‐Cys2:	   250	  µM	   -­‐	   500	  µM	  and	   L-­‐CysH:	   500	  µM	  –	   1000	  µM)	  
were	  unable	  to	  significantly	  influence	  GSH	  levels	  in	  both	  cell	  types	  (Table	  4.2).	  Also,	  
when	   both	   cell	   types	   were	   treated	   with	   the	   SxC-­‐	   inhibitor	   4S-­‐CPG,	   levels	   of	   total	  
intracellular	   GSH	   are	   equally	   decreased.	   Therefore,	   even	   as	   both	   untreated	   and	  
dbcAMP-­‐treated	   astrocytes	   exhibit	   marked	   differences	   in	   SxC-­‐	   activity,	   both	  
apparently	   rely	   equally	   on	   SxC-­‐-­‐mediated	   transport	   of	   L-­‐Cys2	   for	   the	   synthesis	   of	  
GSH.	  These	  findings	  demonstrate	  that	  intracellular	  GSH	  levels	  in	  primary	  astrocytes	  
are	  altered	  by	  both	  dbcAMP	  and	  BSO.	  Additionally,	  in	  dbcAMP-­‐treated	  astrocytes	  it	  
appears	   that	   GSH	   can	   be	   maintained	   at	   higher	   levels	   and	   may	   have	   a	   shorter	  
intracellular	   half-­‐life,	   possibly	   owing	   to	   increased	   efflux,	   utilization	   and/or	  
metabolism.	  As	  these	  results	  confirmed	  the	  intended	  effect	  of	  BSO	  on	  GSH	  levels	  in	  
both	   cell	  models,	   this	   same	   24	   hr	   BSO	   treatment	  was	   used	   to	   assess	   the	   effect	   of	  
GSH-­‐depletion	  on	  SxC-­‐-­‐mediated	  (i.e.	  Na+-­‐independent)	  [3H]-­‐L-­‐glutamate	  uptake.	  	  
When	  the	  dbcAMP-­‐treated	  cells	  were	  assayed	  for	  Na+-­‐independent	  [3H]-­‐L-­‐glutamate	  
transport,	   cultures	   administered	   BSO	   (500	   µM,	   24	   hrs,	   as	   described	   above)	  
exhibited	   a	   nearly	   3-­‐fold	   increase	   in	   uptake	   rates	   compared	   to	   cells	   that	   did	   not	  
(253	  ±	  29	  vs.	  100	  ±	  21	  pmol/min/mg	  protein)	  (Fig.	  4.6).	  	  The	  nearly	  complete	  loss	  of	  
intracellular	  GSH	  likely	  was	  necessary	  for	  the	  induction,	  as	  uptake	  was	  measured	  at	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an	  earlier	   time-­‐point	  characterized	  by	  a	  36%	   loss	  of	   intracellular	  GSH	  (Table	  4.1),	  
and	   no	   significant	   induction	   of	   Na+-­‐independent	   [3H]-­‐L-­‐glutamate	   transport	   was	  
observed.	  In	  order	  to	  verify	  that	  the	  increased	  transport	  activity	  could	  be	  attributed	  
to	  SxC-­‐,	  parallel	  assays	  were	  conducted	  in	  the	  presence	  of	  two	  well	  known	  inhibitors	  
of	  the	  transporter:	  the	  endogenous	  substrate	  L-­‐Cys2	  and	  the	  non-­‐substrate	  inhibitor	  
4-­‐S-­‐carboxyphenyl	  glycine	  (4S-­‐CPG)	  (Patel	  et	  al.	  2004).	   	  Under	   these	  conditions	  L-­‐
Cys2	  and	  4S-­‐CPG	  respectively	  reduced	  uptake	  to	  9	  ±	  2%	  and	  14	  	  ±	  4	  %	  of	  control	  (i.e.,	  
32	  ±	  12	  and	  36	  ±	  8	  pmol/min/mg	  protein),	  consistent	  with	  SxC-­‐	  pharmacology	  (Fig.	  
4.6).	  SxC-­‐	  activity	  in	  cultures	  depleted	  of	  GSH	  over	  an	  extended	  time	  course	  (7	  days	  
of	  BSO	  treatment	  vs.	  24hrs)	  were	  not	  significantly	  different	   than	   those	   treated	   for	  
only	   24	   hrs	   (259	   ±	   31	   and	   213	   ±	   32	   pmol/min/mg	   protein)	   (Fig.	   4.7).	   Thus,	   the	  
effect	  of	  GSH	  depletion	  by	  BSO	  (500	  µM)	  on	  SxC-­‐	  appears	  to	  be	  acute.	  The	  addition	  of	  
BSO	   also	   produced	   an	   increase	   in	   Na+-­‐independent	   [3H]-­‐L-­‐glutamate	   uptake	   in	  
astrocytes	   cultured	   in	   the	   absence	   of	   dbcAMP,	   although	   this	   increase	   was	   much	  
smaller	   in	  both	  absolute	  and	   relative	   terms	  compared	   to	   the	   increase	  observed	   in	  
the	  dbcAMP-­‐treated	  astrocytes,	  and	  should	  be	  interpreted	  within	  the	  context	  of	  the	  
lower	  signal	  to	  noise	  limitations	  mentioned	  above	  (Fig.	  4.6).	  
While	  the	  effects	  of	  dbcAMP	  on	  the	  glial	  expression	  and	  activity	  of	  the	  EAATs	  have	  
been	   reported	   (Schlag	   et	   al.	   1998;	   Swanson	   et	   al.	   1997),	   whether	   or	   not	   these	  
activities,	   like	   SxC-­‐,	   are	   also	   altered	  by	  GSH-­‐depletion	  has	  not	   been	   examined.	  The	  
EAAT	   subtypes	   EAAT1	   (GLAST)	   and	   EAAT2	   (GLT-­‐1)	   are	   the	   predominantly	  
expressed	   isoforms	   in	   cultured	   astrocytes	   (see	   Danbolt	   2001	   for	   review).	   	   EAAT	  
activity	  was	  quantified	  under	  Na+-­‐dependent	  conditions	  using	  [3H]-­‐D-­‐aspartate	  as	  a	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substrate	  (Koch	  et	  al.	  1999).	  As	  expected,	  rates	  of	  EAAT-­‐mediated	  uptake	  increased	  
in	   the	   astrocytes	   cultured	   in	   the	   presence	   of	   dbcAMP	   (240	   ±	   51	   vs.	   686	   ±	   84	  
pmol/min/mg).	  	  In	  contrast	  to	  SxC-­‐	  	  activity,	  however,	  a	  similar	  addition	  of	  BSO	  (500	  
µM,	   24hrs)	   did	   not	   produce	   significant	   differences	   in	   either	   the	   untreated	   or	  
dbcAMP-­‐treated	   astrocytes	   (251	   ±	   58	   and	   738	   ±	   76	   pmol/min/mg,	   respectively)	  
(Fig.	  4.8).	   	  We	  also	   tested	   the	  effect	  of	  GSH-­‐depletion	  on	  a	  highly	  plastic	  neuronal	  
“stem	  cell-­‐like”	  cell	   line	  (C17.2	  cells)	  (see	  Steindler	  2002	  for	  review)	  and	  observed	  
no	   significant	   change	   in	   SxC-­‐	   activity	   (Fig.	   4.9).	   Taken	   together,	   these	   results	  
demonstrate	   that	   SxC-­‐,	   but	  not	   the	  EAAT	   system,	   is	   sensitive	   to	   alterations	   in	  GSH	  
levels	   in	   primary	   astrocytes.	   Additionally,	   while	   both	   SxC-­‐	   and	   EAAT	   systems	  
increase	   as	   a	   result	   of	   dbcAMP	   administration,	   the	   relative	   percentage	   of	   SxC-­‐	  
activity	  to	  the	  total	  activity	  contributed	  by	  both	  systems	  differs	  markedly	  between	  
the	  two	  phenotypes:	  SxC-­‐	  comprises	  ~6%	  of	  the	  total	  uptake	  in	  untreated	  astrocytes,	  
increases	   to	   ~15%	   following	   dbcAMP	   treatment,	   and	   upon	   the	   addition	   of	   BSO	  
increases	  to	  ~26%	  of	  the	  total	  uptake	  (Table	  4.3).	  	  
	  
4.2	  The	  actions	  of	  dbcAMP	  and	  BSO	  on	  SxC-­	  activity	  are	  distinct	  from	  those	  of	  
the	  EpRE/ARE	  activator	  tBHQ	  	  
	  One	  of	  the	  best-­‐studied	  models	  of	  SxC-­‐	  induction	  involves	  the	  use	  of	  an	  electrophile,	  
such	   as	   tBHQ,	   to	   activate	   the	   EpRE/ARE	   (Electrophile	   Response	  
Element/Antioxidant	  Response	  Element)-­‐linked	  signal	   transduction	  pathway	  (Ishii	  
et	  al.	  2000;	  Shih	  et	  al.	  2003).	  	  Characterized	  in	  a	  variety	  of	  cells,	  including	  astrocytes,	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this	   pathway	   leads	   to	   the	   upregulation	   of	   proteins	   associated	   with	   oxidative	  
protection	   and	   xenobiotic	   detoxification,	   including:	   e.g.,	   glutathione-­‐S-­‐transferases	  
(GSTs),	   NAD(P)H:	   quinone	   oxidoreductase	   (NQO1),	   epoxide	   hydrolase,	   and	   UDP	  
glucuronosyltransferases	   (for	   reveiw	   see	   Itoh	   et	   al.	   2004;	   Talalay	   et	   al.	   1995).	  	  
Consistent	   with	   previous	   reports,	   the	   addition	   of	   tBHQ	   (24	   hrs)	   increased	   SxC-­‐	  
activity,	   intracellular	   GSH	   levels,	   and	   the	   nuclear	   presence	   of	   the	   EpRE/ARE-­‐
associated	  transcription	  factor	  Nrf2	  in	  the	  astrocytes	  that	  had	  been	  cultured	  in	  the	  
absence	  of	  dbcAMP	  (Fig.	  4.10,	  Fig.	  4.12A,B).	   	  In	  contrast,	  when	  tBHQ	  was	  added	  to	  
the	   astrocytes	   which	   had	   been	   differentiated	   with	   dbcAMP	   (and	   exhibited	   much	  
higher	  levels	  of	  SxC-­‐	  activity	  compared	  to	  the	  untreated	  cells),	  a	  further	  increase	  in	  
activity	  was	  not	  observed	  (Fig.	  4.11,	  Fig.	  4.12A).	  Similarly,	  the	  intracellular	  levels	  of	  
GSH	   in	   the	   astrocytes	   cultured	  with	   dbcAMP	  were	   also	   comparatively	   higher,	   but	  
were	  not	  significantly	  changed	  following	  exposure	  of	  tBHQ	  (Fig.	  4.12B).	  The	  fact	  that	  
nuclear	   levels	  of	  Nrf2	  protein	   increased	   in	   these	  cells,	   suggests	   that	  any	  change	   in	  
SxC-­‐	  activity	  was	  either	  masked	  by	  the	  much	  larger	  increase	  induced	  by	  dbcAMP	  or	  
was	  limited	  in	  a	  way	  potentially	  related	  to	  dbcAMP	  induced	  cellular	  changes.	  Taken	  
together,	   these	   results	   demonstrate	   that	   the	   phenotypic	   changes	   induced	   by	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4.3	   BSO-­induced	   depletion	   of	   GSH	   increases	   the	   Vmax	   but	   not	   Km	   for	   L-­
glutamate	  transport	  by	  SxC-­	  in	  the	  dbcAMP-­treated	  astrocytes	  
To	   further	   define	   the	   nature	   of	   the	   observed	   increase	   in	   SxC-­‐	   activity	   in	   dbcAMP-­‐
treated	  astrocytes	  depleted	  of	  GSH	  with	  BSO,	  a	  more	  detailed	  kinetic	  analysis	  was	  
carried	   out	   (Fig.	   4.13).	   Rates	   of	   SxC-­‐-­‐mediated,	   Na+-­‐independent	   uptake	   were	  
quantified	   as	   a	   function	   of	   the	   concentration	   of	   L-­‐Glu	   and	   then	   analyzed	   by	  
nonlinear	   curve	   fitting	   using	   the	  Michaelis-­‐Menten	   equation	   (KaleidaGraph	   3.6.5).	  	  
The	  use	  of	  L-­‐Glu	  as	  a	  substrate	  avoids	  the	  complications	  associated	  with	  L-­‐Cys2	  (e.g.,	  
disulfide	  exchange,	  reduction,	  solubility,	  availability,	  etc.).	   	  The	  resulting	  Vmax	  value	  
for	  L-­‐Glu	  uptake	  in	  the	  dbcAMP-­‐treated	  astrocytes	  increased	  from	  147	  ±	  5	  to	  350	  ±	  
15	  pmol/min/mg	  protein	  in	  those	  cultures	  exposed	  to	  BSO	  (500	  µM)	  for	  24hrs.	   	  In	  
contrast,	  the	  Km	  values	  determined	  for	  L-­‐Glu	  in	  the	  presence	  or	  absence	  of	  BSO	  were	  
not	  significantly	  different	  from	  one	  another	  (i.e.,	  17	  ±	  2	  and	  25	  ±	  5	  µM,	  respectively),	  
consistent	   with	   values	   previously	   reported	   in	   dbcAMP-­‐treated	   astrocytes	  
(Gochenauer	   and	   Robinson	   2001)	   and	   significantly	   lower	   (i.e.	   reflecting	   a	   higher	  
affinity	  for	  substrate),	  than	  those	  reported	  in	  glioma,	  astrocytoma,	  and	  other	  tumor	  
lines	  (~50-­‐100	  µM)	  (Bannai	  et	  al.	  1989;	  Patel	  et	  al.	  2004).	  
	  
4.4	  BSO	  mediated	  increase	  in	  SxC-­	  activity	  results	  in	  extracellular	  L-­glutamate	  
accumulation	  	  
To	  complement	  these	  direct	  studies	  on	  the	  SxC-­‐-­‐mediated	  uptake	  of	  [3H]-­‐L-­‐Glu	  into	  
the	  cultured	  astrocytes,	  the	  ability	  of	  L-­‐Cys2	  to	  exchange	  with	  (i.e.,	  produce	  an	  efflux	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of)	   intracellular	   L-­‐Glu	   was	   quantified	   using	   a	   glutamate	   dehydrogenase	  
(GDH)/NADP+	   coupled	   assay	   (Patel	   et	   al.	   2004).	   L-­‐Glu	   present	   in	   the	   buffer	   is	  
enzymatically	   converted	   to	   α-­‐ketoglutarate	   by	   GDH,	   which	   generates	   a	   molar	  
equivalent	   of	   NADPH	   that	   can	   be	   quantified	   fluorometrically	   (Ex	   370λ,	   Em	   450λ)	  
and	  equated	  to	  L-­‐Glu	  concentrations	  with	  a	  standard	  curve.	  	  Thus,	  dbcAMP-­‐treated	  
astrocytes	   (12-­‐well	  plates,	   total	   volume	  =	  0.5	  mL/well)	  were	   rinsed	   free	  of	  media	  
and	   incubated	   for	  15	  minutes	   in	  Na+-­‐free	  buffer	  containing	  various	  concentrations	  
of	  L-­‐Cys2.	  	  As	  shown	  in	  Figure	  4.14,	  L-­‐Cys2	  produced	  a	  dose-­‐dependent	  increase	  the	  
amount	   of	   L-­‐Glu	   present	   in	   Na+-­‐free	   buffer	   surrounding	   the	   dbcAMP-­‐treated	  
astrocytes.	  	  When	  L-­‐Cys2	  was	  incubated	  with	  astrocytes	  that	  were	  also	  treated	  with	  
BSO	  (500	  µM,	  24hrs)	  it	  produced	  a	  markedly	  greater	  accumulation	  of	  extracellular	  
L-­‐Glu,	  consistent	  with	  the	  increased	  activity	  of	  SxC-­‐.	  	  For	  example,	  following	  a	  15	  min	  
incubation	   with	   100	   µM	   L-­‐Cys2,	   the	   extracellular	   concentration	   of	   L-­‐Glu	   in	   the	  
dbcAMP-­‐treated	   astrocytes	   reached	   6.3	   ±	   0.1 µΜ 	   in	   the	   cells	   also	   given	  BSO,	   but	  
only	   3.0	   ±	   0.8 µΜ	   in	   those	   that	   did	   not.	   	   In	   both	   instances	   the	   extracellular	  
accumulation	   of	   L-­‐Glu	   was	   inhibited	   by	   the	   inclusion	   of	   4S-­‐CPG	   (100	   µM)	   in	  
combination	  with	  the	  L-­‐Cys2	  (Fig.	  4.14).	  	  Additionally	  the	  increased	  extracellular	  L-­‐
Glu	  levels	  	  in	  the	  dbcAMP	  +	  BSO-­‐treated	  astrocytes	  is	  still	  below	  the	  levels	  observed	  
in	   a	   cell	   line	   known	   to	   exhibit	   pathogenically	   high	   levels	   of	   SxC-­‐	   activity	   (SNB19	  
human	  glioblastoma	  cells)	  (Fig.	  4.15).	  	  These	  findings	  demonstrate	  that	  increases	  in	  
SxC-­‐	   activity	   following	   GSH-­‐depletion	   can	   be	   quantified	   as	   a	   function	   of	   either	   the	  
direct	  uptake	  of	   [3H]-­‐L-­‐Glu	   	   (Fig.	   4.6	   and	  Fig.	   4.13)	  or	   the	  physiologically	   relevant	  
exchange	  of	  extracellular	  L-­‐Cys2	  for	  intracellular	  L-­‐Glu.	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4.5	  BSO-­induced	  changes	  in	  SxC-­	  protein	  and	  mRNA	  expression	  
SxC-­‐	   is	   heterodimer	   compromised	   of	   a	   non-­‐glycosylated	   xCT	   light	   chain	   (~35-­‐55	  
kDa)	  (Kim	  et	  al.	  2001;	  Lim	  et	  al.	  2005;	  Mysona	  et	  al.	  2009;	  Shih	  et	  al.	  2006)	  and	  a	  
glycosylated	  4F2hc	  (aka	  CD98)	  heavy	  chain	  (80-­‐90	  kDa)	  (Kim	  et	  al.	  2001;	  Nakamura	  
et	  al.	  1999;	  Shih	  et	  al.	  2006).	   	  To	  determine	  if	   the	  observed	  increase	   in	  Vmax	   in	  the	  
astrocytes	  following	  the	  BSO-­‐mediated	  depletion	  of	  GSH	  is	  associated	  with	  changes	  
in	   protein	   expression	   of	   xCT	   and/or	   4F2hc,	   immunoblot	   experiments	   were	  
performed.	  	  As	  the	  two	  subunits	  of	  the	  heterodimer	  are	  disulphide-­‐linked,	  analyses	  
of	   whole	   cell	   lysates	   were	   carried	   out	   in	   the	   presence	   and	   absence	   of	   2-­‐
mercaptoethanol	  (2ME)	  (Figure	  4.16).	  In	  lysates	  prepared	  from	  astrocytes	  cultured	  
in	  the	  absence	  of	  dbcAMP	  and	  exhibiting	  minimal	  activity,	  the	  xCT	  antibody	  revealed	  
two	  distinct	  bands	  at	  an	  estimated	  molecular	  weight	  of	  50	  kDa	  and	  45	  kDa	  under	  
both	  non-­‐reducing	  and	  reducing	  conditions	  (Fig.	  4.16A:	  lanes	  1	  and	  2).	  	  In	  addition	  
to	  these	  same	  50	  kDa	  and	  45	  kDa	  bands,	  lysates	  prepared	  from	  the	  dbcAMP-­‐treated	  
astrocytes	  under	  non-­‐reducing	  conditions	  also	  exhibited	  a	  very	  prominent	  band	  at	  
135	  kDa	   (Fig.	  4.16A,	   lane	  3),	   consistent	  with	   the	  molecular	  weight	  of	   the	  xCT	  and	  
4F2hc	  heterodimer.	  Under	  reducing	  conditions,	  the	  loss	  of	  the	  135	  kDa	  band	  in	  the	  
dbcAMP-­‐treated	  astrocytes	  coincided	  with	   the	  appearance	  of	  a	  prominent	  band	  at	  
40	   kDa	   (Fig.	   4.16A,	   lane	   4).	   	   This	  multiple	   banding	   pattern	   has	   been	   documented	  
previously	   (Kim	  et	  al.	  2001;	  Lim	  et	  al.	  2005;	  Mysona	  et	  al.	  2009;	  Shih	  et	  al.	  2006)	  
and	  all	  bands	  were	  undetectable	  in	  peptide	  blocking	  control	  experiments	  (data	  not	  
shown).	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  Taken	   together,	   the	   appearance	   of	   the	   135	   kDa	   band	   under	   non-­‐reducing	  
conditions	   and	   the	   40	   kDa	   band	   in	   the	   presence	   of	   2ME	   correlated	   with	   the	  
increased	  SxC-­‐	  activity	  observed	  in	  the	  uptake	  and	  exchange	  assays	  carried	  out	  with	  
the	   dbcAMP-­‐treated	   astrocytes	   (Fig.	   4.6	   and	   4.14).	   	   When	   a	   similar	   analysis	   was	  
carried	  out	  on	   the	  dbcAMP-­‐treated	  astrocytes	   that	  had	  been	  depleted	  of	  GSH	  with	  
BSO	  over	  24hrs,	  a	  similar	  banding	  pattern	  was	  observed	  (Fig.	  4.16A,	  lanes	  5	  and	  6).	  	  
While	  there	  was	  only	  a	  small	  change	  (~1.2-­‐fold	  increase,	  as	  judged	  by	  densitometry)	  
in	  the	  amount	  of	  the	  135	  kDa	  band	  in	  these	  cells,	  there	  was	  a	  more	  marked	  increase	  
in	  the	  expression	  of	  the	  40	  kDa	  band	  under	  reducing	  conditions	  (Fig.	  4.16A,	  lane	  6,	  
~1.8	  fold)	  in	  the	  cells	  depleted	  of	  GSH.	  	  
A	  parallel	  series	  of	   immunoblot	  studies	  were	  also	  carried	  out	  to	  examine	  potential	  
changes	   in	   the	   expression	  of	   4F2hc.	   	   In	   the	   astrocytes	   that	   had	  been	   treated	  with	  
dbcAMP,	  the	  4F2hc	  antibody	  also	  revealed	  a	  prominent	  band	  at	  135	  kDa	  under	  non-­‐
reducing	  conditions	   (Fig.	  4.16B,	   lane	  3),	   consistent	  with	   the	  presence	  of	   the	   intact	  
heterodimer.	   	  As	  was	  observed	  with	  xCT,	   the	   inclusion	  of	  2ME	   led	   the	   loss	  of	   this	  
135	  kDa	  band	  and	  the	  appearance	  of	  the	  monomer,	   in	  this	   instance	  at	  a	  molecular	  
weight	  appropriate	  for	  4F2hc,	  ~90	  kDa	  (Fig.	  4.16B,	  lane	  4).	   	  Astrocytes	  cultured	  in	  
the	  absence	  of	  dbcAMP	  exhibited	  only	  very	  faint	  bands	  at	  135	  kDa	  and	  90	  kDa	  under	  
either	  reducing	  or	  non-­‐reducing	  conditions,	  respectively	  (Fig.	  4.16B,	  lanes	  1	  and	  2).	  	  
In	   the	  dbcAMP-­‐treated	  astrocytes	   that	  had	  been	  depleted	  of	  GSH	  with	  BSO,	  4F2hc	  
staining	   density	   for	   the	   135	   kDa	   band	   (non-­‐reducing	   conditions)	   was	   essentially	  
unchanged	  (~0.9-­‐fold),	  while	   the	  90	  kDa	  band	  (reducing)	  exhibited	  only	  a	  modest	  
increase	  of	  ~1.3-­‐fold.	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The	   findings	   from	   the	   immunoblots	   suggest	   that	   the	   increased	   presence	   of	   the	  
heterodimer	   (and	   the	   coincident	   gain	   in	   activity)	   in	   cells	   cultured	   with	   dbcAMP	  
correlates	   to	   the	   increased	   expression	   of	   both	   the	   xCT	   and	   4F2hc,	   rather	   than	   a	  
single,	   rate-­‐limiting,	   subunit.	   	   The	   further	   increase	   in	   SxC-­‐	   activity	   observed	   in	   the	  
dbcAMP-­‐treated	  astrocytes	  that	  had	  also	  been	  depleted	  of	  GSH	  with	  BSO,	  correlated	  
to	   a	   greater	   extent	  with	   the	   increased	   expression	   of	   the	   xCT	   subunit,	   rather	   then	  
either	  4F2hc	  or	  the	  heterodimer.	  	  To	  further	  investigate	  the	  nature	  of	  the	  change	  in	  
expression	  BSO	  (500	  µM,	  24	  hrs)	  was	  added	  to	  the	  dbcAMP-­‐treated	  astrocytes	  in	  the	  
presence	   and	   absence	   of	   50	   µM	   cycloheximide	   (Fig.	   4.17).	   	   While	   the	   astrocytes	  
administered	   BSO	   and	   cycloheximide	   still	   exhibited	   a	   higher	   level	   of	   transporter	  
activity	  (145	  ±	  8.1	  %	  of	  control	  astrocytes),	  the	  activity	  was	  markedly	  reduced	  from	  
the	   levels	   observed	   in	   the	   absence	   of	   cycloheximide	   (256	   ±	   25	   %	   of	   control),	  
indicating	  that	  protein	  synthesis	  was,	  in	  part,	  required	  for	  the	  increased	  SxC-­‐	  activity	  
observed	  following	  GSH	  depletion.	  
The	  results	  of	  Q-­‐PCR	  analysis	  of	  xCT	  and	  4F2hc	  cDNA	   in	  response	   to	  dbcAMP	  and	  
BSO	  in	  primary	  astrocytes	  are	  depicted	  in	  Figure	  4.18.	  Following	  6	  days	   in	  culture	  
with	   or	  without	   dbcAMP,	   a	   subset	   of	   cells	  were	   treated	  with	   500	  µM	  BSO	   for	   an	  
additional	   24	   hrs	   and	  RNA	  was	   extracted.	   RT-­‐PCR	   and	  Q-­‐PCR	  were	   performed	   as	  
described	  in	  Methods.	  A	  69.5	  ±	  9.6	  fold	  increase	  in	  xCT	  message	  in	  astrocytes	  grown	  
in	   the	   presence	   of	   dbcAMP	  was	   observed	  when	   compared	   to	   untreated	   cells	   (Fig.	  
4.18).	   	   Following	   the	   24hr	   exposure	   to	   BSO,	   xCT	   expression	   increased	   by	   an	  
additional	   2-­‐fold	   (144.0	   ±	   5.8	   fold)	   as	   compared	   to	   the	   cultures	   treated	   with	  
dbcAMP	  alone.	  	  In	  contrast,	  comparable	  changes	  in	  the	  levels	  of	  4F2hc	  mRNA	  were	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not	  observed	   in	  response	  to	  either	  dbcAMP	  or	  dbcAMP/BSO	  (Fig.	  4.18).	   	   Indeed,	  a	  
small	  decrease	  (-­‐1.3	  ±	  0.07	  fold)	  in	  expression	  of	  4F2hc	  message	  occurred	  following	  
dbcAMP	  treatment.	  	  When	  these	  cultures	  were	  also	  depleted	  of	  GSH	  with	  BSO,	  4F2hc	  
mRNA	  increased	  only	  by	  1.3	  ±	  0.1	  fold.	  	  These	  data	  indicate	  that	  the	  extent	  to	  which	  
dbcAMP	   and	   dbcAMP/BSO	   treatments	   result	   in	   increased	   mRNA	   and	   protein	  
expression	  differs	  between	  the	  protein	  subunits	  of	  SxC-­‐.	  Whereas	  the	  expression	  of	  
the	   active	   heterodimer	  may	  potentially	   result	   from	   increased	  protein	   synthesis	   of	  
both	  subunits,	  at	  this	  time	  point	  (24	  hrs	  post-­‐BSO)	  only	  xCT	  message	  was	  increased.	  	  
	  
4.6	   Restoration	   of	   intracellular	   GSH	   levels	   in	   BSO-­treated	   cells	   restores	   SxC-­	  
activity	  to	  control	  levels	  
The	  association	  between	  intracellular	  GSH	  concentrations	  and	  SxC-­‐	  activity	  was	  next	  
examined	  by	  quantifying	  transporter	  activity	  as	  GSH	  was	  restored	  to	  normal	  levels.	  
To	   do	   this,	   cultures	   were	   first	   treated	   in	   a	   manner	   identical	   to	   the	   depletion	  
experiments,	  culturing	  cells	  for	  7	  days	  in	  the	  presence	  dbcAMP	  and	  BSO	  for	  the	  final	  
24	  hrs.	  The	   cultures	  were	   then	   rinsed	  and	   supplied	  with	   fresh	  media	   free	  of	  BSO.	  	  
SxC-­‐	  activity	  and	  intracellular	  GSH	  levels	  were	  then	  monitored	  as	  the	  cells	  recovered	  
from	  γ-­‐glutamylcysteine	  synthetase	   inhibition,	  most	   likely	  as	  a	  consequence	  of	   the	  
de	   novo	   synthesis	   of	   new	   γ-­‐glutamylcysteine	   synthetase.	   	   The	   results	   depicted	   in	  
Figure	  4.19	  demonstrate	  a	  close	  temporal	  correlation	  between	  GSH	  levels	  and	  SxC-­‐	  
activity.	   	   For	   example,	   at	   72	  hrs	  post	  BSO	   treatment,	  GSH	   levels	  had	   recovered	   to	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51%	  of	  control	  while	  SxC-­‐	  activity	  had	  decreased	  to	  143%	  of	  control.	  By	  120	  hrs,	  GSH	  
levels	  and	  SxC-­‐	  activity	  had	  both	  reached	  nearly	  100%	  of	  control	  values.	  	  
As	   an	   alternative	   to	   allowing	   GSH	   levels	   to	   be	   replenished	   as	   a	   function	   of	   BSO	  
washout	   and	   the	   restoration	   of	   γ-­‐glutamylcysteine	   synthetase	   activity,	   a	   series	   of	  
compounds,	  including	  GSH	  precursors,	  derivatives,	  and	  antioxidants,	  were	  added	  to	  
the	  cultures	  at	  the	  same	  time	  as	  the	  BSO	  to	  test	  their	  ability	  to	  prevent	  the	  increase	  
in	   SxC-­‐	   activity	   and	   thereby	  provide	   insight	   into	  whether	   or	   not	   it	   is	   specifically	   a	  
decrease	  in	  GSH	  that	  triggers	  the	  SxC-­‐	  response	  (Figs.	  4.20,	  4.21,	  and	  4.23).	  	  Inclusion	  
of	   GSH	   (which	   is	   not	   transported	   into	   cells	   intact)	   or	   γ-­‐glutamylcysteine	   in	   the	  
extracellular	  media	   produced	   only	   a	  modest	   decrease	   in	   the	   amount	   SxC-­‐	   activity	  
normally	   induced	   by	   the	   BSO-­‐mediated	   depletion	   (Fig.	   4.20).	   In	   contrast,	   the	   cell	  
permeable	  GSH	   “pro-­‐drug”	  GSH-­‐ethyl	   ester	  proved	   to	  be	  one	  of	   the	  most	   effective	  
compounds	   in	  preventing	   the	  upregulation,	   reducing	   the	  observed	   increase	   in	  SxC-­‐	  
activity	  from	  262	  ±	  21	  %	  to	  146	  ±	  5	  %	  of	  control	  (Fig.	  4.20).	  Total	  GSH	  levels	  were	  
measured	   to	   confirm	   that	   the	   addition	   of	   GSH-­‐ethyl	   ester	   did	   indeed	   result	   in	  
increased	  intracellular	  GSH.	  Treatment	  with	  1	  mM	  GSH-­‐E	  resulted	  in	  increased	  GSH	  
levels	  (2.2	  ±	  0.4	  nmol/mg	  protein)	  as	  compared	  to	  levels	  from	  BSO-­‐treated	  cultures	  
(0.9	  ±	  0.3	  nmol/mg	  protein).	  	  This	  increase	  was	  enhanced	  in	  cells	  treated	  with	  5	  mM	  
GSH-­‐E	   (11.2	   ±	   0.8	   nmol/mg	   protein)	   and	   surpassed	   even	   the	   levels	   of	   GSH	   in	  
cultures	  grown	  in	  the	  absence	  of	  BSO	  (6.9	  ±	  2.3	  nmol/mg	  protein).	  As	  a	  consequence	  
of	   GSH	   efflux,	   the	   restoration	   of	   intracellular	   GSH	   by	   GSH-­‐E	   treatment	   may	   also	  
contribute	  to	  increased	  levels	  of	  extracellular	  GSH,	  which	  conceptually	  could	  also	  be	  
responsible	  for	  preventing	  the	  effect	  of	  BSO,	  although	  this	  possibility	  appeared	  to	  be	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ruled	   out	   by	   earlier	   experiments.	  However,	   these	   experiments	  were	  performed	   in	  
cells	  without	  the	  inhibition	  of	  γ-­‐glutamyltranspeptidase	  (γ-­‐GT),	  a	  membrane-­‐bound	  
enzyme	  that	  catabolizes	  γ-­‐glutamyl	  bonds	  (in	  the	  case	  of	  GSH	  catabolism	  the	  result	  
is	   the	  production	  of	  L-­‐cysteinylglycine	  and	  often	  a	  γ-­‐amino	  acid,	  depending	  on	   the	  
nucleophilic	   acceptor	   (Tate	   and	   Meister	   1981)).	   Therefore,	   exogenously	   applied	  
GSH	   could	   have	   been	   metabolized	   by	   this	   enzyme,	   potentially	   resulting	   in	   the	  
formation	  and	  transport	  of	  γ-­‐glutamylcysteine	  (a	  known	  side	  product	  of	  the	  enzyme	  
when	  both	  GSH	  and	  L-­‐Cys2	  are	  present)	  which	  could	  bypass	  the	  BSO	  block	  on	  GSH	  
synthesis	  and	  thereby	  prevent	  the	  induction	  of	  uptake	  (Tate	  and	  Meister	  1981).	  To	  
isolate	   this	   potential	   component	   of	   GSH	   treatment,	   cultures	   were	   treated	   with	   a	  
known	  inhibitor	  (Acivicin,	  AC)	  of	  γ-­‐GT	  2	  hours	  prior	  to	  the	  addition	  of	  GSH	  and	  BSO.	  
Through	   transpeptidase	   inhibition,	   co-­‐treatment	   with	   GSH	   essentially	   avoids	  
metabolism	  and	  remains	  in	  the	  extracellular	  space.	  A	  significant	  level	  of	  prevention	  
was	  achieved	  by	  this	  strategy,	  more	  so	  than	  with	  GSH	  alone	  and	  similar	  to	  the	  effect	  
of	  GSH-­‐E	  at	   the	  same	  concentration	  (Fig.	  4.20).	  While	   this	  may	   indeed	  represent	  a	  
GSH-­‐mediated	   extracellular	   mechanism	   of	   prevention,	   further	   experiments	   are	  
needed	   to	   substantiate	   that	   extracellular	   GSH	   levels	   remained	   intact	   during	   the	  
duration	   of	   the	   experiment.	   The	   cell	   permeable	   cysteine	   “pro-­‐drug”	   N-­‐acetyl-­‐
cysteine	   produced	   an	   effect	   essentially	   indistinguishable	   from	   GSH-­‐ethyl	   ester,	  
where	   its	   inclusion	  also	   limited	   the	   increase	   in	  SxC-­‐	   to	  147	  ±	  12	  %	  of	   control	   (Fig.	  
4.21).	  	  To	  test	  whether	  or	  not	  the	  effect	  of	  the	  GSH-­‐ethyl	  ester	  treatment	  was	  related	  
specifically	   to	   GSH	   or	   to	   a	   non-­‐selective	   thiol-­‐mediated	   effect,	   the	   effect	   of	   2-­‐
mercaptoethanol	   (2ME)	  was	  also	   tested.	  2ME	   is	   thought	   to	  react	  catalytically	  with	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extracellular	  L-­‐Cys2	  forming	  a	  disulphide	  of	  L-­‐CysH-­‐2ME	  that	  then	  likely	  enters	  the	  
cell	   through	   neutral	   amino	   acid	   transporters	   (Sato	   et	   al.	   2005;	   Shih	   et	   al.	   2006).	  
Astrocyte	  growth	  media	  contains	  both	  L-­‐Cys2	  and	  L-­‐CysH	  (100	  µM	  each),	  therefore	  
both	   2ME	   alone	   and	   in	   combination	   with	   higher	   doses	   of	   both	   amino	   acids	   was	  
tested.	  No	  significant	  prevention	  in	  the	  BSO-­‐induced	  induction	  of	  SxC-­‐	  was	  observed	  
in	  either	  the	  case	  of	  2ME	  alone	  or	  2ME	  and	  additional	  L-­‐Cys2	  (500	  µM),	  however	  a	  
significant	   increase	   in	   activity	   was	   observed	   when	   L-­‐CysH	   was	   applied	   in	  
combination	  with	  2ME.	  Other	  reducing	  agents	  and	  thiols	  including	  DTT	  and	  L-­‐Cys2	  
(without	  2ME	  present),	  were	  also	  tested	  and	  aside	  from	  a	  modest	  change	  with	  DTT,	  
showed	  no	  significant	  decrease	  in	  activity	  compared	  to	  cells	  treated	  with	  BSO	  alone	  
(Fig.	  4.21).	  	  
As	  it	  is	  likely	  that	  the	  BSO-­‐mediated	  depletion	  of	  GSH	  also	  leads	  to	  an	  increase	  in	  the	  
presence	  of	  reactive	  oxygen	  species	  (ROS),	  which	  in	  turn	  could	  serve	  as	  an	  initiator	  
for	  SxC-­‐	  induction,	  the	  ROS	  levels	  present	  in	  astrocytes	  were	  quantified	  with	  an	  ROS–
sensitive	   dye	   (Carboxy-­‐H2DCFDA).	   As	   reported	   in	   Figure	   4.22,	   the	   BSO-­‐mediated	  
depletion	  of	  GSH	  that	  lead	  to	  an	  increase	  in	  SxC-­‐	  activity	  was	  accompanied	  by	  about	  a	  
3-­‐fold	   increase	   in	   intracellular	   ROS-­‐associated	   fluorescence.	   This	   increase	   in	  
fluorescence	  was	  not	  observed	  when	  GSH-­‐ethyl	   ester	   (5	  mM)	  was	   included	   in	   the	  
extracellular	   media.	   	   As	   an	   additional	   control,	   H2O2	   (50	   µM)	   was	   added	   to	   the	  
astrocytes	   culture	   to	   enhance	   the	   generation	   of	   ROS.	   	   Interestingly,	   while	   the	  
addition	  of	  the	  H2O2	  produced	  a	  similar	  increase	  in	  ROS-­‐associated	  fluorescence	  as	  
was	  observed	  in	  the	  BSO	  treated	  cultures,	  the	  SxC-­‐	  activity	  in	  these	  astrocytes	  did	  not	  
change	   (Figure	   4.24).	   	   Further,	   the	   concomitant	   treatment	   of	   cultures	   with	   the	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antioxidants	   Vitamin	   C	   (1	   mM),	   Trolox	   (100	   µM),	   R-­‐α-­‐Lipoic	   acid	   (50	   µM),	   and	  
catalase	   (3000	   U/mL)	   and	   BSO	   was	   ineffective	   in	   preventing	   the	   BSO-­‐mediated	  
increase	  in	  SxC-­‐	  activity	  (Fig.	  4.23).	  These	  findings	  suggest	  that	  the	  induction	  of	  SxC-­‐	  
in	  the	  dbcAMP-­‐differentiated	  culture	  was	  likely	  not	  the	  result	  of	  a	  general	  increase	  
in	   ROS	   species	   within	   the	   astrocytes.	   Another	   consequence	   of	   γ-­‐glutamylcysteine	  
synthetase	   inhibition	   by	   BSO	   in	   dbcAMP-­‐treated	   cultures	   is	   the	   intracellular	  
accumulation	   of	   the	   amino	   acids	   L-­‐Glu	   and	   L-­‐Cys2,	   the	   substrates	   for	   the	   γ-­‐
glutamylcysteine	  synthetase	  reaction.	  While	  the	  addition	  of	  L-­‐Cys2	  (0.5mM)	  had	  no	  
influence	   on	   SxC-­‐	   activity	   compared	   to	   controls,	   L-­‐Glu	   (1mM)	   led	   to	   an	   increase	  
similar	  to	  that	  of	  BSO	  on	  SxC-­‐	  activity	  (Fig.	  4.24).	  As	  a	  substrate	  for	  SxC-­‐,	  L-­‐Glu	  likely	  
inhibited	  the	  uptake	  of	  extracellular	  L-­‐Cys2,	  effectively	  leading	  to	  a	  drop	  in	  GSH	  and	  
mimicking	   the	   effect	   of	  BSO	  on	  GSH	  not	   the	  high	   intracellular	   levels	   of	   L-­‐Glu.	  The	  
oxidized	   form	   of	   GSH	   (GSSG,	   1mM),	   and	   electrophiles	   diethylmaleate	   (DEM,	   100	  
µM),	   tBHQ,	   and	   sodium	  arsenite	  were	   unable	   to	   fully	   reproduce	   the	   effect	   of	   BSO	  
(Fig.	  4.24).	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Figure	   4.1.	   GFAP	   staining	   of	   primary	   astrocytes.	   Cells	   were	   cultured	   on	   poly-­‐L-­‐
lysine-­‐treated	  glass	  coverslips	  (18mm)	  in	  Costar	  12-­‐well	  culture	  plates	  either	  in	  the	  
absence	  (A)	  or	  presence	  (B)	  of	  dbcAMP	  (250µM)	  for	  7	  days.	  Astrocytes	  were	  fixed	  
with	   4%	   paraformaldehyde,	   permeabilized	   in	   PBS/0.2%	   Triton-­‐X	   for	   5	   min,	   and	  
blocked	  in	  3%	  BSA/PBS	  prior	  to	  anti-­‐GFAP	  incubation	  (1:500,	  overnight,	  4oC,	  DAKO	  
Z0334).	   The	   secondary	   antibody	   used	   was	   Alexaflour	   488	   (1:500,	   Molecular	  
Probes).	   A	   nuclear	   counterstain	   (DAPI	   300nM)	   was	   applied	   prior	   to	   imaging.	  	  
Images	  are	  @	  20x	  magnification.	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Figure	  4.2.	  Time	  dependent	  effect	  of	  dbcAMP	  on	  Na+-­‐independent	  [3H]-­‐L-­‐glutamate	  
uptake	   in	   primary	   astrocytes.	   At	   95%-­‐100%	   confluency,	   astrocytes	   in	   12-­‐well	  
culture	   dishes	   (Costar,	   Corning)	   were	   designated	   day	   0	   and	   given	   fresh	   culture	  
media	  (DMEM/F12	  with	  10%	  FBS)	  alone	  or	  media	  supplemented	  with	  250	  µM	  (F.V.)	  
dbcAMP.	  Culture	  media	  was	  changed	  accordingly	  every	  three	  days	  (days	  0,	  3,	  6)	  and	  
radiolabeled	   uptake	   assays	   performed	   on	   days	   1,	   4,	   and	   7.	   	   Data	   presented	  
represents	  n	  =	  8-­‐13.	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Figure	   4.3.	   Total,	   non-­‐specific,	   and	   specific	   Na+-­‐independent	   [3H]-­‐L-­‐glutamate	  
uptake	   activity	   in	   untreated	   and	   dbcAMP-­‐treated	   astrocytes.	   Cells	   were	   grown	   in	  
culture	  media	  (DMEM/F12	  with	  10%	  FBS)	  supplemented	  with	  250	  µM	  dbcAMP	  for	  
7	   days	   prior	   to	   performing	   uptake	   experiments	   with	   (see	   Methods).	   There	   is	   no	  
significant	  difference	  between	  total	  and	  non-­‐specific	  rates	  of	  L-­‐glutamate	  uptake	  in	  
untreated	   astrocytes	   as	   determined	   by	   t-­‐test.	   	   Data	   represent	   mean	   rates	  
(pmol/min/mg	  protein)	  ±	  SEM,	  n	  =	  11-­‐13.	  *P	  <0.0001	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Figure	  4.4.	  	  Total,	  non-­‐specific,	  and	  specific	  Na+-­‐dependent	  [3H]-­‐D-­‐aspartate	  uptake	  
activity	   in	   untreated	   and	   dbcAMP-­‐treated	   astrocytes.	   Cells	  were	   grown	   in	   culture	  
media	  (DMEM/F12	  with	  10%	  FBS)	  supplemented	  with	  250	  µM	  dbcAMP	  for	  7	  days	  
prior	  to	  performing	  uptake	  experiments	  (see	  Methods).	  Data	  represent	  mean	  rates	  
(pmol/min/mg	  protein)	  ±	  SEM,	  n	  =	  3-­‐12.	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Figure	  4.5.	  The	  effect	  of	  BSO	  on	  GSH	  levels	  in	  primary	  astrocytes.	  Following	  7	  days	  
in	  culture	  with	  or	  without	  dbcAMP	  (250	  µM),	  BSO	  (500	  µM)	  was	  administered	  and	  
astrocytes	   were	   assayed	   for	   intracellular	   GSH	   0,	   2,	   6,	   and	   24	   hrs	   later.	   Data	  
represents	  mean	  GSH	  levels	  (nmol/mg	  protein)	  ±	  SEM,	  n	  =	  3-­‐13.	  *	  P	  <0.0001	  when	  
comparing	   intracellular	   GSH	   levels	   at	   time	   0hr	   to	   levels	   following	   24	   hrs	   of	   BSO-­‐
treatment	  in	  both	  untreated	  and	  dbcAMP	  treated	  cultures.	  **	  P	  =	  0.006	  and	  ***	  P	  =	  
0.004	   when	   comparing	   GSH	   levels	   in	   untreated	   to	   dbcAMP-­‐treated	   astrocytes,	   at	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Figure	   4.6.	   Na+-­‐	   independent	   [3H]-­‐L-­‐glutamate	   uptake	   in	   primary	   astrocytes	  
exposed	   to	   dbcAMP	   (7	   days)	   and	   BSO	   (500	   µM,	   final	   24hrs).	   Pharmacological	  
inhibition	  of	  [3H]-­‐L-­‐glutamate	  uptake	  activity	  by	  L-­‐cystine	  (500	  µM)	  or	  4S-­‐CPG	  (100	  
µM)	  occurred	  in	  cells	  treated	  with	  BSO.	  Data	  represents	  mean	  rates	  (pmol/min/mg)	  
±	  SEM,	  n	  =	  3-­‐8.	  *	  P=0.006,	  **	  P<0.0001	  as	  determined	  by	  student	  t-­‐test.	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Figure	  4.7.	  The	  effect	  of	  GSH	  depletion	  by	  BSO	  (500	  µM)	  on	  Na+-­‐independent	  [3H]-­‐
L-­‐glutamate	   uptake.	   Astrocytes	   in	   culture	   were	   treated	   with	   dbcAMP	   alone	   for	   7	  
days	  (1),	  a	  combination	  of	  dbcAMP	  +	  BSO	  (2),	  dbcAMP	  for	  7	  days	  with	  an	  addition	  of	  
BSO	  for	  the	  final	  24	  hrs	  (3),	  or	  with	  dbcAMP	  +	  BSO	  on	  day	  0	  only	  (4)	  and	  assayed	  at	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Figure	  4.8.	  Na+-­‐dependent	  [3H]-­‐D-­‐aspartate	  medicated	  uptake	  (EAAT-­‐mediated)	  in	  
primary	  astrocytes.	  Astrocytes	  grown	   in	   the	  presence	  or	  absence	  of	  dbcAMP	   for	  7	  
days	  were	  treated	  with	  or	  without	  500	  µM	  BSO	  for	  the	  final	  24	  hrs	  and	  assayed	  for	  
Na+-­‐	   dependent	   [3H]-­‐D-­‐aspartate	   uptake	   activity.	   Data	   represents	   mean	   rates	  
(pmol/min/mg	  protein)	  ±	  SEM,	  n	  =	  3.	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Figure	  4.9.	  Na+-­‐independent	  [3H]-­‐L-­‐glutamate	  uptake	  in	  C17.2	  neuronal	  “stem	  cell-­‐
like”	   cells.	  C17.2	   cells	  were	   cultured	   to	   confluency	  and	   treated	  with	  dbcAMP	   (250	  
µM),	  BSO	  (500	  µM)	  or	  both	  dbcAMP	  +	  BSO	  for	  24	  hrs	  prior	  to	  performing	  the	  uptake	  
assay,	  n	  =3.	  	  




Figure	   4.10.	   The	   effect	   of	   tBHQ	   on	   SxC-­‐	   -­‐mediated	   uptake	   in	   primary	   astrocytes	  
cultured	  without	  dbcAMP.	  Astrocytes	  received	  a	  dose	  (0-­‐50	  µM)	  of	  tBHQ	  for	  24	  hrs	  
and	   were	   subsequently	   assayed	   for	   SxC-­‐	   -­‐mediated	   [3H]-­‐L-­‐glutamate	   uptake.	   Data	  
represents	  mean	  %	  of	  control	  uptake,	  n	  =	  4-­‐8,	  *P	  <	  0.01	  when	  25	  µM	  and	  50	  µM	  are	  
compared	  to	  0	  µM	  and	  between	  50	  µM	  and	  25	  µM.	  




















Figure	   4.11.	   The	   effect	   of	   tBHQ	   on	   SxC-­‐	   -­‐mediated	   uptake	   in	   primary	   astrocytes	  
cultured	   in	   the	   presence	   of	   dbcAMP.	  Astrocytes	   cultured	  with	   dbcAMP	   for	   7	   days	  
received	  various	  doses	  of	  tBHQ	  (0	  -­‐100	  µM)	  for	  the	  final	  24	  hrs	  in	  culture	  and	  were	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Figure	   4.12.	   The	   effect	   of	   tBHQ	   on	   SxC-­‐	   activity	   and	   intracellular	   GSH	   levels	   in	  
untreated	   and	   dbcAMP-­‐treated	   astrocytes.	   Astrocytes	   cultured	   with	   and	   without	  
dbcAMP	  for	  7	  days	  received	  various	  doses	  of	  tBHQ	  for	  the	  final	  24	  hrs	  in	  culture	  and	  
Na+-­‐independent	   [3H]-­‐L-­‐glutamate	  uptake	   (pmol/min/mg	  protein)	  or	  GSH	   content	  
(nmol/mg	  protein)	  was	  measured	  as	  described	  in	  Methods.	  A.	  SxC-­‐	  -­‐mediated	  [3H]-­‐L-­‐
glutamate	   uptake	   in	   untreated	   and	   dbcAMP-­‐treated	   astrocytes	   treated	  with	   tBHQ	  
(25	  µM).	   Immunoblots	   for	   nuclear	   Nrf2	   correspond	   to	   conditions	   in	   graph.	   In	   all	  
blots	   the	   Nrf2	   antibody	   (Santa	   Cruz	   Biotechnology)	   revealed	   higher	   molecular	  
weight	   bands	   (>100	   kDa)	   than	   the	   predicted	   value	   (69	   kDa),	   an	   observation	  
consistent	  with	   other	   reports	  with	   this	   antibody	   (Alam	   et	   al.	   1999;	   Danilov	   et	   al.	  
2009;	  Shih	  et	  al.	  2003).	  B.	  GSH	  content	  in	  both	  untreated	  and	  dbcAMP-­‐treated	  cells	  
in	  response	  to	  tBHQ.	  




Figure	   4.13.	   Kinetic	   analysis	   of	   [3H]-­‐L-­‐glutamate	   uptake	   activity	   in	   primary	  
astrocytes	  depleted	  of	  GSH	  with	  BSO.	  Data	  was	  fitted	  to	  y	  =	  m1*m0/(m2+m0)	  and	  
followed	  Michaelis-­‐Menten	  kinetics.	  The	  plot	  yielded	  a	  Km	  of	  	  17.4	  ±	  2.2	  and	  Vmax	  of	  
146.6	  ±	  4.6,	  (n	  =	  6)	  in	  dbcAMP-­‐treated	  astrocytes	  and	  a	  Km	  of	  25.1	  ±	  4.8	  and	  Vmax	  of	  
349.9	   ±	   15.0,	   (n	   =	   5)	   for	   astrocytes	   treated	   with	   dbcAMP/BSO.	   We	   found	   no	  
statistical	  difference	  between	  Km	  values,	  P	  =	  0.05	  when	  comparing	  Vmax	  values	  using	  
the	  student’s	  t-­‐test	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Figure	   4.14.	   Fluorometric	   quantification	   of	   L-­‐cystine	   induced	   L-­‐glutamate	   efflux	  
and	  accumulation	  via	  NADP+	   generation	   in	   astrocytes.	  Astrocyte	   cultures	   received	  
250	  µM	  dbcAMP	  for	  7	  days	  and	  were	  treated	  with	  500	  µM	  BSO	  for	  the	  final	  24hrs.	  
Following	  a	  15	  minute	  incubation	  in	  Na+-­‐free	  buffer	  containing	  0	  µM,	  10	  µM,	  or	  100	  
µM	   L-­‐cystine,	   and	   100	   µM	   L-­‐cystine	   +	   100	   µM	   4SCPG,	   aliquots	   of	   buffer	   were	  
analyzed	  for	  extracellular	  L-­‐glutamate	  accumulation	  as	  described	  in	  Methods.	  Total	  
L-­‐glutamate	  from	  lysed	  cells	  treated	  with	  either	  dbcAMP	  or	  dbcAMP/BSO	  were	  13.9	  
±	  4.5	  and	  14.6	  ±	  3.0	  µM	  respectively.	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Figure	   4.15.	   Fluorometric	   quantification	   of	   L-­‐cystine	   induced	   L-­‐glutamate	   efflux	  
and	   accumulation	   via	   NADP+	   generation	   in	   SNB19	   cells.	   Following	   a	   15	   minute	  
incubation	  in	  NaCl	  buffer	  containing	  the	  EAAT	  inhibitor	  TBOA	  and	  0	  µM,	  10	  µM,	  or	  
100	  µM	  L-­‐cystine,	  and	  100	  µM	  L-­‐cystine	  +	  100	  µM	  4SCPG,	  aliquots	  of	  buffer	  were	  
analyzed	  for	  extracellular	  L-­‐glutamate	  accumulation	  as	  described	  in	  Methods,	  n	  =	  3.	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Figure	  4.16.	  Immunoblot	  analysis	  of	  A.	  xCT	  and	  B.	  CD98	  in	  primary	  astrocytes,	  R	  =	  
reducing	   (355	   mM	   2ME)	   ,	   NR	   =	   non-­‐reducing	   conditions.	   Lanes	   1,2:	   untreated	  
astrocytes,	   3,4:	   250	   µM	   dbcAMP–treated,	   4,5:	   250	   µM	   dbcAMP-­‐treated	   and	  
incubated	   with	   500	   µM	   BSO	   for	   24	   hrs.	   The	   xCT	   antibody	   detected	   four	   bands	  
specific	  to	  the	  xCT	  antibody	  as	  determined	  by	  peptide	  blocking,	  135	  kDa,	  50	  kDa	  ,	  45	  
kDa,	   and	   40	   kDa.	   The	   135	   kDa	   band	   is	   consistent	   with	   an	   xCT/CD98	   dimer	   and	  
appears	  only	  in	  blots	  under	  nonreducing	  conditions.	  xCT	  and	  CD98	  heterodimerize	  
through	   an	   extracellular	   disulphide	   bond	   that	   can	   be	   disrupted	   with	   2ME.	  
Immunoblotting	  for	  xCT	  under	  reducing	  conditions	  resulted	  in	  the	  disappearance	  of	  
the	  higher	  mw	  band	  and	  the	  appearance	  of	  a	  band	  at	  40	  kDa,	  consistent	  with	  xCT.	  
Likewise	  the	  140	  kDa	  band	  disappears	  in	  CD98	  blots	  under	  reducing	  conditions	  and	  
a	  band	  consistent	  with	  CD98	  appears	  at	  90	  kDa.	  Representative	  blot	  of	  at	  least	  three	  
experiments.	   xCT	   (1:500,	   1%	   milk),	   CD98	   ((SC-­‐7094)	   1:200,	   0.1%	   milk),	   GAPDH	  
(1:500	  (SC-­‐20357)),	  20	  µg	  loaded,	  4-­‐15%	  gel.	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Figure	  4.17.	  Inhibition	  of	  protein	  synthesis	  by	  cycloheximide	  (CX,	  50	  µM)	  treatment	  
in	  GSH-­‐depleted	  astrocytes.	  Astrocytes	  were	  cultured	  for	  7	  days	  in	  the	  presence	  of	  
dbcAMP	   and	   treated	   with	   BSO	   or	   BSO+CX	   for	   the	   final	   24	   hrs.	   Data	   shown	  




















Figure	  4.18.	  Q-­‐PCR	  analysis	  of	  cDNA	  from	  untreated,	  cAMP-­‐treated,	  and	  cAMP/BSO	  
treated	  primary	  astrocytes	   for	  xCT	  and	  4F2hc.	  Following	  6	  days	   in	  culture	  with	  or	  
without	  dbcAMP,	  a	  subset	  of	  dbcAMP-­‐treated	  cells	  were	  treated	  with	  500	  µM	  BSO	  
for	  an	  additional	  24hrs	  and	  RNA	  was	  extracted	  and	  PCR	  performed	  as	  described	  in	  
Methods.	   The	   fold	   change	   was	   calculated	   by	   first	   normalizing	   against	   GAPDH	   Ct	  
values,	   and	   then	   taking	   the	   difference	   of	   the	   ΔΔCT	   values	   for	   dbcAMP	   and	  
dbcAMP/BSO	  from	  the	  ΔΔCT	  for	  untreated	  samples	  and	  calculating	  fold	  change	  with	  
the	   following	   formula	   2-­‐ΔΔCT.	   If	   this	   value	   was	   less	   than	   one,	   the	   fold	   change	   is	  
represented	  as	  the	  negative	  reciprocal	  (i.e.	  a	  change	  of	  0.75	  from	  control	  is	  listed	  as	  
a	  -­‐1.3	  fold	  change).	  The	  reported	  data	  are	  the	  average	  of	  two	  independent	  cultures.	  
The	  low	  expression	  levels	  for	  xCT	  in	  untreated	  samples	  results	  in	  large	  fold-­‐changes	  
in	  dbcAMP	  and	  dbcAMP/BSO	  samples.	  It	  is	  perhaps	  more	  instructive	  to	  compare	  the	  
fold-­‐change	  of	  xCT	  expression	  in	  dbcAMP/BSO	  treated	  cells	  to	  dbcAMP-­‐treated	  cells,	  
which	  is	  2.4	  ±	  	  0.1.	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Figure	   4.19.	   The	   recovery	   of	   system	   xC-­‐	   activity	   and	   GSH	   levels	   following	   BSO	  
washout.	   Following	   a	   24	   hr	   exposure	   to	   BSO,	   astrocytes	   received	   media	   changes	  
daily	   and	   were	   assayed	   for	   intracellular	   GSH	   and	   [3H]-­‐L-­‐glutamate	   uptake	   at	   the	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Figure	   4.20.	  The	   ability	   of	   GSH	   to	   prevent	   the	   induction	   of	   system	   xC-­‐	   activity	   in	  
primary	  astrocytes.	  All	   agents	  were	   co-­‐applied	  at	   the	   time	  of	  BSO-­‐treatment.	  Data	  
represents	  mean	  %	  of	  control	  ±	  SEM,	  n	  =	  3-­‐5,	  statistical	  significance	  is	  in	  relation	  to	  
rates	  from	  BSO-­‐treated	  astrocytes,	  *P	  <	  0.01,	  **P	  <	  0.0001	  as	  determined	  by	  student	  
t-­‐test.	  Abbreviations	  are	  as	  follows:	  BSO,	  buthionine	  sulfoximine;	  GSH,	  glutathione;	  
GSH-­‐E,	  glutathione	  ethyl	  ester;	  AC,	  acivicin;	  GC,	  γ-­‐glutamylcysteine.	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Figure	  4.21.	   The	   ability	   of	   reducing	   agents	   and	   thiols	   to	  prevent	   the	   induction	  of	  
system	  xC-­‐	  activity	   in	  primary	  astrocytes.	  All	  agents	  were	  co-­‐applied	  at	   the	   time	  of	  
BSO-­‐treatment.	   Data	   represents	   mean	   %	   of	   control	   ±	   SEM,	   n	   =	   3-­‐5,	   statistical	  
significance	   is	   in	   relation	   to	   rates	   from	   BSO-­‐treated	   	   astrocytes,	   *P	   <	   0.01,	   **P	   <	  
0.0001	   as	   determined	   by	   student	   t-­‐test.	   Abbreviations	   are	   as	   follows:	   2ME,	   2-­‐
mercaptoethanol;	   CysH,	   L-­‐cysteine;	   Cys2,	   L-­‐cystine;	   DTT,	   dithiothreitol;	   NAC,	   N-­‐
acetylcysteine.	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Figure	   4.22.	   ROS-­‐mediated	   fluorescence	   in	   primary	   astrocytes.	   Astrocytes	   were	  
grown	  in	  96-­‐well	  plates	  and	  were	  treated	  with	  or	  without	  BSO	  for	  24	  hrs	  following	  7	  
days	  of	  dbcAMP-­‐treatment.	  An	  additional	  group	  of	  cells	  was	  also	  treated	  with	  GSH-­‐
ethyl	  ester	  (5	  mM)	  in	  conjunction	  with	  BSO.	  The	  addition	  of	  H2O2	  (50	  µM)	  served	  as	  
the	   positive	   control.	   Following	   the	   24	   hr	   treatments,	   cells	   were	   incubated	   for	   25	  
minutes	  @	  37oC	  with	  carboxy-­‐H2DCFDA	  (10	  µM),	  rinsed	  with	  PBS,	  and	  read	  at	  Ex	  
485nm,	  Em	  530nm.	  *P	  <	  0.03,	  **	  <	  0.0001	  as	  determined	  by	  student	  t-­‐test.	  There	  is	  
no	  significant	  difference	  between	  BSO	  and	  H2O2	  treated	  samples.	  n	  =	  4.	  	  




Figure	   4.23.	   The	   ability	   of	   antioxidants	   to	   prevent	   the	   induction	   of	   system	   xC-­‐	  
activity	   in	   primary	   astrocytes.	   All	   agents	   were	   co-­‐applied	   at	   the	   time	   of	   BSO-­‐
treatment.	  Data	  represents	  mean	  %	  of	  control	  ±	  SEM,	  n	  =	  3-­‐5,	  statistical	  significance	  
is	   in	   relation	   to	   rates	   from	   BSO-­‐treated	   	   astrocytes,	   *P	   <	   0.01,	   **P	   <	   0.0001	   as	  
determined	  by	  student	  t-­‐test.	  Abbreviations	  are	  as	  follows:	  LA,	  R-­‐α-­‐lipoic	  acid;	  CAT,	  
catalase.	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Figure	   4.24.	   The	   ability	   of	   oxidants,	   electrophiles,	   and	   other	   agents	   to	  mimic	   the	  
BSO-­‐mediated	   induction	   of	   system	   xC-­‐	   activity	   in	   primary	   astrocytes.	   Astrocytes	  
were	  cultured	  for	  7	  days	  in	  the	  presence	  of	  dbcAMP	  and	  treated	  with	  BSO	  or	  other	  
agents	   for	   the	   final	   24	   hrs.	   Data	   represents	   mean	   %	   of	   control	   ±	   SEM,	   n	   =	   3-­‐5,	  
statistical	   significance	   is	   in	   relation	   to	   rates	   from	   control	   astrocytes	   (dbcAMP-­‐
treated),	  *P	  <	  0.01,	  **P	  <	  0.0001	  as	  determined	  by	  student	  t-­‐test.	  Abbreviations	  as	  
follows:	  BSO,	  buthionine	  sulfoximine	  (500	  µM);	  H2O2,	  hydrogen	  peroxide	  (50	  µM);	  
GSSG,	  oxidized	  glutathione	  (1	  mM),	  L-­‐Cys2,	  L-­‐cystine	  (0.5	  mM),	  L-­‐Glu,	  L-­‐glutamate	  
(1	  mM);	  DEM,	  diethylmaleate	  (100	  µM);	  As	  III,	  sodium	  arsenite	  (2.5	  µM);	  tBHQ,	  tert-­‐
butylhydroquinone	  (25	  µM).	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Table	  4.1.	  Differences	   in	   total	  GSH	   levels	   following	  2	  hrs	  of	  BSO	  and	  the	  effect	  on	  
SxC-­‐	   activity	   in	   dbcAMP-­‐treated	   astrocytes.	   Total	   intracellular	   GSH	   levels	   were	  
determined	   following	  a	  2hr	  exposure	   to	  BSO	   in	   cultures	   treated	  with	  and	  without	  
dbcAMP	   (p	   =	   0.002).	   SxC-­‐	   -­‐mediated	   [3H]-­‐L-­‐glutamate	   uptake	   experiments	   were	  
performed	  in	  parallel	  with	  cultures	  treated	  with	  dbcAMP.	  Data	  represents	  mean	  %	  
of	  control	  values,	  *P	  <	  0.01	  as	  determined	  by	  student	  t-­‐test,	  there	  is	  no	  statistically	  
significant	   difference	   between	  %	   of	   control	   values	   for	   dbcAMP+BSO	   and	   dbcAMP	  
controls	  (100%),	  n	  =	  3-­‐4.	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Table	   4.2.	   GSH	   levels	   in	   astrocytes	   cultured	   in	   the	   presence	   of	   GSH	   precursors.	  
Astrocytes	  cultured	  in	  the	  presence	  or	  absence	  of	  dbcAMP	  (250	  µM)	  were	  supplied	  
with	  fresh	  growth	  media	  and	  the	  amino	  acids	  at	  the	  final	  concentration	  listed	  above	  
at	  the	  beginning	  of	  the	  incubation	  period.	  This	  concentration	  represents	  the	  amount	  
added	  to	  the	  growth	  media	  and	  does	  not	   include	  the	  concentration	  of	  amino	  acids	  
already	  contained	   in	  the	  media	  (0.1	  mM	  L-­‐cystine	  (L-­‐Cys2)	  and	  0.1	  mM	  L-­‐cysteine	  
(L-­‐CysH)).	   Data	   represents	  mean	   percent	   of	   control	   GSH	   for	   n	   =	   3-­‐4.	   Intracellular	  
GSH	  content	  is	  shown	  (nmol/mg	  protein)	  for	  controls.	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Table	   4.3.	   Summary	   of	   SxC-­‐	   and	   EAAT	   mediated	   uptake	   in	   primary	   astrocytes	  
cultured	  with	  and	  without	  dbcAMP	  in	  response	  to	  GSH-­‐depletion	  by	  BSO	  (Figs.	  4.6	  
and	  4.8).	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  5.	  	  Discussion	  	  
In	  a	  majority	  of	  mammalian	  cells,	  the	  SxC-­‐-­‐mediated	  exchange	  of	  intracellular	  L-­‐Glu	  
with	  extracellular	  L-­‐Cys2	  and	  its	  subsequent	  reduction	  to	  L-­‐CysH	  is	  a	  primary	  route	  
through	   which	   this	   sulfur-­‐containing	   amino	   acid	   enters	   cells	   as	   a	   rate-­‐limiting	  
precursor	   in	   the	   synthesis	   of	   the	   antioxidant	   GSH	   (Bannai	   1984;	   Bannai	   and	  
Kitamura	  1980;	  Cho	  and	  Bannai	  1990;	  Kranich	  et	  al.	  1998;	  Sagara	  et	  al.	  1993a).	  	  In	  
the	  instance	  of	  astrocytes,	  this	  process	  takes	  on	  greater	  significance	  as	  it	  is	  needed	  
not	  only	  for	  the	  maintenance	  of	  astrocytic	  GSH	  pools,	  but	  is	  also	  the	  first	  step	  in	  the	  
Cys2/CysH	   shuttle	   in	   which	   astrocytes	   supply	   the	   extracellular	   L-­‐CysH	   needed	   to	  
support	  GSH	  synthesis	  in	  neurons	  (Dringen	  et	  al.	  2001;	  Dringen	  et	  al.	  1999;	  Sagara	  
et	  al.	  1993b;	  Wang	  and	  Cynader	  2000).	  Altered levels of GSH in the CNS have been 
associated with Parkinson’s	   disease,	   schizophrenia,	   and	   glioma	   growth.	   These 
neuropathological outcomes could potentially involve an aberration in GSH-mediated 
feedback regulation of Sxc-. Just	  as	  significant,	   the	  efflux	  of	  L-­‐Glu	  that	  occurs	  during	  
the	  exchange	  with	  L-­‐Cys2	  also	  provides	  a	  mechanism	  through	  which	  glial	  L-­‐Glu	  can	  
be	  exported	  from	  the	  cells,	  gain	  access	  to	  EAA	  receptors,	  and	  thereby	  contribute	  to	  
either	  excitatory	  signaling	  (Baker	  et	  al.	  2003;	  Baker	  et	  al.	  2002a;	  Baker	  et	  al.	  2002b)	  
or	  excitotoxicity	  (Barger	  and	  Basile	  2001;	  Piani	  and	  Fontana	  1994;	  Piani	  et	  al.	  1991;	  
Ye	   and	   Sontheimer	   1999).	   These	   studies,	   which	   detail	   the	   physiological	  
consequences	   of	   both	   reductions	   (e.g.,	   in	   neurodegeneration	   and	   susceptibility	   to	  
relapse	   behavior	   in	   addiction	   models)	   and	   increases	   (e.g.,	   in	   CNS	   infection,	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glioblastomas,	  and	  relapse	  prevention)	   in	  SxC-­‐	  activity,	  highlight	   the	   importance	  of	  
understanding	  how	  this	  transporter	  system	  is	  regulated.	  	  	  	  
In	   the	   present	   work	   we	   have	   used	   primary	   astrocyte	   cultures	   to	   study	   the	  
relationship	  between	  GSH	  and	  the	  expression	  of	  SxC-­‐	  and	  find	  that	  the	  regulation	  of	  
the	   transporter	   in	   astrocytes	   appears	   to	   be	   cell	   and	   phenotype-­‐dependent.	   	   Thus,	  
primary	   cells	   cultures	   treated	  with	   dbcAMP	   not	   only	   express	   higher	   levels	   of	   the	  
transporter,	   the	   differentiated	   astrocytes	   also	   respond	   to	   low	   intracellular	   GSH	  
levels	  by	  acutely	  and	  selectively	  increasing	  SxC-­‐	  activity	  in	  a	  manner	  not	  observed	  in	  
control	   (untreated)	   cultures	   (Fig.	   4.6).	   Using	   primary	   cultures	   as	   an	   experimental	  
system	  permitted	  the	  direct	  quantification	  of	  SxC-­‐	  activity	  and	  the	  consequences	  of	  
alterations	   in	  GSH	   levels	   to	  be	   selectively	  examined	   in	  astrocytes.	   	   Further,	   it	   also	  
allowed	  GSH	  to	  be	  depleted	  by	  BSO-­‐mediated	  inhibition	  of	  synthesis	  (BSO	  does	  not	  
cross	  the	  blood-­‐brain-­‐barrier),	  thereby	  avoiding	  the	  complicating	  effects	  associated	  
with	  using	  xenobiotics,	  electrophiles	  or	  toxins	  to	  alter	  GSH	  levels	  (Bannai	  1984;	  Ishii	  
et	   al.	   2000;	   Meister	   1991).	   That	   the	   observed	   increase	   in	   SxC-­‐	   expression	   that	  
followed	   GSH	   depletion	   was	   most	   robust	   in	   those	   astrocytes	   that	   had	   been	  
differentiated	  with	  dbcAMP	   is	   also	  notable,	   as	   these	   cells	   are	  believed	   to	  be	  more	  
representative	   of	   an	   in	   vivo	   or	   activated	   phenotype	   with	   greater	   neuroprotective	  
and	  neurotrophic	  functions	  (for	  reviews	  see	  Escartin	  and	  Bonvento	  2008;	  Hertz	  et	  
al.	   1998;	   Juurlink	   and	   Hertz	   1985).	   In	   particular,	   the	   expression	   of	   other	   key	  
glutamate-­‐associated	   glial	   proteins,	   including	   the	   EAAT	   transporters	   GLT-­‐1	   and	  
GLAST	  and	  glutamine	  synthetase,	  are	  enhanced	  when	  glia	  are	  exposed	  to	  dbcAMP	  or	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co-­‐cultured	  with	  neurons	  (Schlag	  et	  al.	  1998;	  Stanimirovic	  et	  al.	  1999;	  Swanson	  et	  al.	  
1997).	  	  
	  
5.1	  The	  effect	  of	  dbcAMP	  treatment	  in	  astrocytes	  on	  SXc-­	  	  
As	  we	   and	   others	   have	   observed,	   the	   expression	   and	   functional	   activity	   of	   SXc-­‐	   in	  
primary	   astrocytes	   is	   very	   low,	   so	   much	   so	   that	   the	   quantification	   of	   either	   L-­‐
Cys2/L-­‐Glu	  transport	  or	  intracellular	  GSH	  levels	  in	  these	  cells	  can	  be	  highly	  variable,	  
even	  between	  individual	  experiments	  (Cho	  1990,	  Dringen	  1999,	  Kranich	  1998,	  Sato	  
1995).	   Advantageously,	   we	   and	   others	   find	   that	   dbcAMP	   induces	   a	   significant	  
increase	   in	   SxC-­‐-­‐mediated	   uptake	   of	   L-­‐Glu	   (Gochenauer	   and	  Robinson	   2001).	   That	  
this	  activity	  is,	  indeed,	  attributable	  to	  SxC-­‐	  was	  confirmed	  using	  inhibitors	  (e.g.,	  Cys2	  
and	   4-­‐S-­‐CPG),	   as	   well	   as	   a	   parallel	   assay	   directly	   quantifying	   Cys2-­‐-­‐mediated	  
exchange	   with	   L-­‐Glu	   (Fig.	   4.6	   and	   4.14).	   	   This	   increase	   in	   transport	   activity	   also	  
correlated	  with	  a	  marked	  increase	  in	  the	  135	  kDa	  SxC-­‐	  heterodimer	  as	  detected	  with	  
antibodies	  to	  either	  the	  xCT	  or	  4F2hc	  subunits	  (Fig.	  4.16).	  When	  examined	  following	  
reduction	  with	  2ME,	  very	  prominent	  bands	  were	  observed	  at	  40	  kDa	  and	  90	  kDa,	  
corresponding	   to	   the	   individual	   subunits	   of	   the	   heterodimer,	   xCT	   and	   4F2hc,	  
respectively.	  	  When	  examined	  in	  murine	  retinal	  Muller	  cells,	  Mysona	  et	  al.	  reported	  
the	  presence	  of	  both	  a	  50	  kDa	  and	  40	  kDa	  isoform	  of	  xCT,	  of	  which	  only	  the	  latter	  
increased	  in	  response	  to	  oxidative	  stress	  and	  accounted	  for	  the	  observed	  changes	  in	  
activity	   (Mysona	   et	   al.	   2009).	   	   	   Similarly,	   in	   the	   present	   investigation	   the	   40	   kDa	  
isoform	   of	   xCT	   appears	   responsible	   for	   the	   significant	   increase	   in	   activity	   that	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follows	   the	   phenotypic	   change	   induced	   by	   dbcAMP,	   as	   the	   it	   was	   only	   readily	  
observable	   in	   the	   treated	   cultures.	   	   Isoforms	   of	   50	   kDa	   and	   45	   kDa	   were	   also	  
observed	  in	  all	  of	  the	  cultures.	  	  However,	  as	  these	  subunits	  were	  equally	  present	  in	  
the	   untreated	   cultures	   in	   which	   activity	   was	   difficult	   to	   distinguish	   from	  
background,	  it	  would	  suggest	  that	  these	  subunits	  are	  much	  less	  functional	  than	  the	  
40	   kDa	   isoform,	   possibly	   due	   to	   differences	   in	   structure	   and/or	   localization.	  	  
Consistent	  with	   the	   activity	   and	  protein	   results,	   the	   astrocytes	  differentiated	  with	  
the	  dbcAMP	  also	  exhibited	  about	  a	  70-­‐fold	  increase	  in	  xCT	  message	  as	  determined	  
by	   Q-­‐PCR.	   While	   parallel	   immunoblot	   assays	   with	   a	   4F2hc	   antibody	   also	  
demonstrated	  that	  the	  90	  kDa	  subunit	  was	  markedly	  increased	  in	  the	  differentiated	  
astrocytes,	   this	   subunit	   was	   also	   detected	   in	   the	   untreated	   cells.	   It	   must	   be	  
remembered	   that,	   as	   the	   4F2hc	   subunit	   can	   associate	   with	   other	   “light	   chain”	  
transporter	   subunits,	   its	   presences	   may	   or	   may	   not	   correlate	   closely	   with	   SxC-­‐	  
activity.	  	  When	  examined	  by	  Q-­‐PCR,	  the	  message	  levels	  for	  the	  4F2hc	  subunit	  did	  not	  
change	  with	  the	  dbcAMP	  induced	  phenotype.	  	  These	  findings	  indicate	  that	  SxC-­‐	  and,	  
in	  particular,	  the	  expression	  of	  the	  40	  kDa	  xCT	  subunit,	  should	  be	  added	  to	  the	  list	  of	  
glutamate-­‐associated	  astrocytic	  proteins	  that	  are	  expressed	  in	  the	  dbcAMP-­‐induced	  
phenotype.	  	  The	  increased	  activity	  of	  this	  transport	  system	  might	  also	  contribute,	  in	  
part,	  to	  the	  ability	  of	  these	  astrocytes	  to	  maintain	  intracellular	  GSH	  pools	  at	  higher	  
concentrations	  (Fig.	  4.5).	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5.2	  The	  phenotypic-­specific	  effect	  of	  BSO	  on	  SxC-­	  
SxC-­‐	   activity	   increased	   by	   another	   3-­‐fold	   24	   hrs	   after	   BSO	   had	   been	   added	   to	   the	  
dbcAMP-­‐treated	   cultures	   to	   deplete	   intracellular	   GSH	   levels.	   This	   response	  
appeared	   to	   be	  phenotype/cell	   specific,	   as	   the	   addition	   of	  BSO	  had	   little	   effect	   on	  
SxC-­‐	  activity	  in	  untreated	  astrocytes	  (i.e.,	  grown	  in	  the	  absence	  of	  dbcAMP),	  and	  has	  
been	   reported	   to	  be	   ineffective	   in	  BHK21	  cells	   (Sasaki	   et	   al.	   2002)	  and	   rat	  kidney	  
fibroblasts	  (Kang	  and	  Enger	  1992).	  	  
In	  previous	  studies	  of	  astrocytes	  cultured	  in	  the	  absence	  of	  dbcAMP,	  BSO	  treatment	  
had	  been	  reported	  to	  result	  in	  a	  modest	  increase	  (140%	  of	  control)	  in	  activity	  (Allen	  
et	   al.	   2001),	   consistent	   with	   our	   data	   (Fig.	   4.6)	   and	   the	   range	   of	   variability	  
characteristic	   of	   this	   phenotype.	   	  However,	   in	   another	   study	   of	   astrocytes	   treated	  
with	  both	  dbcAMP	  and	  BSO,	  the	  authors	  reported	  a	  non-­‐significant	  down-­‐regulation	  
of	  L-­‐Cys2	  transport	  (Bender	  et	  al.	  2000),	  a	  distinctly	  different	  result	  from	  the	  work	  
presented	  here.	   It	   is	   likely	   that	  differences	   in	  experimental	  protocols	   in	   this	   latter	  
study	  (e.g.,	  exposure	  time	  to	  BSO	  (3hrs)	  and	  use	  of	  NaCl-­‐containing	  uptake	  buffer)	  
are	  partly	  responsible	  for	  the	  inconsistencies.	  In	  agreement	  with	  the	  data	  observed	  
in	  our	  dbcAMP-­‐treated	  astrocytes,	  GSH-­‐depletion	  in	  C1	  cells	  (simian	  virus	  40	  large	  
T-­‐antigen	  immortalized	  line)	  has	  lead	  to	  increased	  levels	  of	  xCT	  (Qiang	  et	  al.	  2004)	  
and	  the	  i.p.	  administration	  of	  BSO,	  while	  ineffective	  at	  entering	  the	  brain	  intact	  and	  
altering	   GSH	   levels	   there,	   also	   leads	   to	   increases	   in	   xCT	   mRNA	   in	   whole	   brain	  
homogenates	   (likely	   reflecting	   changes	   at	   or	   near	   the	  BBB)	   (Limon-­‐Pacheco	   et	   al.	  
2007).	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Our	   data	   demonstrate	   that	   the	   increased	   activity	   in	   response	   to	   BSO	   could	   be	  
ascribed	   specifically	   to	   SxC-­‐	   based	   upon	   both	   pharmacological	   inhibition	   (Fig.	   4.6)	  
and	  parallel	   L-­‐Cys2/L-­‐Glu	   exchange	   assays	   (Fig.	   4.14).	   Several	   findings	   lead	   to	   the	  
conclusion	   that	   the	   increase	   in	   transporter	   activity	   following	   GSH	   depletion	   is	  
primarily	  attributable	   to	  an	  enhanced	  expression	  of	  SxC-­‐,	   including:	  kinetic	   studies	  
demonstrating	   an	   increase	   in	   Vmax	   without	   a	   significant	   change	   in	   Km	   (Fig.	   4.13),	  
increased	   presence	   of	   both	  mRNA	   (Fig.	   4.18)	   and	   protein	   (Fig.	   4.16)	   for	   the	   xCT	  
subunit,	  and	  the	  attenuation	  of	  the	  increase	  by	  co-­‐administration	  of	  cycloheximide	  
(Fig.	  4.17).	  	  In	  contrast	  to	  changes	  in	  the	  xCT	  subunit,	  the	  BSO-­‐induced	  depletion	  of	  
the	  GSH	  levels	  did	  not	  appear	  to	  alter	  the	  expression	  of	  the	  4F2hc	  subunit	  at	  either	  
the	  message	   or	   protein	   levels.	   	   4F2hc,	   like	   other	   heavy	   chain	   subunits,	   associates	  
with	   a	   variety	   of	   light	   chains	   in	   the	   HAT	   family	   of	   transporters,	   where	   it	   plays	   a	  
critical	  role	  in	  surface	  expression	  (Nakamura	  et	  al.	  1999).	  	  Given	  the	  increase	  in	  both	  
SxC-­‐	  activity	  and	  the	  expression	  of	  the	  xCT	  subunit,	  our	  findings	  could	  indicate	  that	  
while	   the	   absolute	   amount	   of	   the	   4F2hc	   subunit	   did	   not	   change,	   a	   greater	  
proportion	  of	   it	   is	   associated	  with	  xCT	   in	  SxC-­‐	  heterodimers	  as	  part	  of	   the	   cellular	  
response	  to	  decreased	  GSH	  levels.	  
	  
5.3	  The	  biochemical	  trigger	  of	  the	  BSO-­mediated	  effect	  on	  SXc-­	  
While	   it	   was	   the	   treatment	   of	   the	   astrocyte	   cultures	   with	   BSO	   that	   led	   to	   the	  
phenotype-­‐specific	   induction	   of	   SxC-­‐,	   there	   are	   any	   number	   of	   biochemical	   events	  
that	  may	  have	   actually	   triggered	   the	   response,	   especially	   given	   that	   the	   transport	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system	   is	   upregulated	   by	   amino	   acid	   starvation,	   electrophiles,	   xenobiotics,	   toxins,	  
and	  oxidative	   stress	   (Bannai	  1984;	  Bannai	  et	  al.	  1989;	   Ishii	   et	   al.	  2000;	  Sato	  et	  al.	  
1995).	   	   Thus,	   beyond	   the	   ability	   of	   BSO	   to	   deplete	   intracellular	   GSH	   levels	   by	  
inhibiting γ-­‐glutamylcysteine	   synthetase,	   secondary	   effects	   could	   include	   an	  
influence	  on	  extracellular	  GSH	  levels,	  intracellular	  or	  extracellular	  levels	  of	  L-­‐Glu	  or	  
L-­‐CysH,	   the	   production	   or	   accumulation	   of	   ROS,	   or	   the	   redox	   state	   of	   signaling	  
proteins.	  	  	  
To	  sort	  through	  these	  possibilities	  and	  try	  to	  elucidate	  the	  signal	  that	  triggered	  the	  
induction,	  we	  first	  examined	  the	  well-­‐characterized	  EpRE/ARE-­‐associated	  pathway	  
through	   which	   electrophiles	   or	   oxidative	   stress	   up-­‐regulate	   SXc-­‐	   via	   an	   Nrf2-­‐
dependent	   mechanism.	   	   The	   cytoskeletal	   protein	   Keap1	   is	   thought	   to	   negatively	  
regulate	   Nrf2-­‐mediated	   gene	   activation	   by	   retaining	   Nrf2	   in	   the	   cytoplasm	   and	  
targeting	   it	   for	   ubiquinization	   and	   degradation.	   Likely	   through	   a	   thiol-­‐sensing	  
mechanism	  (Keap1	  contains	  25	  L-­‐CysH	  residues),	  Keap1	  releases	  Nrf2	  which	   then	  
migrates	  to	  the	  nucleus,	  forms	  heterodimers	  with	  other	  transcription	  factors	  (ATF4,	  
Jun,	  Maf	  proteins)	  and	  initiates	  the	  transcriptional	  activation	  of	  target	  genes	  (He	  et	  
al.	  2001;	  	  for	  review	  see	  Itoh	  et	  al.	  2004).	  
We	   find	   that	   the	   classic	   EpRE-­‐gene	   inducer	   tBHQ	   did	   indeed	   produce	   a	   similar	  
increase	   in	   the	  nuclear	  presence	  of	  Nrf2	  when	  added	   to	  either	  control	  or	  dbcAMP	  
treated	   astrocytes	   (Fig	   4.12).	   Interestingly,	   however,	   tBHQ	   only	   produced	   the	  
expected	   increase	   in	   SXc-­‐	   activity	   and	  GSH	   levels	   in	   the	  untreated	   astrocytes.	   	   The	  
failure	   of	   tBHQ	   to	   produce	   any	   further	   increase	   in	   transporter	   activity	   over	   the	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much	  higher	  basal	   levels	  present	   in	  the	  dbcAMP-­‐differentiated	  cells	   infers	  that	  the	  
signaling	  pathway	  is	  different	  in	  this	  phenotype	  or	  that	  the	  tBHQ	  induced	  increase	  
was	   small	   enough	   to	   be	   masked	   by	   the	   higher	   levels	   of	   activity.	   Either	   way,	   it	  
suggests	   that	   the	  upregulation	  of	   the	   transporter	  observed	  with	  dbcAMP	  and	  GSH	  
depletion	   is	   unlikely	   attributable	   simply	   to	   the	   classic	   EpRE/ARE-­‐associated	  
pathway,	  a	  notion	  supported	  by	  similar	  data	  reported	  in	  a	  mammary	  cell	  line	  (Wang	  
et	   al.	   2006)	   and	  mouse	   embryonic	   fibroblasts	   (Sasaki	   et	   al.	   2002).	  Notably,	   in	   the	  
latter	   study,	   electrophiles	   and	   known	   inducers	   (arsenic,	   cadmium,	   hydroquinone,	  
and	  DEM)	  of	   the	  EpRE	  were	   shown	   to	  be	  effective	  at	  upregulating	   SxC-­‐,	   advancing	  
the	  argument	  that	  BSO	  and	  electrophiles	  may	  act	   independently	  to	  regulate	  L-­‐Cys2	  
transport.	  Further,	  GSH	   levels	   in	  glia	  of	  Nrf2	   -­‐/-­‐	  animals	  are	  not	  different	   than	  that	  
from	  wildtypes	   (Shih	  et	   al.	   2005),	   suggesting	  other	  mechanisms	   in	   control	  of	  GSH	  
homeostasis	   in	   these	  animals.	  Aside	   from	  Nrf2,	   the	   transcription	   factor	  ATF4	  (aka	  
Creb2)	   has	   also	   been	   shown	   to	   induce	   SXc-­‐	   activity	   (Lewerenz	   and	   Maher	   2009),	  
specifically	   in	  response	  to	  L-­‐Cys2	  deprivation	  (Sato	  et	  al.	  2004).	   Indeed,	  consistent	  
with	  these	  results	  it	  has	  been	  demonstrated	  here	  that	  astrocyte	  cultures	  exposed	  to	  
high	  levels	  of	  L-­‐Glu	  (5	  mM)	  (effectively	  outcompeting	  the	  transport	  of	  L-­‐Cys2)	  also	  
exhibit	   increased	   levels	   of	   SXc-­‐	   activity	   (Fig.	   4.24).	   However,	   unlike	   amino	   acid	  
deprivation	  scenarios,	  treatment	  with	  BSO	  would	  be	  expected	  to	  lead	  to	  an	  increase	  
in	  intracellular	  L-­‐Cys2/L-­‐CysH	  and	  L-­‐Glu,	  as	  these	  amino	  acids	  would	  not	  be	  utilized	  
by	   the	   synthetase.	   Therefore,	   in	   the	   model	   of	   BSO-­‐mediated	   GSH-­‐depletion	   it	   is	  
unlikely	  that	  the	  increase	  in	  SXc-­‐	  is	  related	  to	  ATF4-­‐mediated	  activation	  of	  the	  AARE.	  
Interestingly,	   the	   induction	   of	   xCT	   by	   the	   reactive	   tocopherol	   metabolite	   γ-­‐
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tocopheryl	   quinone	   has	   been	   shown	   to	   be	   attenuated	   by	   siRNA	   for	   ATF4	   but	   not	  
Nrf2	   in	   PC-­‐12	   cells	   (Ogawa	   et	   al.	   2008).	   This	   suggests	   that	  ATF4	   can	  mediate	   the	  
transcriptional	  control	  of	  xCT	  via	  the	  AARE	  in	  ways	  potentially	  distinct	  from	  amino	  
acid	  deprivation	  or	  through	  a	  means	  independent	  of	  the	  AARE.	  	  
Alternatively,	  given	  the	  presence	  of	  Nrf2	  in	  the	  nuclei	  of	  the	  dbcAMP	  +	  BSO	  –	  treated	  
astrocytes	   and	   the	   heterodimeric	   nature	   of	   Nrf2-­‐mediated	   gene	   activation,	   it	   is	  
feasible	  that	  the	  stimulation	  of	  a	  converging	  signaling	  pathway	  may	  be	  involved	  in	  
SxC-­‐	  regulation.	  In	  a	  model	  of	  systemic	  GSH-­‐depletion	  in	  mice	  it	  was	  found	  that	  the	  
upregulation	  of	  SxC-­‐	  was	   linked	  to	  p38MAPK	  and	  ERK2	  signaling	  cascades	  (Limon-­‐
Pacheco	  et	  al.	  2007),	  potentially	  leading	  to	  the	  activation/synthesis	  of	  any	  number	  
of	  additional	  transcription	  factors	  linked	  to	  either	  the	  Nrf2-­‐associated	  activation	  of	  
SxC-­‐	   or	   an	   as	   yet	   unspecified	   Nrf2-­‐independent	   pathway	   of	   gene	   activation.	   Thus,	  
there	  may	   be	   other	   points	   along	   the	   pathway	   to	   EpRE	   stimulation	   on	  which	   BSO	  
could	  be	  having	   its	   effect	   apart	   from	   the	   release	  of	   cytoplasmic	   sequestered	  Nrf2.	  
This	  type	  of	  regulatory	  control	  is	  observed	  in	  the	  cases	  of	  arsenic	  (sodium	  arsenite)	  
exposure	   in	   hepa1c1c7	   cells	   (He	   et	   al.	   2006).	   In	   this	   study,	   arsenic,	   but	   not	   tBHQ	  
treatment,	   was	   associated	   with	   the	   disruption	   of	   Nrf2-­‐keap1-­‐Cu3	   complexes	   and	  
dimerization	  of	  Nrf2	  and	  Maf	  proteins	   in	  the	  nucleus,	  resulting	  in	   increased	  EpRE-­‐
dependent	   transcription	   of	   the	   NQO1	   gene.	   This	   observation	   of	   the	   differential	  
actions	  of	  arsenic	  and	  tBHQ	  on	  EpRE-­‐mediated	  gene	  expression	  may	  be	  relevant	  to	  
the	   results	   presented	   here.	   Specifically,	   while	   tBHQ	   did	   not	   have	   an	   effect	   on	  
dbcAMP-­‐treated	   astrocytes,	   arsenic	   did	   have	   a	   modest	   inductive	   effect	   in	   this	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phenotype	  (Fig.	  24),	  again	  lending	  credence	  to	  the	  concept	  of	  multi-­‐point	  regulatory	  
control	  over	  genes	  containing	  EpRE	  response	  elements,	  in	  particular,	  SXc-­‐.	  	  
Additionally,	  in	  our	  model	  of	  GSH-­‐depletion,	  ROS	  levels	  may	  be	  postulated	  to	  play	  a	  
role	   in	   the	   regulation	   of	   SXc-­‐.	   However,	   ROS	   levels	  were	   comparable	   in	   astrocytes	  
treated	  with	  either	  BSO	  or	  H2O2,	  although	  it	  was	  only	  the	  addition	  of	  BSO	  that	  led	  to	  
an	   increase	   in	   SXc-­‐	   activity.	   Similarly,	   antioxidant	   treatment	   was	   ineffective	   at	  
preventing	  the	  effect	  of	  GSH-­‐depletion.	  There	   is	  evidence	  for	  the	   induction	  of	  MAP	  
kinase	   pathways	   by	   oxidative	   stress	   and	   H2O2,	   specifically	   the	   activation	   of	   p38	  
MAPK	   and	   ERK	   (Rosenberger	   et	   al.	   2001).	   As	   these	   pathways	   can	   lead	   to	   the	  
activation	  of	  CREB,	  thereby	  mimicking	  the	  action	  of	  dbcAMP,	  it	  is	  possible	  that	  cells	  
treated	  with	  H2O2	  could	  induce	  SXc-­‐	  in	  a	  manner	  similar	  to	  dbcAMP.	  	  One	  explanation	  
then	  is	  that	  astrocytes	  were	  already	  close	  to	  if	  not	  at	  their	  maximal	  level	  of	  dbcAMP-­‐
mediated	   SXc-­‐	   expression	  prior	   to	   the	   addition	  of	  H2O2	   and	   therefore	   could	  not	   be	  
further	  stimulated.	  These	  findings	  tie	  the	  induction	  of	  SXc-­‐	  more	  directly	  to	  changes	  
in	  GSH	  itself,	  rather	  than	  secondary	  effects,	  such	  as	  a	  general	   increase	   in	  oxidative	  
stress	  or	  ROS.	  	  Such	  a	  relationship	  would	  also	  be	  consistent	  with	  the	  close	  temporal	  
correlation	  observed	  between	  SXc-­‐	  activity	  and	  GSH	  levels	  as	  both	  returned	  to	  basal	  
levels	  following	  the	  washout	  of	  BSO	  (Fig.	  4.19).	  	  
The	  strongest	  evidence	  that	  the	  induction	  of	  SXc-­‐	  was	  actually	  triggered	  by	  changes	  
in	   intracellular	   GSH	   levels	   came	   from	   experiments	   demonstrating	   that	   the	   ethyl-­‐
ester	   of	   GSH	   (GSH-­‐E)	  was	   able	   to	   prevent	   the	   increase	   in	   activity	  when	   added	   in	  
combination	   with	   BSO.	   	   GSH-­‐E	   is	   considered	   a	   	   “pro-­‐drug”	   that	   enhances	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permeability	   and	   intracellular	   accumulation	   of	   GSH	   and	  does	   so	   in	   a	  manner	   that	  
bypasses	   the	   inhibition	  of	  γ-­‐glutamylcysteine	  synthetase	  by	  BSO.	   	  The	   finding	   that	  
additions	  of	  GSH	  (which	  cannot	  be	   transported	   into	  cells	   intact),	  L-­‐CysH	  or	  L-­‐Cys2	  
failed	   to	   mimic	   the	   effectiveness	   of	   GSH-­‐E	   in	   preventing	   the	   induction	   is	   not	  
surprising,	   as	   the	   capacity	   of	   these	   precursors	   to	   replenish	   GSH	   levels	   would	   be	  
dependent	   upon	   the	   activity	   of	   γ-­‐glutamylcysteine	   synthetase.	   	   Further,	   the	  
observation	   that	   γ-­‐glutamylcysteine	   did	   have	   a	   modest	   effect	   on	   attenuating	   the	  
increase	  SXc-­‐	  activity,	  provides	  an	  explanation	  as	  to	  how	  GSH	  may	  have	  produced	  its	  
effect.	  	  	  The	  ineffectiveness	  of	  GSH,	  L-­‐CysH	  or	  L-­‐Cys2	  also	  suggests	  that	  the	  induction	  
of	  SXc-­‐	  was	  not	   triggered	  by	  an	  extracellular	  decrease	   in	  any	  of	   these	   three,	  which	  
would	  be	  expected	  to	  follow	  a	  reduction	  in	  the	  synthesis	  and	  export	  of	  intracellular	  
GSH.	  	  The	  surprise	  among	  the	  compounds	  tested	  was,	  however,	  the	  other	  pro-­‐drug	  
N-­‐acetyl-­‐CysH	  (NAC),	  which	  was	  as	  effective	  as	  GSH-­‐E	  in	  counteracting	  the	  action	  of	  
BSO.	  	  When	  interpreted	  in	  view	  of	  the	  inactivity	  of	  L-­‐CysH,	  it	  suggests	  that	  NAC	  may	  
have	  been	  acting	  as	  a	  GSH	  mimic,	  rather	  than	  a	  source	  of	  intracellular	  of	  L-­‐CysH.	  	  In	  
this	  respect,	  NAC	  may	  more	  closely	  resemble	  L-­‐CysH	  as	   it	   is	  embedded	  within	   the	  
GSH	   tri-­‐peptide.	   	   Following	   internalization	   and	   deacylation,	   this	   effect	   would	   be	  
expected	   to	   be	   lost	   however.	   The	  potential	   for	  NAC	   to	   be	   acting	   extracellularly	   to	  
alter	   the	   redox	   status	   on	   the	   surface	   of	   glia	   is	   a	   possibility.	   Alternatively,	   it	   may	  
indicate	   that	   the	   induction	   of	   SXc-­‐	   was	   triggered	   by	   a	   more	   general	   loss	   of	  
intracellular	  free	  thiols	  (whether	  GSH	  or	  L-­‐CysH)	  and	  that	  the	  extracellular	  addition	  
of	  NAC	  was	  more	  effective	  in	  this	  regard	  than	  L-­‐CysH.	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While	  the	  exact	  mechanism	  involved	  in	  the	  induction	  of	  SXc-­‐	  	  by	  the	  GSH/thiol	  trigger	  
is	   unknown,	   recent	   evidence	   suggests	   that	   the	   redox	   state	   of	   protein	   sulfhydryl	  
moieties	   can	   serve	   as	   signaling	   intermediates	   in	   a	   number	   of	   transcriptional	  
activation	  events	  (Ahn	  and	  Thiele	  2003;	  Delaunay	  et	  al.	  2002;	  Limon-­‐Pacheco	  et	  al.	  
2007;	  Tachibana	  et	  al.	  2009).	  The	  role	  of	  GSH	  in	  these	  signaling	  events	  may	  involve	  
interacting	   with	   cysteines	   located	   in	   the	   modulatory	   or	   active	   site	   of	   kinases,	  
phosphatases,	   and	   transcription	   factors.	   As	   mentioned	   above,	   Nrf2	   activation	  
involves	  the	  redox	  status	  of	  cysteine	  moieties	  within	  the	  Keap1-­‐Nrf2	  complex.	  Other	  
examples	   of	   redox-­‐related	   activation	   exist	   as	   well.	   For	   instance,	   the	   HSF1	  
transcription	   factor	   is	  activated	  to	   the	   trimeric	   form	  in	  response	  to	  stress	   through	  
the	  formation	  of	  disulfide	  bonds,	  and	  is	  inactivated	  by	  GSH,	  NAC,	  and	  DTT	  (Ahn	  and	  
Thiele	  2003).	  Along	  a	  similar	  vein,	  a	  decrease	  in	  liver,	  kidney,	  and	  brain	  GSH	  has	  led	  
to	  varying	  levels	  of	  p38MAPK	  and	  ERK	  activation	  leading	  to	  NF-­‐KB,	  ATF-­‐2,	  and	  c-­‐Jun	  
phosphorylation	   (Limon-­‐Pacheco	   et	   al.	   2007).	   Also,	   the	   formation	   of	   disulphide	  
bonds	   is	  responsible	   for	   the	  activation	  of	  Yap1	  (a	  tf	   involved	   in	  oxidative	  stress	   in	  
budding	   yeast)	   (Tachibana	   et	   al.	   2009).	   Conversely,	   increases	   in	   the	   cellular	  
reducing	   environment	   also	   serve	   to	   initiate	   signaling	   cascades.	   The	   application	   of	  
reducing	  voltages	   to	  Caco-­‐2	  cells	  doubled	   the	   rate	  of	  BrDU	   incorporation	  and	  was	  
found	   to	   increase	   EGF	   receptor	   phosphorylation	   and	   subsequently	   p44/42	  MAPK	  
activation	  (Nkabyo	  et	  al.	  2005).	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5.4	  Physiological	  significance	  of	  the	  depletion	  of	  GSH	  
Perhaps	   the	   best	   correlation	   of	   our	   GSH-­‐depletion	  model	  with	   known	   diseases	   is	  
with	   inborn	   deficiencies	   in	   synthesis	   and	   GSH	   regeneration.	   GSSG	   reductase	   and	  
GSH	   synthetase	   deficiencies	   have	   been	   associated	   with	   increased	   tendency	   to	  
hemolytic	   disease,	   cataracts,	   and	   CNS	   function	   (Meister	   1991).	   GSH	   synthetase	  
deficiencies	   are	   interesting	   as	   they	   often	   involve	   a	   cascade	   of	   secondary	   effects	  
related	   to	   normal	   GSH	   feedback	   and	   metabolism.	   Specifically,	   under	   normal	  
conditions,	   GSH	   feedback	   inhibits	   γ-­‐glutamylcysteine	   synthetase	   (γGCS),	   which	  
catalyzes	   dipeptide	   (γ-­‐glutamylcysteine)	   formation	   at	   sub-­‐maximal	   rates.	  Without	  
GSH	  synthetase	  activity,	  GSH	   levels	  are	   low,	   thus	   releasing	  γGCS	   inhibition.	  Excess	  
formation	   of	   γ-­‐glutamylcysteine	   (something	   that	   wouldn’t	   occur	   in	   our	   BSO	  
regimen),	  leads	  to	  the	  increased	  formation	  of	  5-­‐oxoproline	  as	  γ-­‐glutamylcysteine	  is	  a	  
good	   substrate	   for	   γ-­‐glutamylcyclotransferase.	   5-­‐oxoproline	   accumulates	   in	   the	  
blood	   as	   it	   overwhelms	   the	   degradation	   ability	   of	   5-­‐oxoprolinase.	   This	   causes	  
acidosis	   which	   can	   be	   life	   threatening	   (Meister	   1991).	   As	   an	   aside,	   in	   this	   case	  
inhibition	  of	  SxC-­‐	  or	  BSO	  treatment	  could	  possibly	  have	  therapeutic	  effects.	  
In	   light	   of	   our	   findings,	   the	   functional	   link	   between	   GSH	   and	   SXc-­‐	   may	   also	   be	  
relevant	   to	   a	   variety	   of	   pathologies	   characterized	   by	   decreases	   in	   GSH,	   such	   as	  
Parkinsonian	  disorders	  (Chinta	  et	  al.	  2007;	  Schulz	  et	  al.	  2000a;	  Wullner	  et	  al.	  1996)	  
and	  schizophrenia	  (Berk	  et	  al.	  2008;	  Do	  et	  al.	  2000;	  Grima	  et	  al.	  2003;	  Hirrlinger	  et	  
al.	  2002)	  as	  disease	  development	  and/or	  progression	  may	  conceivably	  be	  linked	  to	  
an	  aberration	  in	  the	  GSH-­‐mediated	  regulation	  of	  SXc-­‐	  described	  here.	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In	   Parkinson’s	   disease,	   sufficient	   GSH	   concentrations	   in	   astrocytes	   are	   critical	   for	  
the	  survival	  of	  dopaminergic	  neurons,	  and	  neuronal	  GSH	  loss	  tends	  to	  correlate	  with	  
PD	   severity	   (Schulz	   et	   al.	   2000b).	   Interestingly,	   GSH	   is	   also	   decreased	   during	   the	  
preclinical	  asymptomatic	  phase	  of	   the	  disease,	   suggesting	  an	  early	   role	   for	  GSH	   in	  
pathogenesis	   of	   PD.	   Although	   GSH	   depletion	   is	   not	   sufficient	   to	   mimic	   PD	   in	   the	  
healthy	   substantia	   nigra,	   it	   does	   lead	   to	   greater	   dopaminergic	   neurodegeneration	  
(Chinta	   et	   al.	   2007)	   and	   neurotoxicity	   upon	   subsequent	   exposure	   to	   MPTP,	   a	  
meperidine	  analog	  that	  mimics	  the	  idiopathic	  effects	  of	  PD	  (Wullner	  et	  al.	  1996).	  In	  
addition	   to	   GSH	   loss,	   the	   potential	   generation	   of	   ROS	   as	   a	   result	   of	   dopamine	  
metabolism	   by	  MAO	   is	   also	   thought	   to	   contribute	   to	   dopaminergic	   cell	   death	   and	  
pathogenesis.	   In	   fact,	   the	   inhibition	   of	   MAO	   in	   Parkinson’s	   patients	   remains	   an	  
important	   therapeutic	   approach	   (Chen	   et	   al.	   2008).	   Dopamine	   release	   from	  
presynaptic	  neurons	  has	  been	   shown	   to	  be	  negatively	   regulated	  by	   the	  binding	  of	  
glutamate	   released	   from	   SxC-­‐	   to	   mGlur2/3	   (Baker	   et	   al.	   2002b).	   Therefore,	  
attenuated	   SxC-­‐	   could	   potentially	   lead	   to	   excess	   dopamine	   release	   and	   extensive	  
MAO	  metabolism,	  with	  potentially	  significant	  ROS	  generation.	  	  The	  current	  data	  on	  
this	  topic	  is	  intriguing	  however	  the	  exact	  role	  of	  GSH	  or	  SxC-­‐	  in	  PD	  pathogenesis	  has	  
not	  been	  fully	  elucidated.	  	  
Schizophrenia	   is	   a	   disorder	   of	   the	   CNS	   for	   which	   the	   etiology	   is	   currently	  
incomplete,	   but	   for	   which	   there	   is	   evidence	   of	   both	   dopaminergic	   hyperfunction	  
(Howes	   et	   al.	   2009;	   Howes	   and	   Kapur	   2009)and	   glutamatergic	   hypofunction	  
(Carlsson	  et	  al.	  2001;	  Carlsson	  and	  Carlsson	  1989;	  Olney	  1990).	  Decreases	   in	  GSH	  
have	  been	  observed	  in	  schizophrenics	  in	  vivo	  as	  well	  as	  in	  in	  vitro	  models	  (Do	  et	  al.	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2000)	   and	   polymorphisms	   in	   GSH-­‐metabolism	   and	   synthesis	   genes	   (i.e.	   GSTT1,	  
GCLC,	   and	   GCLM)	   are	   associated	  with	   increased	   susceptibility	   to	   the	   disorder	   for	  
review	  see:	  (Berk	  et	  al.	  2008).	  GSH	  depletion	  is	  now	  thought	  to	  be	  a	  consequence	  of	  
increased	   levels	  of	  dopamine	  (DA)	   in	   the	  CNS	  of	   schizophrenics.	  Free	  radicals	  and	  
reactive	  oxygen	  species	  (namely	  superoxide	  and	  hydrogen	  peroxide)	  are	  produced	  
as	  a	   result	  of	  dopamine	  metabolism	  (Chen	  et	  al.	  2008;	  Hirrlinger	  et	  al.	  2002),	  and	  
consequently	   deplete	   cellular	   levels	   of	  GSH	   (Hirrlinger	   et	   al.	   2002).	   In	   addition	   to	  
increased	  DA	  metabolism,	  a	  number	  alterations	  in	  brain	  energy	  metabolism	  occur	  in	  
schizophrenia,	   including	   polymorphisms	   in	   mitochondrial	   genes	   and	   proteins	  
involved	   in	   the	   electron	   transport	   chain,	   potentially	   leading	   to	   ever	   greater	  
production	   of	   oxidative	   species(Karry	   et	   al.	   2004).	   Therefore,	   glutathione	   and,	   by	  
association,	   SxC-­‐,	   may	   play	   a	   critical	   role	   in	   protecting	   cells	   from	   damage	   by	   ROS	  
generated	   in	   schizophrenia.	   In	   fact,	   GSH-­‐deficiency	   sensitizes	   neurons	   to	   DA-­‐
induced	   dendritic	   degeneration	   (Grima	   et	   al.	   2003).	   Considering	   the	   connection	  
between	   oxidative	   stress	   and	   psychiatric	   disorders,	   GSH	   may	   represent	   a	   novel	  
target	   for	   treatment	   (Berk	   et	   al.	   2008).	   In	   support	   of	   this,	  N-­‐acetylcysteine	   (NAC)	  
treatment	   led	   to	   higher	   ratings	   than	   placebo	   in	   a	   variety	   of	   categories.	   As	   the	  
acetylated	  precursor	  of	  L-­‐cysteine,	  NAC	  likely	  enters	  the	  cell	  through	  neutral	  amino	  
acid	   transporters	   and	   once	   deacetylated	   supplies	   cysteine,	   the	   rate-­‐limiting	  
precursor	  to	  GSH	  synthesis.	  Along	  these	  lines,	  clinical	  data	  have	  demonstrated	  that	  
the	   antioxidant	   effects	   of	   certain	   antipsychotic	   drugs	   may	   play	   a	   role	   in	   their	  
therapeutic	  effect	  as	  they	  are	  capable	  of	  decreasing	  the	  oxidative	  stress	  reported	  in	  
schizophrenia,	  bipolar,	  and	  major	  depressive	  disorders	  (Berk	  et	  al.	  2008).	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Decreases	  in	  cellular	  GSH	  could	  also	  alter	  the	  function	  of	  the	  glutamatergic	  system,	  
in	   particular	   the	   NMDA	   receptor	   (NMDAR).	   In	   vitro,	   the	   NMDAR	   is	   positively	  
modulated	  by	  reductants,	   including	  GSH	  (Aizenman	  et	  al.	  1989;	  Janaky	  et	  al.	  1993;	  
Regan	  and	  Guo	  1999a;	  Regan	  and	  Guo	  1999b).	  Thus,	  a	  decrease	  in	  GSH	  could	  result	  
in	  a	  reduction	  in	  NMDAR	  function.	  	  Indeed	  NMDAR	  dysfunction	  has	  been	  proposed	  
as	   part	   of	   schizophrenia	   etiology	   as	   NMDAR	   antagonists	   like	   phencyclidine	   (PCP)	  
and	  ketamine	  can	   induce	  schizophreniform	  psychotic	  symptoms	   in	  healthy	  human	  
volunteers	   (Moghaddam	   2003).	   Studies	   have	   also	   demonstrated	   that	   NMDA	  
receptor	   dysfunction	   may	   underlie	   the	   increases	   in	   dopamine	   release	   seen	   in	  
schizophrenic	   patients	   (Kegeles	   et	   al.	   2000),	   supporting	   the	   notion	   that	   both	   the	  
hyperdopaminergic	   and	   hypoglutamatergic	   theories	  may	   in	   fact	   overlap.	   From	   an	  
experimental-­‐model	  perspective,	  as	  compared	  to	  untreated	  astrocytes	  the	  dbcAMP-­‐
treated	  glial	  phenotype	  may	  represent	  a	  useful	  model	  for	  the	  study	  of	  Sxc	  regulation	  
as	   it	   could	   represent	   how	   astrocytes,	   either	   in	   the	   presence	   of	   neurons	   or	   in	  
response	  to	  disease	  (Daginakatte	  et	  al.	  2008),	  uniquely	  respond	  to	  changes	  in	  GSH	  
status.	  	  
	  
5.5	  Concluding	  remarks	  
Collectively,	   these	   findings	   support	   the	   conclusion	   that,	   like	   other	   glial	   proteins	  
involved	   in	   the	   regulation	   of	   L-­‐Glu	   (e.g.,	   GLT1,	   GLAST,	   glutamine	   synthetase),	   the	  
expression	   of	   SXc-­‐	   in	   astrocytes	   is	   phenotype	   dependent	   and	   markedly	   increases	  
when	   the	   cells	   are	   differentiated	   with	   dbcAMP	   into	   a	   phenotype	   more	  
	   93	  
representative	  of	  that	  found	  in	  vivo	  or	  following	  injury-­‐induced	  activation.	  	  Further,	  
the	  depletion	  of	  GSH	  levels	  in	  these	  astrocytes	  appears	  to	  serve	  as	  a	  trigger	  for	  the	  
rapid	   induction	  of	   SXc-­‐,	   a	   pathway	  not	   observed	   in	  other	   cell	   types.	   	   The	   ability	   of	  
these	   cells	   to	   regulate	   SXc-­‐	   in	   this	   manner	   likely	   reflects	   the	   specialized	   role	   of	  
astrocytes	   and	   SXc-­‐	   in	   maintaining	   glial,	   as	   well	   as	   neuronal,	   GSH	   levels	   as	   a	  
protective	  mechanism	  and	  the	  inherent	  vulnerability	  of	  the	  CNS	  to	  oxidative	  injury.	  	  
Ironically,	  while	  this	  pathway	  allows	  the	  CNS	  to	  rapidly	  up-­‐regulate	  SXc-­‐	  in	  response	  
to	   an	   oxidative	   or	   toxic	   challenge,	   it	   also	   holds	   the	   potential	   to	   exacerbate	   CNS	  
pathology	  as	  a	  consequence	  of	   increasing	  extracellular	  L-­‐Glu	   levels	  and	   the	  risk	  of	  
excitotoxicity.	   Whether	   related	   to	   the	   progression	   of	   a	   disease	   or	   a	   therapeutic	  
intervention,	   it	   is	   the	   balance	   between	   these	   two	   possible	   outcomes	   that	   must	  
always	   be	   kept	   in	   mind	   when	   considering	   the	   physiological	   consequences	   of	  
alterations	  in	  SXc-­‐.	  	  
	  
	   94	  
Appendix	  I:	  Nrf2	  involvement	  in	  the	  regulation	  of	  SxC-­,	  a	  history	  	  
	  
Early	  work	  with	  DEM,	  L-­Cys2	  deprivation,	  and	  LPS	  	  
Given	  the	  link	  between	  GSH	  production	  and	  SxC-­‐	  activity,	  it	  is	  perhaps	  not	  surprising	  
that	  some	  of	  the	  first	  investigations	  into	  the	  induction	  of	  SxC-­‐	  involved	  the	  treatment	  
of	  cells	  with	  electrophilic	  agents	  in	  an	  attempt	  to	  deplete	  GSH	  (Bannai	  1984).	  At	  that	  
time	   it	   was	   known	   that	   electrophiles	   (most	   commonly	   diethyl	   maleate	   or	   DEM)	  
interact	  with	  sulphydryl	  groups	  and	  accordingly	  deplete	  GSH	  levels	  both	  in	  vivo	  and	  
in	  vitro	  through	  GSH	  conjugation	  reactions	  (Boyland	  and	  Chasseaud	  1970;	  Brodie	  et	  
al.	   1982;	  Chuang	  et	   al.	   1978;	  Early	   and	  Schnell	   1982;	  Tietze	  1969).	  The	   results	   of	  
Shiro	   Bannai’s	   1984	   study	   are	   striking	   however	   in	   that	   GSH	   depletion	   was	   not	  
correlated	  with	   an	   upregulation	   of	   SxC-­‐.	   The	   treatment	   of	   human	   lung	   fibroblasts	  
with	  DEM	  at	  concentrations	  high	  enough	  to	  deplete	  GSH	  (above	  250	  µM)	  resulted	  in	  
a	  decrease	   in	  L-­‐cystine/L-­‐glutamate	  exchange	  activity,	  but	  at	   lower	  concentrations	  
(<100	  µM)	  both	  GSH	  and	  SxC-­‐	  activity	  increased	  (Bannai	  1984).	  In	  this	  same	  study,	  
and	  consistent	  with	  a	  negative	  feedback	  mechanism	  of	  regulation,	  it	  was	  also	  found	  
that	  L-­‐cystine	  deprivation	   led	   to	   a	   similar	   increase	   in	  SxC-­‐	   activity	   (a	  phenomenon	  
now	   known	   to	   be	  mediated	   by	   the	   transcription	   factor	   ATF4	   and	   the	   amino	   acid	  
response	   element	   (AARE)	   (Lewerenz	   and	   Maher	   2009;	   Sato	   et	   al.	   2004)).	   Soon	  
thereafter,	   fibroblasts	   were	   shown	   to	   respond	   to	   increased	   oxygen	   tension	   by	  
upregulating	  SxC-­‐,	  likely	  in	  a	  manner	  distinct	  from	  DEM	  (Bannai	  et	  al.	  1989).	  Then,	  in	  
1995,	  Sato	  et	  al	  demonstrated	  that	  lipopolysaccharide	  (LPS),	  like	  DEM,	  was	  capable	  
of	   increasing	   both	   the	   activity	   of	   the	   transporter	   and	   GSH	   levels	   in	   peritoneal	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macrophages	  (Sato	  et	  al.	  1995).	  Interestingly	  these	  same	  changes	  in	  system	  xC-­‐	  were	  
not	   observed	   when	   fibroblasts	   were	   treated	   with	   LPS.	   This	   and	   the	   fact	   that	   the	  
effect	  of	  LPS	  and	  DEM	  were	  additive	  suggested	  not	  only	  cell-­‐type	  specific	  regulation	  
but	  also	  another	  possible	  means	  by	  which	  system	  xC-­‐	  may	  respond	  to	  environmental	  
factors.	  	  
Two	   of	   the	  most	   common	   transcription	   factors	   known	   to	   respond	   to	   the	   cellular	  
redox	   status	   are	   nuclear	   factor-­‐kB	   (NF-­‐κB)	   and	   activator	   protein-­‐1	   (AP1).	   	   NF-­‐κB	  
and	  AP-­‐1	  have	  been	  implicated	  in	  the	  inducible	  expression	  of	  a	  wide	  range	  of	  genes	  
involved	  in	  oxidative	  stress	  and	  NF-­‐κB	  is	  known	  to	  be	  activated	  by	  a	  wide	  spectrum	  
of	   agents	   (eg.	   bacteria,	   oxidants,	   pathogens,	   viruses,	   UV	   radiation,	   phorbol	   esters,	  
TNF-­‐alpha,	   and	   others)	   (see	   Sen	   and	   Packer	   1996	   for	   review).	   GSH	   depletion	   has	  
been	   shown	   to	   inactivate	   (Wu	   and	   Cederbaum	   2004)	  whereas	   L-­‐Glu	   (500	  µM)	   is	  
known	  to	  activate	  (Caccamo	  et	  al.	  2005)	  NF-­‐κB	  and	  DNA	  binding.	  Interestingly,	  LPS,	  
a	  toxic	  product	  of	  bacterial	  infection,	  does	  not	  activate	  AP-­‐1	  nor	  NF-­‐κB	  (Sato	  1995,	  
Sato	  2001),	  a	   finding	  that	  at	  the	  time	  hinted	  at	  the	  presence	  of	  other	  transcription	  
factors	  responsible	  for	  the	  control	  of	  SxC-­‐	  expression.	  
	  
ARE/EpRE	  –	  the	  results	  of	  studies	  with	  electrophiles	  	  
In	  the	  late	  1980’s	  and	  early	  1990’s	  research	  began	  to	  link	  the	  ability	  of	  electrophilic	  
compounds	   (oxidizable	   phenols,	   quinines,	   Michael	   reaction	   acceptors,	  
isothiocyanates,	  peroxides,	  vicinal	  dimercaptans,	  divalent	  mercury	  derivatives,	  and	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trivalent	  arsenicals)	  to	  induce	  phase	  II	  enzymes	  such	  as	  glutathione-­‐S-­‐transferases	  
(GSTs),	   NAD(P)H:	   quinone	   oxidoreductase	   (NQO1),	   epoxide	   hydrolase,	   and	   UDP	  
glucuronosyltransferases	  (Prochaska	  et	  al.	  1985;	  Spencer	  et	  al.	  1991;	  Talalay	  1989;	  
Talalay	   et	   al.	   1988).	   These	   enzymes	   reportedly	   detoxify	   electrophiles	   through	  
various	   mechanisms,	   including	   increasing	   GSH	   synthesis	   and	   conjugation,	   which	  
protects	  against	  the	  toxic	  and	  neoplastic	  effect	  of	  carcinogens.	  The	  protective	  effects	  
of	  these	  compounds	  is	  demonstrated	  by	  the	  isothiocyanate	  sulphoraphane	  (a	  potent	  
NQO1	   inducer	   found	   in	   broccoli).	   Sulphoraphane	   or	   broccoli	   sprout	   extracts	  
reduced	   the	   incidence,	   multiplicity,	   tumor	   progression,	   and	   weight	   of	   mammary	  
tumors	   in	   rats	   (Fahey	   et	   al.	   1997;	   Zhang	   et	   al.	   1994).	   	   Around	   the	   same	   time,	  
upstream	  enhancer	  elements	  of	  mouse	  and	  rat	  liver	  GST	  genes	  that	  respond	  to	  these	  
electrophilic	  inducers	  were	  identified	  as	  nearly	  identical	  41-­‐bp	  segments	  termed	  the	  
EpRE	  (electrophile	   response	  element	  and	   the	  antioxidant-­‐response	  element	   (ARE)	  
respectively	   (Prestera	   et	   al.	   1993;	   Prestera	   and	   Talalay	   1995).	   These	   sites	   were	  
shown	   to	   be	   distinct	   from	   AP-­‐1	   binding	   sites	   and	   tert-­‐butylhydroquinone	   (tBHQ)	  
was	   identified	   as	   one	   of	   a	   number	   of	   electrophiles	   shown	   to	   activate	   the	   EpRE	  
(Prestera	  and	  Talalay	  1995).	  
	  
Nrf2-­	  identified	  as	  link	  to	  electrophilic	  activation	  
Other	  groups	  were	  beginning	   to	  suspect	  proteins	  other	   than	  AP-­‐1	  were	  mediating	  
transcription	  of	  genes	  in	  response	  to	  stress.	  It	  appears	  that	  while	  AP-­‐1	  and	  AP-­‐1-­‐like	  
sites	   exist	   in	   ARE/EpREs,	   AP-­‐1	   proteins	   do	   not	   induce	   the	   genes	   under	   the	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ARE/EpRE	  control	  in	  all	  cases	  (Alam	  et	  al.	  1999;	  Venugopal	  and	  Jaiswal	  1996).	  The	  
nuclear	  erythroid	  specific	  transcription	  factor	  2	  (NE-­‐F2)	  related	  factors	  1-­‐3	  (Nrf1-­‐3)	  
were	   first	   suspected	   as	   potential	   mediator	   of	   ARE/EpRE	   activation	   as	   a	   result	   of	  
both	   the	   similar	   tissue	   expression	   as	   genes	   regulated	   by	   ARE/EpRE,	   and	   for	  
exhibiting	   similar	   binding	   site	   sequences	   consistent	   with	   ARE/EpRE	   (Chan	   et	   al.	  
1993;	  Moi	  et	  al.	  1994).	  Additionally,	  mutation	  studies	  of	  AP-­‐1-­‐like	  enhancer	  regions	  
of	  other	  phase	  II	  genes	  revealed	  that	  the	  sequences	  responsible	  for	  activation	  were	  
in	   fact	   NF-­‐E2	   binding	   sites	   (Inamdar	   et	   al.	   1996).	   The	   NF-­‐E2	   protein	   is	   a	   dimer	  
consisting	  of	  Maf	  and	  other	  proteins.	  Maf,	  Nrf1,	  Nrf2,	  Nrf3	  are	  basic	   leucine	  zipper	  
(bZIP)	   proteins	   that	   contain	   a	   Cap’nCollar	   (CNC)	   domain	   and	   are	   collectively	  
referred	  to	  as	  CNC-­‐bZIP	  proteins.	  	  
One	  of	  the	  first	  lines	  of	  evidence	  for	  the	  involvement	  of	  Nrf	  proteins	  came	  when	  the	  
ARE	  contained	  within	  the	  NQO1	  gene	  was	  studied	  (this	  region	  contains	  one	  perfect	  
and	  one	  imperfect	  AP1	  element)	  (Venugopal	  and	  Jaiswal	  1996).	  A	  gene	  expression	  
reporter	   assay	   was	   performed	   in	   which	   Hep-­‐G2	   cells	   were	   co-­‐transfected	   with	   a	  
reporter	  plasmid	  containing	  the	  ARE	  of	  the	  NQO1	  gene	  and	  either	  AP-­‐1	  proteins	  (c-­‐
Fos	   and	  Fra1,c-­‐Jun,	   Jun-­‐B,	   and	   Jun-­‐D)	  or	  Nrf1	   and	  Nrf2.	  They	   found	   that	  plasmids	  
expressing	  c-­‐Fos	  and	  Fra1	  had	  a	  repressive	  effect	  on	  transcription	  and	  observed	  no	  
effect	   with	   the	   Jun	   proteins.	   Interestingly,	   over-­‐expression	   of	   Nrf1	   and	   Nrf2	  
significantly	   increased	   gene	   expression	   and	   these	   cells	   responded	   similarly	   to	   b-­‐
naphthoflavone	  and	  tBHQ.	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Similar	  experiments	  were	  performed	  to	  test	  the	  ability	  of	  AP-­‐1,	  Maf,	  and	  CNC-­‐bZIP	  
families	  of	  transcription	  factors	  on	  the	  activation	  of	  the	  HO-­‐1	  gene.	  RAW264.7	  and	  
L929	   cells	   (mouse	   macrophage	   and	   fibroblast	   lines)	   were	   transfected	   with	   a	  
reporter	   plasmid	   containing	   the	   HO	   gene	   enhancer	   along	  with	   plasmids	   for	   AP-­‐1	  
proteins	   (c-­‐Jun	   and	   c-­‐Fos),	   Maf,	   and	   CNC-­‐bZIP	   proteins.	   The	   Nrf2-­‐expressing	  
plasmid	   induced	   the	   reporter	   by	   25-­‐30	   fold	   (trans-­‐activation)	   (Alam	   et	   al.	   1999).	  
This	   effect	   was	   mimicked	   by	   heme,	   t-­‐BHQ,	   cadmium,	   arsenite,	   and	   zinc	   and	  
attenuated	  by	  overexpression	  of	  an	  Nrf2	  mutant.	  Lending	  more	  support	  for	  the	  role	  
of	   Nrf2	   in	   Phase	   II	   gene	   regulation,	   Nrf2	   knockout	   mice	   were	   shown	   to	   lack	  
inducible	   expression	   of	   these	   defensive	   genes	   (Itoh	   et	   al.	   1997).These	   results	  
represent	  the	  early	  evidence	  that	  Nrf2	  acts	  as	  a	  primary	  transcription	  factor	  for	  the	  
induction	   ARE/EpRE	   controlled	   genes,	   and	   that	   in	   some	   instances,	   AP-­‐1	   plays	   a	  
repressive	  role	  in	  the	  regulation	  of	  these	  genes.	  	  
Nrf2	  is	  a	  member	  of	  the	  basic	  leucine	  zipper	  family	  of	  transcription	  factors.	  Nrf2	  has	  
homology	   with	   chicken	   ECH	   (Erythroid	   derived	   CNC	   homology	   protein).	   The	  
conserved	  regions	  are	  referred	  to	  as	  Neh1	  through	  Neh6	  (Nrf2-­‐ECH	  homology)	  (Itoh	  
et	   al.	   1999).	   The	   N-­‐terminus	   contains	   a	   transactivation	   domain	   (Neh2)	   that	   is	  
responsible	   for	   binding	   Kelch-­‐like	   ECH	   associating	   protein	   1	   (Keap1).	   The	   C-­‐
terminus	  contains	  a	  basic	  leucine	  zipper	  structure	  responsible	  for	  dimerization	  with	  
small	  Maf	  proteins	  and	  for	  DNA-­‐binding.	  Nrf2	  resides	  in	  cytoplasm,	  associated	  with	  
the	   chaperone	   Keap1.	   Keap1	   is	   in	   turn	   associated	   with	   the	   cytoskeleton,	   and	   is	  
thought	   to	  negatively	   regulate	  Nrf2	  mediated	   gene	   activation	  by	   retaining	  Nrf2	   in	  
the	  cytoplasm	  and	  targeting	  it	  for	  ubiquination	  and	  degradation.	  As	  Keap1	  is	  known	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to	  contain	  25	  cysteine	  residues	  and	  given	   the	  reactivity	  of	  electrophiles	  and	  other	  
Nrf2-­‐activators	   with	   thiols,	   Keap1	   is	   thought	   to	   act	   through	   a	   thiol	   sensing	  
mechanism	   to	   initiate	   gene	   transcription	   by	   Nrf2.	   Cysteine	   mutation	   studies	   and	  
experiments	   with	   Keap1	   knock-­‐outs	   support	   this	   hypothesis	   (Wakabayashi	   et	   al.	  
2004).	  	  
After	   exposure	   of	   cells	   to	   electrophiles	   or	   oxidative	   stress-­‐generating	   agents,	   the	  
Keap1	  cytoplasmic	   retention	  mechanism	   is	   inactivated,	   and	  Nrf2	   is	   transported	   to	  
the	  nucleus.	  Once	  within	  the	  nucleus,	  Nrf2	  activates	  the	  transcription	  of	  target	  genes	  
by	   binding	   in	   heterodimeric	   forms	  with	   other	   transcription	   factors	   (Maf	   proteins,	  
ATF4,	  Jun)	  to	  distinct	  DNA	  elements,	  including	  the	  EpRE	  enhancer	  regions	  of	  phase	  
II	  genes	  (He	  et	  al.	  2001;	  for	  review	  see	  Itoh	  et	  al.	  2004).	  Accumulating	  evidence	  has	  
shown	  Nrf2	  mediated	  transcription	  to	  be	  protective	  from	  electrophilic	  drug-­‐induced	  
damage	   (Copple	   et	   al.	   2008a;	   Copple	   et	   al.	   2008b;	   Enomoto	   et	   al.	   2001)	   and	   in	  
carcinogenesis	   (Dinkova-­‐Kostova	   2002;	   Dinkova-­‐Kostova	   et	   al.	   2001;	   Fahey	   et	   al.	  
1997;	  Ramos-­‐Gomez	  et	  al.	  2001)	  
	  
SxC-­	  is	  regulated	  through	  Nrf2	  activation	  of	  the	  EpRE	  
The	   discovery	   of	   the	   Nrf2	   protein	   helped	   explain	   previous	   results	   involving	  
electrophilic	   induction	   (i.e.	   observation	   with	   DEM)	   of	   protective	   genes,	   including	  
SxC-­‐.	   By	   using	   peritoneal	   macrophages	   from	   Nrf2-­‐deficient	   mice,	   Ishii	   et	   al	  
demonstrated	  that	  the	  Nrf2	  protein	  mediated	  the	  inducible	  expression	  and	  activity	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of	   SxC-­‐	   and	   other	   protective	   genes	   (e.g.	   HO-­‐1,	   peroxiredoxin)	   by	   electrophiles	   and	  
other	  agents	  (DEM,	  tBHQ,	  paraquat,	  cadmium,	  arsenic)	  (Ishii	  et	  al.	  2000).	  
To	   further	   investigate	   the	   mechanism	   of	   transcriptional	   regulation	   of	   SxC-­‐	   by	  
electrophiles,	   5’	   deletion	   mutants	   of	   the	   EpRE-­‐like	   sequences	   of	   xCT	   gene	   were	  
cloned	   into	   a	   luciferase	   reporter	   and	   transfected	   into	   BHK21	   cells	   (Sasaki	   et	   al.	  
2002).	  Separate	  sequences	  were	  found	  to	  control	  the	  basal	  and	  inducible	  expression	  
of	   xCT	   mRNA	   and	   induction	   by	   electrophiles	   (arsenic,	   cadmium,	   hydroquinone,	  
DEM)	  was	  mediated	   by	   Nrf2	   (Sasaki	   et	   al.	   2002).	   Similar	   to	   earlier	   findings,	   GSH	  
levels	   increased	   with	   DEM	   treatment	   along	   with	   SxC-­‐	   (Sasaki	   et	   al.	   2002).	   Unlike	  
what	  has	  been	  shown	  in	  macrophages	  (Sato	  et	  al.	  1995),	  PMA	  and	  LPS	  had	  no	  effect	  
on	  SxC-­‐	  activity	  in	  these	  cells.	  	  
The	   EpRE	   driven	   gene	   expression	   has	   been	   found	   in	   macrophages,	   hepatocytes,	  
BHK21	   cells,	   fibroblasts,	   and	   the	   brain.	   By	   using	   a	   reporter	   gene	   and	   co-­‐labeling	  
Murphy	  et	  al	  demonstrated	   in	  both	  slice	   cultures	  and	  mixed	  cell	   cultures	   that	  glia	  
(but	   not	   neurons)	   exhibit	   EpRE	   mediated	   gene	   expression	   (Murphy	   et	   al.	   2001).	  
Since	   EpRE-­‐mediated	   gene	   expression	   is	   restricted	   to	   glial	   cells,	   they	   many	  
represent	   a	  protective	   cell	   type	   in	   situations	   characterized	  by	  ROS	  and	   stress	   and	  
respond	  by	  inducing	  EpRE-­‐containing	  genes,	  including	  SxC-­‐.	  	  
	  
	  
	   101	  
Activation	   of	   the	   genes	   under	   control	   of	   EpRE,	   including	   SxC-­,	   is	  
neuroprotective	  	  
In	  vitro	  and	  in	  vivo	  work	  has	  shown	  that	  the	  upregulation	  of	  SxC-­‐	  and	  other	  genes	  by	  
Nrf2,	   specifically	   those	   involved	   in	   GSH	   synthesis	   and	   release,	   results	   in	  
considerable	   protection	   of	   neurons	   from	   oxidative	   stress	   and	   glutamate	   toxicity	  
(Kraft	   et	   al.	   2004;	   Lee	   et	   al.	   2003a;	   Lee	   et	   al.	   2003b;	   Shih	   et	   al.	   2005;	   Shih	   et	   al.	  
2003).	   Using	   microarray,	   mixed	   glia/neuronal	   cultures	   infected	   with	   Nrf2	  
adenovirus	   are	   shown	   to	   upregulate	   NQO1,	   GST,	   HO-­‐1,	   MT,	   xCT,	   GCS,	   GSH	  
synthetase,	  GGT,	  GSH	  reductase,	  and	  MRP1,	  confirming	  the	  ability	  of	  Nrf2	  to	  control	  
the	  coordinated	  expression	  of	  many	  important	  antioxidant	  and	  detoxification	  genes.	  
Nrf2-­‐infected	   cells	   have	   increased	   SxC-­‐	   activity	   and	   GSH	   content.	   To	   test	   if	   Nrf2-­‐
induced	   gene	   expression	  mediates	   protection	   of	   neurons	   from	   glutamate	   toxicity,	  
mixed	  cultures	  were	  exposed	  to	  neurotoxic	  levels	  of	  L-­‐glutamate	  (3mM)	  and	  grown	  
either	   with	   or	   without	   Nrf2-­‐infected	   glia.	  When	   glia,	   either	   infected	  with	   Nrf2	   or	  
exposed	   to	   the	   prototypical	   Nrf2	   activator	   t-­‐BHQ,	   were	   grown	   on	   top	   of	   mixed	  
cultures,	   they	   were	   able	   to	   protect	   the	   neurons	   from	   glutamate	   toxicity.	   This	  
protection	  was	  potent	  (only	  requiring	  a	  1	  to	  100	  ratio	  of	  glia	  to	  neurons)	  and	  shown	  
to	  result	  from	  increased	  GSH	  synthesis	  and	  release	  by	  glia	  (Shih	  et	  al.	  2003).	  Similar	  
protection	  of	  neurons	  by	  Nrf2	  expression	  has	  also	  been	  demonstrated	  in	  vivo	  (Shih	  
et	   al.	   2005).	   To	   further	   ascertain	   the	   role	   of	   xCT	   in	   this	   protection,	   Shih	   et	   al.	  
examined	   the	   ability	   of	   cultured	   astrocytes,	   normally	   expressing	   nearly	  
undetectable	   levels	   of	   SxC-­‐,	   astrocytes	   expressing	   a	   mutant	   non-­‐functional	   xCT	  
(sut/sut	   mouse),	   and	   astrocytes	   infected	   with	   xCT,	   to	   protect	   neurons	   from	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oxidative	  glutamate	   toxicity.	  Only	  xCT	   infected	  astrocytes	  were	  protective	  (Shih	  et	  
al.	  2006).	  Implicit	  in	  the	  neuronal	  protection	  is	  the	  ability	  of	  SxC-­‐	  to	  control	  glial	  GSH	  
levels,	   made	   available	   for	   release,	   and	   further	   metabolism	   and	   utilization	   by	  
neurons.	   The	   regulation	   of	   SxC-­‐,	   by	   Nrf2	   or	   other	  means,	   therefore	   represents	   an	  
important	   thiol-­‐mediated	   strategy	   of	   protection	   from	   the	   potentially	   neurotoxic	  
episodes	  initiated	  by	  electrophiles,	  reactive	  oxidative	  species,	  and	  excitotoxicity.	  	  
	  
Unresolved	  questions	  remain,	  LPS	  as	  example	  
The	   inseparable	   link	   between	   cystine	   entry	   via	   system	   xC-­‐	   and	   GSH	   synthesis	  
capacity	   presents	   the	   potential	   for	   a	   negative	   feedback	   loop	   for	   GSH	   levels	   to	  
regulate	  SxC-­‐	  activity,	  potentially	  via	  Nrf2.	  However,	  this	   level	  of	  regulatory	  control	  
appears	   to	   differ	   among	   cell	   types	   suggesting	   that	   not	   all	   cases	   of	   GSH-­‐depletion	  
lead	   to	  Nrf2	  mediated	  gene	  activation.	  For	  example	  while	  arsenic,	  DEM,	  cadmium,	  
and	   hydroquinone	   all	   induced	   SxC-­‐	   activity	   and	   xCT	   mRNA	   in	   an	   EpRE-­‐driven	  
luciferase	   reporter	   in	  BHK21	  embryonic	   fibroblasts,	   treatment	  with	   either	  BSO	  or	  
LPS	  did	  not	  (Sasaki	  et	  al.	  2002).	  GSH-­‐depletion	  by	  BSO	  also	  did	  not	  induce	  Nrf2	  in	  a	  
mammary	   cell	   line	   (Wang	   et	   al.	   2006).	   Conversely,	   GSH-­‐depletion	   did	   lead	   to	  
increased	   levels	   of	   Nrf2	   and	   xCT	   in	   C1	   cells	   (simian	   virus	   40	   large	   T-­‐antigen	  
immortalized	   line)	   (Qiang	   et	   al.	   2004).	   Interestingly,	  GSH	   levels	   in	   glia	   of	  Nrf2	   -­‐/-­‐	  
animals	  is	  not	  different	  than	  that	  from	  wildtypes	  (Shih	  et	  al.	  2005),	  suggesting	  other	  
mechanisms	   in	   control	   of	   GSH	   homeostasis	   in	   these	   animals.	   Just	   as	   the	   effect	   of	  
GSH-­‐depletion	  on	  Nrf2	  appear	  to	  be	  cell-­‐type	  specific,	  so	  is	  the	  effect	  of	  BSO	  on	  SxC-­‐.	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For	  example,	  GSH-­‐depletion	  has	  been	  reported	  to	  have	  no	  effect	  on	  L-­‐Cys2	  transport	  
in	  BHK21	  fibroblasts	  (Sasaki	  et	  al.	  2002)	  and	  rat	  kidney	  fibroblasts	  (Kang	  and	  Enger	  
1992),	   an	   inductive-­‐effect	   in	   astrocytes	   (no	   dbcAMP)	   (Allen	   et	   al.	   2001),	   C1	   cells	  	  
(Qiang	  et	  al.	  2004)	  and	  whole-­‐brain	  homegenates	  (Limon-­‐Pacheco	  et	  al.	  2007),	  and	  
a	  down-­‐regulatory	  effect	   in	  astrocytes	  (treated	  with	  dbcAMP)	  (Bender	  et	  al.	  2000)	  
and	  HAIN-­‐6	  lung	  fibroblasts	  (Bannai	  1984).	  	  
While	   evidence	   for	  universal	  Nrf2-­‐mediated	   control	   over	   SxC-­‐	   is	   lacking,	   there	   lies	  
the	  possibility	  that	  the	  EpRE	  driven	  gene	  regulation	  mediated	  by	  Nrf2	  is	  a	  system	  of	  
control	  that	  overlaps	  with	  the	  function	  of	  other	  transcription	  factors.	  In	  a	  model	  of	  
systemic	  GSH-­‐depletion	  in	  mice	  it	  was	  found	  that	  the	  upregulation	  of	  SxC-­‐	  was	  linked	  
to	  p38MAPK	  and	  ERK2	  signaling	  cascades	  (Limon-­‐Pacheco	  et	  al.	  2007),	  potentially	  
leading	  to	  the	  activation/synthesis	  of	  any	  number	  of	  additional	  transcription	  factors	  
linked	  to	  either	  the	  Nrf2-­‐associated	  activation	  of	  SxC-­‐	  or	  an	  as	  yet	  unspecified	  Nrf2-­‐
independent	  pathway	  of	  gene	  activation.	  Thus,	  there	  may	  be	  other	  points	  along	  the	  
pathway	  to	  EpRE	  stimulation	  on	  which	  BSO	  could	  be	  having	  its	  effect	  apart	  from	  the	  
release	  of	  cytoplasmic	  sequestered	  Nrf2.	  This	  type	  of	  regulatory	  control	  is	  observed	  
in	   the	   cases	   of	   arsenic	   (sodium	   arsenite)	   exposure	   in	   hepa1c1c7	   cells	   (He	   et	   al.	  
2006).	   In	   this	   study,	   arsenic,	   but	   not	   tBHQ	   treatment,	   was	   associated	   with	   the	  
disruption	  of	  Nrf2-­‐keap1-­‐Cu3	  complexes	  and	  dimerization	  of	  Nrf2	  and	  Maf	  proteins	  
in	   the	   nucleus,	   resulting	   in	   increased	   EpRE-­‐dependent	   transcription	   of	   the	   NQO1	  
gene.	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Additionally,	   there	   is	   now	   evidence	   that	   the	   up-­‐regulation	   of	   SxC-­‐	   through	   L-­‐Cys2	  
deprivation	  and	  potentially	  other	   inducers,	   assumed	   to	  be	  mediated	  by	   the	  amino	  
acid	   response	   element	   (AARE),	   is	   mediated	   not	   by	   Nrf2	   but	   by	   the	   transcription	  
factor	  ATF4	  (aka	  Creb2)(Lewerenz	  and	  Maher	  2009;	  Ogawa	  et	  al.	  2008;	  Sato	  et	  al.	  
2004),	  specifically	  in	  response	  to	  L-­‐Cys2	  deprivation	  (Sato	  et	  al.	  2004).	  Interestingly,	  
the	  induction	  of	  xCT	  by	  the	  reactive	  tocopherol	  metabolite	  γ-­‐tocopheryl	  quinone	  has	  
been	  shown	  to	  be	  attenuated	  by	  siRNA	  for	  ATF4	  but	  not	  Nrf2	  in	  PC-­‐12	  cells	  (Ogawa	  
et	  al.	  2008).	  This	  suggests	  that	  ATF4	  can	  mediate	  the	  transcriptional	  control	  of	  xCT	  
via	  the	  AARE	  in	  ways	  potentially	  distinct	  from	  amino	  acid	  deprivation	  or	  through	  a	  
means	  independent	  of	  the	  AARE.	  
It	   is	   reasonable	   that	   the	   whole	   of	   SxC-­‐	   regulation	   cannot	   be	   explained	   by	   the	  
activation	   of	   the	   ARE/EpRE	   by	   Nrf2.	  Most	   notably,	   studies	  with	   LPS	   suggest	   that	  
other	  regulatory	  mechanisms	  exist.	  Like	  tBHQ,	  DEM,	  arsenic	  and	  other	  electrophilic	  
agents,	  LPS	  is	  capable	  of	  inducing	  SxC-­‐	   in	  macrophages	  (Sato	  et	  al.	  1995).	  However,	  
this	   same	   induction	   is	   also	   observed	   in	  macrophages	   from	  mice	   deficient	   in	   Nrf2	  
(Ishii	  et	  al.	  2000).	  In	  addition	  to	  Nrf2,	  The	  increase	  in	  SxC-­‐	  activity	  and	  intracellular	  
levels	  of	  GSH	   in	  macrophages	   following	  LPS	   treatment	  has	  also	  been	   shown	   to	  be	  
independent	   of	   AP1	   and	   NFκB	   and	   dependent	   on	   oxygen	   (Sato	   et	   al.	   1995).	   This	  
effect	  of	  LPS	  is	  also	  cell-­‐type	  specific,	  as	  the	  induction	  ability	  on	  SxC-­‐	  is	  not	  observed	  
in	   fibroblasts	   (Sato	   et	   al.	   1995)	   or	   BHK21	   cells	   (Sasaki	   et	   al.	   2002).	   Interestingly,	  
there	   is	  a	   lack	  of	  data	  examining	  LPS	   treatment	  on	  SxC-­‐	   in	   the	  CNS,	  and	  some	  of	   it	  
sounds	  contradictory.	   	  For	  instance,	  indirect	  evidence	  suggests	  that	  LPS	  in	  the	  CNS	  
may	   involve	   the	   downregulaton	   of	   SxC-­‐.	   While	   some	   evidence	   suggests	   a	   lack	   of	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effect	   of	   LPS	   on	   GSH	   levels	   in	   glia	   (McNaught	   and	   Jenner	   2000),	   LPS	   exposure	   in	  
other	   in	   vitro	   (mesencephalic	   cultures)	   and	   in	   vivo	   (subranigral	   injection)	   studies	  
results	   in	   a	   loss	   of	   GSH,	   which	   suggests	   a	   down-­‐regulatory	   effect	   by	   LPS	   on	   SxC-­‐	  
function	  (Bharath	  et	  al.	  2002;	  Kramer	  et	  al.	  2002;	  Zhu	  et	  al.	  2007).	  	  
	  
Concluding	  Remarks	  
In	  summary,	  electrophile	  exposure	  and	  oxidative	  stress	  elicits	  an	  adaptive	  response	  
aimed	   at	   maintaining	   redox	   homeostasis	   and	   reducing	   cellular	   damage.	   This	  
response	   involves	   the	   activation	   of	   genes	   encoding	   detoxification	   and	   antioxidant	  
proteins	  (e.g.	  γGCS,GST,	  NQO1,	  HO-­‐1).	  Gene	  activation	   is	  mediated	   in	  part	  by	  a	  cis-­‐
acting	   element	   referred	   to	   as	   the	   ARE	   or	   EpRE	   located	   in	   the	   regulatory	   region	  
within	   target	   genes.	   Nrf2	   is	   now	   considered	   to	   be	   the	   major	   transcription	   factor	  
responsible	   for	   regulating	   EpRE-­‐mediated	   gene	   expression.	   Nrf2	   is	   one	  
transcription	  factor	  known	  to	  control	  the	  expression	  and	  activity	  of	  SxC-­‐,	  the	  proper	  
functioning	   of	   which	   is	   neuroprotective.	   	   The	   intermediate	   events	   that	   tie	   GSH-­‐
depletion,	  electrophile	  exposure,	  and	  LPS	  treatments	  to	  SxC-­‐	  remain	  unclear,	  do	  not	  
universally	   involve	   Nrf2,	   and	   deserve	   further	   study.	   As	   the	   effectiveness	   of	   these	  
induction	   strategies	   appear	   to	  be	  dependent	  on	   cell	   type,	   studies	   that	   incorporate	  
animal	  and	  cell-­‐type	  considerations	  into	  the	  experimental	  design	  are	  likely	  to	  yield	  
important	  new	  information	  for	  the	  field.	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